










The handle http://hdl.handle.net/1887/32943 holds various files of this Leiden University 
dissertation. 
 
Author: Albers, Heleen Marion 
Title: Genetics in juvenile idiopathic arthritis 






This research project was supported by research grants of the Dutch Arthritis Associa-
tion (grant number NR 05-1-403 and KFS-04-2-202) and by the Gisela Thier Foundation
Cover: DNA11
Printed by: Optima Grafische Communicatie, Rotterdam
ISBN 978-94-6169-640-3
©2015 H.M. Albers, Rotterdam, the Netherlands
All rights reserved. No part of this publication may be reproduced in any form or by any 
means without prior permission of the author




de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties







Promotores Prof. Dr. R.M. Egeler
  Prof. Dr. T.W.J. Huizinga
Co-promotores Dr. R. ten Cate
  Dr. M.W. Schilham
Overige leden Prof. Dr. T.W. Kuijpers (Academisch Medisch Centrum, Amsterdam)
  Prof. Dr. F. Koning
  Prof. Dr. J.J. Houwing-Duistermaat
“It is more important to know what sort of 
person has a disease than to know what 




Chapter 1 General introduction 9
Part a Genetic risk factors for juvenile idiopathic arthritis
Chapter 2 The TRAF1/C5 region is a risk factor for polyarthritis in juvenile 
idiopathic arthritis
Ann Rheum Dis. 2008 Nov;67(11):1578-80
41
Chapter 3 Association of the autoimmunity locus 4q27 with juvenile 
idiopathic arthritis
Arthritis Rheum. 2009 Mar;60(3):901-4
51
Chapter 4 CD226 (DNAM-1) is associated with susceptibility to juvenile 
idiopathic arthritis
Ann Rheum Dis. 2014 Jul 23[Epub ahead of print]
59
Part b clinical and genetic factors involved in the course of disease and 
response to treatment
Chapter 5 Clinical course and prognostic value of disease activity in 
the first two years in different subtypes of juvenile idiopathic 
arthritis
Arthritis Care Res (Hoboken). 2010 Feb;62(2):204-12
107
Chapter 6 Genetic variation in VTCN1 (B7-H4) is associated with course 
of disease in juvenile idiopathic arthritis
Ann Rheum Dis. 2014 Jun 1;73(6):1198-201. 
125
Chapter 7 Time to treatment as an important factor for the response to 
methotrexate in juvenile idiopathic arthritis
Arthritis Rheum. 2009 Jan 15;61(1):46-51
141
Chapter 8 General discussion 155
Chapter 9 Future plans 191
Chapter 10 Summary 197













In this thesis the uncommon childhood disease Juvenile Idiopathic Arthritis (JIA) was 
studied. In a large cohort of JIA patients the association of genetic markers with the 
susceptibility to JIA was investigated. Associated markers would represent the genetic 
predisposition for developing disease, but could also be helpful in elucidating the 
pathophysiology of JIA, which is still largely unknown. Additionally, genetic markers 
have been studied in relation to the course of disease in order to identify prognostic 
markers for disease severity. Finally the role of genetic parameters in the ability to 
predict the response to treatment was examined with the aim of serving the pediatric 
rheumatologist in selecting the best individual treatment. 
Definition and classification of JIA  
About 100 years ago the first attempt was made to classify chronic arthritis in children, 
although the first report of juvenile arthritis by Boticelli dates back to 1483.1 From the 
1940’s in Europe a classification of Juvenile Chronic Arthritis (JCA) was used, as defined 
by the European League against Rheumatism (EULAR).2 In North America the nomen-
clature of the American Rheumatism Association (ACR), defining Juvenile Rheumatoid 
Arthritis (JRA), has been adhered to.3 In the following years more distinct phenotypes 
were recognized, for example juvenile onset of spondyloarthritis, arthritis associated 
with psoriasis and progression of oligoarthritis into a polyarticular course. In 1994 the 
International League of Associations for Rheumatology (ILAR) was founded and cre-
ated a worldwide consensus on re-classifying juvenile arthritis as Juvenile Idiopathic 
Arthritis (JIA). The first version of this JIA classification was proposed in 19944 which 
was subsequently revised, incorporating the results of several studies validating these 
classification criteria.5;6
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JIA is defined as arthritis of unknown etiology that begins before the sixteenth 
birthday and persists for at least 6 weeks with other known conditions having been 
excluded. JIA encompasses a group of heterogeneous diseases that are character-
ized by chronic arthritis. The ILAR classification is based predominantly on clinical 
features and some laboratory parameters and has the intention to define homo-
geneous subtypes (Table 1). The major criterion is the number of affected joints 
present at disease onset. 
Systemic JIA accounts for 10-15% of patients with JIA. Nowadays systemic JIA is 
considered to be an auto-inflammatory disease or syndrome due to the activation 
of the innate immune system and the prominent role of IL-1 and IL-6.7 The course of 
disease can be monocyclic, can follow a relapsing course or be continuously active. 
The subtypes oligoarthritis (persistent and extended) and rheumatoid factor (RF) 
negative polyarthritis share many clinical features. Antinuclear antibodies (ANA) 
are predominantly present in these subtypes. Oligoarthritis has a higher prevalence 
in the Western world and comprises up to 50% of the JIA patients. JIA-associated 
uveitis is an extra-articular manifestation, which mainly develops in patients with 
oligoarthritis (10-30%) and will be discussed in more detail later on. Almost 20% of 
the total group of JIA patients has RF-negative polyarthritis. RF-positive polyarthritis 
is the juvenile equivalent of adult rheumatoid arthritis (RA) and is present in only a 
small percentage (about 5%) of JIA patients. It is the only subtype in which antibod-
ies to cyclic citrullinated peptides (anti-CCP) are found.8 Psoriatic arthritis (5-10% 
of all JIA patients) represents a heterogeneous group of patients. Two categories 
seem to be present: patients with psoriasis and arthritis resembling enthesitis 
related arthritis and patients that have early-onset, ANA positive oligoarthritis and 
also psoriasis.9 Enthesitis related arthritis accounts for 5-10% of JIA patients and is 
an undifferentiated spondyloarthritis. Most patients are HLA-B27 positive, which is 
also related to more active joints involved.10
Many features have not been included in the ILAR classification and are subject 
of discussion.11 Some of these parameters are: age at onset, detailed description 
of arthritis (smaller or larger joints/ symmetric or asymmetric joint involvement), 
total number of joints affected, presence of ANA,12-14 presence of (chronic) anterior 
uveitis and (family history of) psoriasis.15;16  In the near future genetic, immunologic, 
genome wide mRNA-expression and proteomic studies might reveal parameters that 
could also be incorporated into the JIA classification or even lead to a novel classifi-
cation. As described, the classification of chronic arthritis in children is still evolving. 
The ultimate goal is to determine biologically distinct subtypes with a predictable 
response to treatment and outcome. However this situation is still far from being 
realized. 
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table 1. The ILAR classification of the different categories (or subtypes) of JIA6
subtype Definition Exclusion 
criteria*
Distribution#
Systemic JIA Arthritis in one or more joints with or preceded
by fever of at least 2 weeks’ duration that is 
documented to be daily (“quotidian”) for at least 
3 days, and accompanied by one or more of the 
following:
1. Evanescent (nonfixed) erythematous rash
2. Generalized lymph node enlargement





Arthritis affecting one to 4 joints during the first 6 
months of disease and affecting not more than 4 




Arthritis affecting one to 4 joints during the first 6 
months of disease and affecting a total of more than 




Arthritis affecting 5 or more joints during the




Arthritis affecting 5 or more joints during the
first 6 months of disease; 2 or more tests for RF at 
least 3 months apart during the first 6 months of 
disease are positive
a,b,c,e 5%
Psoriatic arthritis Arthritis and psoriasis, 
or arthritis and at least 2 of the following:
1. Dactylitis
2. Nail pitting or onycholysis




Arthritis and enthesitis, 
or arthritis or enthesitis with at least 2 of the 
following:
1. The presence of or a history of sacroiliac joint 
tenderness
and/or inflammatory lumbosacral pain
2. The presence of HLA-B27 antigen
3. Onset of arthritis in a male over 6 years of age
4. Acute (symptomatic) anterior uveitis
5. History of ankylosing spondylitis, enthesitis 
related arthritis, sacroiliitis with inflammatory bowel 
disease, Reiter’s syndrome, or acute anterior uveitis 




Arthritis that fulfills criteria in no category or in
2 or more of the above categories.
RF: rheumatoid factor
*) Exclusion criteria:
a) Psoriasis or a history of psoriasis in the patient or first degree relative.
b) Arthritis in an HLA-B27 positive male beginning after the 6th birthday.
c) Ankylosing spondylitis, enthesitis related arthritis, sacroiliitis with inflammatory bowel disease, Reiter’s syn-
drome, or acute anterior uveitis, or a history of one of these disorders in a first-degree relative.
d) The presence of IgM rheumatoid factor on at least 2 occasions at least 3 months apart.
e) The presence of systemic JIA in the patient. 
#) Distribution in patients with a Caucasian European ethnicity
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Prevalence of JIA
Worldwide the prevalence of JIA has been variably described, with a prevalence 
varying between 15/100.000 and 150/100.000.17 Prevalence seems to be higher in 
the more northern countries of the northern hemisphere, as compared to countries 
lying closer to the equator. Remarkable is a difference in the distribution of subtypes; 
in the “Western world” the oligoarticular subtypes are the most frequent, whereas 
polyarthritis predominates in countries such as India, New Zealand and South Africa.18 
It should be noted this variation could be explained by methodological differences 
(like diagnostic difficulty of JIA, change in diagnostic criteria over time and variation in 
study design) or accessibility to health care. However this difference in prevalence of 
JIA subtypes might well be caused by differences in genetic background. Even when 
corrected for geographical differences, the genetic background (or ethnicity) is still 
related to the distribution of JIA subtype.19 At this moment worldwide research is in 
progress to collect more data concerning the epidemiology of JIA (EPOCA study).20
Course of disease in JIA
Remission
Until 2004 each reported study of remission rates in JIA used a different definition 
of remission, making comparison of clinical outcome and efficacy of treatment dif-
ficult. An international consensus project has attempted to develop a definition of 
clinical remission and inactive disease. This project is still on-going.21-23 The criteria 
for clinical inactive disease in oligoarthritis (persistent and extended), polyarthritis (RF 
negative and positive) and systemic JIA are: no joints with active disease, no fever, 
rash, serositis, splenomegaly or generalized lymphadenopathy attributable to JIA, no 
active uveitis (defined by the SUN Working Group), ESR or CRP level within normal 
limits or if elevated not attributable to JIA, physician’s global assessment of disease 
activity score of best possible on the scale used and duration of morning stiffness 
<= 15 minutes.22 The preliminary definition of clinical remission on medication is met 
when clinical inactive disease is present for a minimum of six continuous months with 
the patient on medication. Clinical remission is defined as clinical inactive disease that 
is present for a minimum of 12 continuous months with no use of medication.21 Several 
studies using these definitions demonstrated only a small percentage of patients (ap-
proximately 30%) reaching clinical remission and a large percentage of patients with 
persistent active arthritis.24;25 Consistently observed in different studies is that patients 
with persistent oligoarthritis have a more favorable outcome with a higher percentage 
of clinical remission and inactive disease (but varying from 43-84%).24-27 The course of 
disease in the persistent oligoarthritis subtype is less progressive compared to both ex-
General introduction 15
tended oligoarthritis and RF-negative polyarthritis. Patients with polyarticular JIA, and 
especially RF-positive polyarthritis, have a more progressive course with less remission 
and inactive disease.24-26;28 Likewise, a recent prospective study with a follow-up of 17 
years showed a large variability in disease course between the different subtypes, with 
remission overall present in only 40% of the JIA patients.29
Pattern of disease activity
The course of disease in JIA follows an unpredictable pattern of episodes with different 
levels of active disease and episodes of disease quiescence. This pattern of disease 
activity was described in more detail for the first time by Wallace et al,30 who also 
introduced the term “cumulative time spent in a state of active or inactive disease”. 
This outcome measure is the only one that takes the fluctuating character of disease 
activity in JIA into account. Patients with persistent oligoarthritis spend almost 60% of 
the time in a state of inactive disease, whereas patients with extended oligoarthritis or 
RF-negative polyarthritis have inactive disease only 30-36% of their time.28;30 These 
outcomes are consistent with the higher percentage of continuous active disease de-
scribed in extended oligoarthritis and RF-negative polyarthritis compared to persistent 
oligoarthritis.27 
The aim of treatment is achieving a total absence of disease activity. However in 
patients with clinical remission, a biological disturbance is still present.31;32 Differ-
ent biomarkers (such as phagocyte activation marker S100A12 and myeloid-related 
protein MRP8/14) are under investigation for their role in defining immunological 
quiescence of JIA.33 
Radiological damage
Many different scoring systems for radiological assessment of damage of the joints 
have been used in JIA; the Steinbrocker score (the most original radiologic score in 
RA), the Sharp/van der Heijde score and the Poznanski score.34-36 Because of the lack 
of scoring systems for JIA patients, the Dijkstra composite score has been developed 
to describe radiological features of patients with JIA in a standardized manner.37;38 Also 
specific for JIA is the Juvenile Arthritis Damage Index (JADI) that has been developed 
for articular (JADI-A) and extra-articular damage (JADI-E). This measure uses informa-
tion obtained by physical examination and by a brief review of the patient’s clinical 
history.39 This scoring system correlates with radiological damage.39 Most recently, 
a MRI scoring system (JAMRIS) for evaluating disease activity in the knee has been 
developed.40
Due to these different scoring systems and various study designs, the percentage 
of patients with radiological damage varies widely between 12% and 60%.41-44 The 
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RF-positive polyarticular JIA patients have the most articular damage. A prolonged 
disease activity is associated with more radiologic damage, underlining the need of 
aggressive treatment inducing clinical remission at an early stage.41;44;45
JIA- associated uveitis
The most common extra-articular manifestation in JIA, is JIA-associated uveitis or 
chronic anterior uveitis.46 It is also called silent uveitis because of the lack of symptoms, 
until complications cause symptoms of visual loss. This type of uveitis is associated 
with oligoarthritis, RF-negative polyarthritis and psoriatic arthritis, but is especially 
related to ANA positive, early-onset oligoarthritis (10-30%).46-49 JIA-associated uveitis 
mostly develops during the first years after diagnosis of JIA, but can also precede the 
symptoms of arthritis or develop only many years after the JIA onset. Guidelines for 
ophthalmologic screening in patients with JIA have been formulated, taking the differ-
ent risk factors into account.50-52 
The course of JIA-associated uveitis is fluctuating and not always related to the 
activity level of arthritis. Uveitis that is already present at first screening and most 
likely preceded symptoms of arthritis, together with sustained inflammation of the 
eye are factors associated with complications and visual loss. Several complications 
of uveitis can be seen; cataract, band keratopathy, posterior synechiae, glaucoma, 
ocular hypotonia and macular edema. Recent studies reported complications, mainly 
cataract, in 15-20% of the uveitis patients and a few patients developed blindness. 
Both frequent screening and an altered therapeutic regime, with more aggressive 
medication, has led to a decrease in complication rate and a better outcome.53-55 
Treatment of JIA-associated uveitis is based on a step-up approach and consists of 
topical or/and systemic glucocorticoids, followed by systemic methotrexate or aza-
thioprine. When treatment fails adalimumab, infliximab, cyclosporin A or abatacept 
are administered as last step.56;57
Treatment of JIA
In the last decades, the treatment of JIA has changed dramatically. In 1981treatment of 
JIA was dominated by salicylate and non-steroidal anti-inflammatory drugs (NSAIDs). 
Treatment modalities such as gold, antimalarials or penicillamine were used in progres-
sive polyarthritis and glucocorticoids only in selected patients with ongoing disease.58 
The latest JIA treatment recommendations of the American College of Rheumatology, 
dating from 2011 (with an update concerning systemic JIA in 2013), are focused on 
disease modifying anti-rheumatic drugs (DMARDs) like methotrexate (MTX) and TNF-
alpha-inhibitors for treating polyarticular JIA in an early stage as well as treating 
oligoarthritis following the use of intra-articular steroids (IAS) or NSAIDs.59;60 The use of 
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IAS still has an important role in the treatment of oligoarthritis, however the long term 
benefits seem limited.61
DMARDs
In JIA the most frequently used non-biological DMARD is MTX, followed by Sulfasalazine. 
The biological DMARD that is mainly used in JIA is the TNF-alpha-inhibitor etanercept.
Methotrexate
Methotrexate (MTX) has an anti-proliferative effect, by acting as a folate antagonist 
interfering in (amongst others) purine and pyrimidine biosynthesis. It is also involved 
in an increased adenosine release, that has an immune-suppressive effect,62 and acts 
as an inhibitor of cytokine production induced by T-cell activation.63 Randomized con-
trolled trials have proven the efficacy of a weekly low dose of MTX (10 mg/m2) in the 
different subtypes of JIA (polyarticular JIA,64 systemic JIA and extended oligoarthritis65). 
It is described that in recent years about 75% of all patients with JIA have used MTX 
during the first year of treatment.66,67 When remission is reached, the time to withdrawal 
of MTX doesn’t seem to have an influence on the relapse-rate or time to relapse.68 No 
evidence-based guidelines for withdrawing MTX are available. MTX will be discussed in 
more detail in the General Discussion (Pharmacogenetics) section.
Etanercept 
TNF-alpha is a pro-inflammatory cytokine that plays a (major) role in the pathogenesis 
of JIA. Soluble TNF-alpha-receptor acts as an inhibitor by binding TNF-alpha. Etanercept 
(Enbrel) is a fully human dimeric fusion protein consisting of the extracellular portion 
of the human TNF-alpha-receptor linked to the Fc portion of human lgG1. Clinical stud-
ies have first been performed in RA and thereafter the efficacy and safety has been 
investigated in polyarticular JIA in a double-blind study.69 The dosage of etanercept is 
0.4 mg per kilogram of body weight and it is given subcutaneously by injection twice 
weekly or at 0.8 mg per kilogram once weekly. Combining etanercept with prevailing 
DMARDs leads to a good response,70;71 whereas etanercept as mono-treatment seems 
to be less effective.72 In recent years, applying etanercept early in the disease course is 
not common, as only 5% of the patients have started in the first year after diagnosis.66 
Besides the effective use in polyarthritis, with a response to treatment in 74% of the 
patients,69 etanercept results in a good response in extended oligoarthritis as well 
with a response defined by ACR 30 in 88.6% of the patients.73 Although not registered 
for persistent oligoarthritis, it seems a justifiable option when treatment with IAS and 
MTX has failed.74 Long-term efficacy (up to 8 years) and safety has been described 
in JIA.75-80 Different registries have been established to monitor the efficacy and side 
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effects of treatment with etanercept in patients with JIA (German76; Dutch79; British81 
and Polish registry82). Several factors have been proposed as prognostic factors for a 
good response; a lower baseline disability score, the use of fewer DMARDs prior to 
initiating etanercept and a younger age at onset.83;84 Successful withdrawal from etan-
ercept has been described,85 but also early flares in a substantial proportion of patients 
after discontinuation of treatment.86 Several side effects have been suggested, such 
as infectious disease (for example tuberculosis), malignancies and the development 
of inflammatory bowel disease. However the relation with etanercept has not been 
clarified. 
Other TNF-alpha-inhibitors such as adalimumab (Humira), a (humanized) monoclonal 
antibody against TNF-alpha and Infliximab (Remicade), a (human-mouse) chimeric 
monoclonal antibody against TNF-alpha, are less frequently used in JIA. Adalimumab 
especially seems to be the TNF-alpha-inhibitor of choice when JIA-associated uveitis 
is present.87 Infliximab is used in high dosage in case of refractory or highly active 
arthritis and seems to be effective without serious side effects (most importantly 
infections) or infusion reactions.88 Long-term data concerning the use of infliximab 
or adalimumab are lacking.89
Other biologic DMARDs
In JIA subtypes, besides systemic JIA, biologic DMARDs (or biologicals) other than TNF-
alpha inhibitors, are not frequently used. One of the biologicals sometimes used in 
polyarticular JIA is abatacept. Abatacept is a recombinant fusion protein comprising 
the extracellular part of human CTLA-4 connected to a modified Fc part of IgG-1. It 
selectively modulates the T-cell co-stimulation, inhibiting the T-cell activation. It is 
proven effective in JIA patients not responding to previous treatment.90;91 Tocilizumab, 
an interleukin-6 receptor inhibitor, has recently been proven effective and safe for 
treating patients with polyarticular JIA who failed to respond to MTX.92
In clinical practice, a large variability is observed in the treatment of patients with 
different subtypes of JIA. Various approaches for treating polyarticular JIA can be dif-
ferentiated, such as a step up approach (non-biologic DMARD followed by a biologic 
DMARD), non-biologic and biologic DMARD combined, and direct use of a biologic 
DMARD.93 The use of an early aggressive treatment (for example combining MTX and 
anti-TNF-alpha plus glucocorticoids versus MTX alone) seems to be more beneficial.94;95 
Also a large variation in treating mono-arthritis has been described, varying from IAS 
alone, a combination of IAS and NSAIDs or even NSAIDs with non-biological DMARD 
(mainly MTX).96 This illustrates that the choice of best treatment has still not been re-
solved. An ability to better predict the course of disease and the response to treatment 
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would be helpful in guiding the pediatric rheumatologist in his/her decision about the 
best individual treatment. 
Prognostic factors
In the last decades numerous studies have been performed to identify prognostic 
factors for the outcome of JIA. Outcome has been defined in different ways; as joint 
erosions, persistent disease and physical disability. Many factors have been suggested 
as prognostic factor: time to diagnosis, young age at onset, female sex, large number 
of affected joints, greater severity of arthritis or higher disability at onset (C-HAQ), 
symmetric disease, hip/wrist involvement, long duration of elevated erythrocyte sedi-
mentation rate or inflammatory markers and a positive RF.29;97-101 Of all these factors, 
only the different JIA subtypes have consistently been associated with a different rate 
of remission and can be regarded as having some prognostic value. Also a prolonged 
active disease in the first 6- 12 months seems to be associated with a worse long-term 
outcome.29;98 However this is not a predictive factor that is present at disease onset. 
The aim of treatment is to reduce the time with active disease, as early in the disease 
course as possible. Prognostic factors or a predictive model that can be determined at 
disease onset are still needed. 
etiology 
JIA is thought to be an autoimmune disease, although the pathogenesis remains largely 
unknown.102-104 The initial trigger is supposed to be a self-antigen, that has not been 
identified, but cartilage-derived autoantigens (like aggrecan, fibrillin and MMP3) might 
be involved.105 Following an autoreactive trigger, different parts of the immune response 
are activated such as (antigen-specific) T-cell response (T-helper-1/ T-helper-17 cells), 
activation of neutrophils, expansion of regulatory T-cells and the release of cytokines 
and chemokines. In JIA, as well as in other autoimmune diseases, the possible role of 
regulatory T-cells has been described.106;107 Regulatory T-cells are supposed to maintain 
self-tolerance and suppress inflammation. Interleukin (IL)-2 plays an important role in 
the development and function of regulatory T-cells through its interaction with CD25 
(IL2-receptor-alpha). At the site of inflammation increased levels of regulatory T-cells 
are consistently reported, although their exact contribution in the local inflammatory 
environment remains unclear.108 Besides regulatory T-cells, also T-helper-17 cells have 
been reported to play a central role in the initiation and maintenance of the autoim-
mune reaction in JIA.109;110 T-helper-17 cells produce the pro-inflammatory cytokines 
IL17 and IL22. An imbalance between pro-inflammatory T-helper-1/T-helper-17 cells 
and anti-inflammatory regulatory T-cells seems to be essential for developing JIA. The 
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persistent inflammation of the synovium eventually leads to cartilage destruction and 
bone erosions.
Systemic JIA has similarities with autoinflammatory syndromes. An overproduction 
of IL6 is present and patients have a unique IL1 signature. Treatment with tocilizumab 
(a humanized recombinant anti-IL6 receptor antibody) has been successful111;112 and 
clinical trials show effect of IL1 blockade.113
complex disease
JIA is thought to be a complex disease, in which interaction of environmental factors 
and multiple genetic factors exists.114 
Environmental factors
A causal association between environmental factors and the development of JIA re-
mains difficult. The trigger of the (auto)immune reaction might be a (viral) infection. 
Seasonal variation, suggesting an infectious etiology, is described only in systemic 
JIA, with a higher incidence in spring and summer. Stressful life events, physiological 
factors, perinatal factors, several viral and bacterial (such as streptococcal) infections 
have all been related to some degree to JIA and described in detail.17
Genetic factors
Familiar risk
A higher occurrence and similar clinical features of disease in affected siblings and 
families are suggestive for a genetic trait. As early as 1939 juvenile arthritis has been 
described in monozygotic twins.115 Most of the (monozygotic) twins and affected sib 
pairs that have been studied have a concordance for disease subtype and course of 
disease.116-120 Clinical features of juvenile arthritis are the same in familial cases and 
sporadic cases.120;121 The relative risk (lambda) for first-degree family members has 
been estimated in small study cohorts to be 15-30.114;117;118 Recently the relative risk 
was calculated using a large cohort of JIA patients combined with data from a popula-
tion database and showed a relative risk in siblings of 11.6, declining to 5.8 in first 
cousins.122 The risk for JIA attributable to familial factors was about 13%. These data 
strengthen the hypothesis that genetic factors play a role in the pathogenesis of JIA.
Ethnicity and gender 
Differences in phenotypes of JIA are observed in different ethnic groups. African and 
Asian patients are more likely to have polyarticular JIA with a higher incidence of a 
positive RF.123;124 In Caucasian patients (European and North American) the oligoarticu-
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lar subtype is more common. Oligoarticular JIA with positive ANA and JIA-associated 
uveitis is even more rare in the non-Caucasian population.125 As in other autoimmune 
diseases, a female preponderance is seen in JIA, with a female:male ratio of 7:1.
Clustering of autoimmune diseases in JIA families 
Clustering of multiple autoimmune diseases in one family, and even in one patient, 
has been known for many years. The pattern of clustering of the 5 major autoimmune 
diseases, amongst which is RA, has been described and reviewed in detail.126;127 Several 
studies have described the familial autoimmunity in JIA families. All studies indicate a 
higher prevalence of autoimmunity in JIA families compared to controls.128-131 
Genetic association studies 
The aim of genetic studies is to identify associations between genetic variations (like a 
single nucleotide polymorphism (SNP), microsatellite, variable number tandem repeat, 
insertions/deletions) and phenotypic traits. In order to establish a genetic association, 
different types of studies can be performed.132 
In a family based study (the transmission disequilibrium test (TDT)), the transmis-
sion of a genetic marker from parents to their offspring is studied. It is expected 
that when a genetic variation is associated with disease, the transmission of that 
variation to affected offspring is more frequent than expected by Mendelian laws. 
In this type of study, the potential confounding effect of population stratification is 
avoided because parents act as controls for the cases (affected offspring). To gener-
ate enough power to detect associations with only small effects, the same number 
of cases is needed as in a case-control study, together with DNA of both parents. 
In a case-control association study the difference in frequency of a genetic marker is 
studied between cases with a specific trait and controls lacking this trait. If a genetic 
marker is significantly more/less frequent in cases, than there is an association with 
the specific trait. When the genetic marker is the causal variant, a direct association 
is revealed. However most of the time a genetic marker is not the causal variant, but 
is in linkage disequilibrium (LD) with nearby (and possible causal) variants situated 
in one LD block (that is located between two recombination hot spots) and is called 
an indirect association. In case SNPs have been studied, the genetic marker of such 
an indirect association is called a tag SNP, representing an LD block. In case-control 
studies admixture of the population (population stratification) should be avoided, 
because it can cause false positive or false negative associations. 
Different types of case-control association studies can be performed. In a candidate 
gene study the selected genetic markers are located in genes of specific interest and 
are thought to play a role in the mechanism that is investigated. In studies focusing 
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on the susceptibility of disease, genes are selected that might be involved in the 
pathogenesis and in studies that focus on the severity of disease, genes can be 
selected from pathways involved in ongoing inflammation. In genome wide associa-
tion studies (GWAS) multiple genetic markers (covering a small fraction of the total 
sequence variation) are studied without underlying hypothesis, which could result in 
discovery of totally new and unexpected associations. Unfortunately a large cohort 
of cases and controls is needed to be able to correct for multiple testing. Nowadays 
the Human Genome Project has identified about 10 million common SNPs. Because 
of the LD, it is estimated that about 300,000 to 600,000 (tag)SNPs will cover the 
genetic variation between individuals.133
The aim of genetic association studies is to identify a genetic association, replicate/
validate this association in an independent cohort and examine the functional con-
sequence of this genetic marker (or associated causal variant). Thereafter the role in 
pathogenesis of disease (leading to better diagnosis and classification) or possible 
therapeutic consequences may be investigated.
Genetics association studies in JIA
HLA
The first genetics factor that has been studied in JIA was the human leukocyte antigen 
(HLA), because of its major role in T-cell immunity and because it is polymorphic and 
easily typed.134 There are common HLA associations in the overall JIA patient group, 
but also different patterns of HLA association in different JIA subgroups are described. 
These subgroups do not always follow the ILAR classification.135;136 Nowadays many 
genetic factors have been studied, however HLA remains to have the strongest associa-
tion in JIA.137
Non-HLA associations
From 1998 onwards multiple case-control candidate gene association studies have 
been performed in JIA in selected genes (like IL-6, TNF-alpha, IL-1, IL-10, MIF). In most 
of these studies only a small cohort was available for study (median of 130 cases vs 
276 controls)138 and, therefore, these studies were underpowered to detect associa-
tions with a small effect size. The positive associations that were detected were often 
difficult to replicate. Systematic review of these studies identified that about 100 loci 
had been investigated until 2008.138 However at that point in time (which was also the 
starting point of our study) only 5 associations were independently confirmed; PTPN22, 
MIF, SLC11A1 (NRAMP1), TNFA, and WISP3.
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In recent years more loci associated with JIA have been replicated ; STAT4, TNFAIP3, 
IL2RA, TRAF1/C5, and VTCN1.139 In addition to candidate gene studies, genome wide 
association studies (GWAS) have also been performed in JIA. The first GWAS revealed 
(besides HLA) a new association; VTCN1.140 VTCN1 was discovered and replicated 
in an independent cohort. The GWAS published in 2012 revealed 3q13 as a novel 
susceptibility locus for JIA.141 The most recent study using large scale genotyping 
focused on different regions of interest using dense genotyping on an Immunochip. 
This study revealed 14 new loci of interest.137
PTPN22 is a good example of an association in JIA that has been replicated in mul-
tiple independent cohorts (in both candidate gene studies and GWAS) and this will 
therefore be discussed in more detail.
PTPN22
PTPN22 encodes lymphoid-specific phosphatase, which is an inhibitor of the T-cell 
activation, preventing spontaneous activation and restricting the response to antigen. 
A functional SNP was discovered in codon 620, changing arginine into tryptophan, 
leading to a more efficient inhibition of T-cell activation that could have a part in failure 
to delete autoreactive T-cells during thymic selection or insufficient activity of regula-
tory T-cells.142 In a candidate gene approach the association of this SNP was tested in 
diabetes mellitus type 1 (DM1) and a positive association of the tryptophan variant 
(allele 1858T) was found and replicated in an independent cohort.143 Functional stud-
ies show that only lymphoid-specific phosphatase with Arg620 (allele 1858C) forms a 
complex with the C-terminal Src kinase (CSK), whereas lymphoid-specific phosphatase 
with Trp620 (allele 1858T) does not bind to CSK, resulting in a reduced T-cell receptor-
mediated signaling.144 
When the candidate gene study in DM1 was performed, a large genome wide as-
sociation study of putative functional SNPs in RA was simultaneously conducted,145 
identifying PTPN22 as a risk factor for RA. PTPN22 (allele 1858) has since then been 
found to be associated with multiple autoimmune diseases such as SLE, celiac 
disease, Crohn’s disease and thyroid autoimmunity. A positive association with JIA 
was first described in 2005146 followed by mostly positive associations in several 
cohort studies (some of them with different ethnicities).147-150 In the first genome 
wide association study in JIA, the association with PTPN22 was only modest, most 
likely because the SNPs that had been genotyped, had only low correlation with the 
causal variant.140
The precise implication of this altered function of lymphoid-specific phosphatase 
is still under investigation.151;152 Lymphoid-specific phosphatase is currently being 
investigated as a possible drug target for treatment of autoimmunity.144;153
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common autoimmune susceptibility loci
Because of the familial clustering of autoimmune diseases it has always been thought 
that shared immunological pathways exist. When data from GWAS of multiple 
autoimmune diseases were compared (not including JIA), a large overlap in genetic 
susceptibility became clear.154 Distinct shared immunological pathways were revealed; 
T-cell differentiation (e.g. IL10, IL18RAP, STAT3, STAT4, IL2RA), immune-cell signaling 
(e.g. CTLA4, PTPN22) and innate immunological response and TNF-alpha-signaling (e.g. 
TRAF/C5, TNFAIP3). Shared susceptibility genes encoding cytokines and chemokines 
were consistently found, together with shared loci with an (as yet) unknown function, 
that might include transcription factor binding sites.155
This Thesis
The aim of this thesis is to identify on the one hand non-HLA genetic factors that are 
associated with the susceptibility to develop JIA (part A) and additionally identify clini-
cal and genetic factors that are associated with the differences in the course of disease 
and the response to treatment (part B).
In order to address these questions, a new independent cohort of Caucasian JIA 
patient has been created through collaboration with multiple rheumatology refer-
ral centers in North-Western Europe. Both DNA and detailed data on the course of 
disease and use of medication have been collected. 
Several case-control candidate gene association studies have been performed in 
this new cohort of JIA patients comparing them to a population of healthy controls. 
Some of these studies only tested one hypothesis, such as TRAF1/C5 (Chapter 2) 
and the 4q27 locus (Chapter 3), based on the latest (at that time) discovered associa-
tions in RA (which of all the autoimmune diseases mostly resembles JIA). In Chapter 
4 large scale genotyping is described, involving genes/ loci that have already been 
associated with JIA (in order to replicate associations) or other autoimmune diseases 
(in order to identify common autoimmune susceptibility loci that also concern JIA) 
or are involved in immune-regulation (in order to discover new associations).
To capture the fluctuating pattern of different levels of disease activity during the 
course of JIA, the parameter “percentage of active disease (in the first two years after 
disease onset)” has been used to define the course of disease. Both clinical (Chapter 
5) and genetic factors (Chapter 6) have been studied in relation to the course of 
disease. Due to the fact that MTX is the most used DMARD in JIA, clinical and genetic 
factors associated with the response to MTX are of major interest and are explored 
in Chapter 7.
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Associations with the susceptibility and the severity of JIA might reveal pathways 
involved in the pathogenesis of JIA and could bring to light important lead points 
for treatment of JIA. Clinical and genetic factors that are associated with the course 
of disease or the response to treatment could act as predictive parameters, alone or 
combined in a predictive model.
26 Chapter 1
references
 (1)  Hofer M, Southwood TR. Classification of childhood arthritis. Best Pract Res Clin Rheumatol 
2002; 16(3):379-396.
 (2)  Prieur AM. What’s in a name? Nomenclature of juvenile arthritis. A European view. J Rheu-
matol Suppl 1993; 40:9-11.
 (3)  Cassidy JT. What’s in a name? Nomenclature of juvenile arthritis. A North American view. J 
Rheumatol Suppl 1993; 40:4-8.
 (4)  Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of 
childhood. J Rheumatol 1995; 22(8):1566-1569.
 (5)  Petty RE. Classification of childhood arthritis: a work in progress. Baillieres Clin Rheumatol 
1998; 12(2):181-190.
 (6)  Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International 
League of Associations for Rheumatology classification of juvenile idiopathic arthritis: 
second revision, Edmonton, 2001. J Rheumatol 2004; 31(2):390-392.
 (7)  Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012; 12(1):56-59.
 (8)  van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B et al. 
Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic 
arthritis. J Rheumatol 2003; 30(4):825-828.
 (9)  Stoll ML, Nigrovic PA. Subpopulations within juvenile psoriatic arthritis: a review of the 
literature. Clin Dev Immunol 2006; 13(2-4):377-380.
 (10)  Berntson L, Damgard M, Andersson-Gare B, Herlin T, Nielsen S, Nordal E et al. HLA-B27 pre-
dicts a more extended disease with increasing age at onset in boys with juvenile idiopathic 
arthritis. J Rheumatol 2008; 35(10):2055-2061.
 (11)  Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. 
Ann Rheum Dis 2012; 71(9):1437-1439.
 (12)  Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E et al. Patients with anti-
nuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup 
irrespective of the course of joint disease. Arthritis Rheum 2005; 52(3):826-832.
 (13)  Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A et al. Antinuclear 
antibody-positive patients should be grouped as a separate category in the classification 
of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63(1):267-275.
 (14)  Nordal E, Songstad NT, Rygg M. Difficulties in defining antinuclear antibody-positive pa-
tients as a separate category in the classification of juvenile idiopathic arthritis: comment 
on the article by Ravelli et al. Arthritis Rheum 2011; 63(9):2835-2836.
 (15)  Butbul YA, Tyrrell PN, Schneider R, Dhillon S, Feldman BM, Laxer RM et al. Comparison of 
patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how 
different are they? J Rheumatol 2009; 36(9):2033-2041.
General introduction 27
 (16)  Merino R, de IJ, Garcia-Consuegra J. Evaluation of revised International League of Asso-
ciations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish 
children (Edmonton 2001). J Rheumatol 2005; 32(3):559-561.
 (17)  Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic 
arthritis. Autoimmun Rev 2010; 9(5):A319-A324.
 (18)  Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? 
J Rheumatol 2002; 29(7):1520-1530.
 (19)  Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R et al. Epidemiology 
of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis 
Rheum 2007; 56(6):1974-1984.
 (20)  Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, Garrone M et al. Seeking insights 
into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multina-
tional collaborative effort: Introduction of the EPOCA study. Pediatr Rheumatol Online J 
2012; 10(1):39.
 (21)  Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select 
categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31(11):2290-2294.
 (22)  Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology 
provisional criteria for defining clinical inactive disease in select categories of juvenile 
idiopathic arthritis. Arthritis Care Res (Hoboken ) 2011; 63(7):929-936.
 (23)  Shenoi S, Wallace CA. Remission in juvenile idiopathic arthritis: current facts. Curr Rheuma-
tol Rep 2010; 12(2):80-86.
 (24)  Lurati A, Salmaso A, Gerloni V, Gattinara M, Fantini F. Accuracy of Wallace criteria for clinical 
remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheu-
matol 2009; 36(7):1532-1535.
 (25)  Fernandes TA, Corrente JE, Magalhaes CS. Remission status follow-up in children with 
juvenile idiopathic arthritis. J Pediatr (Rio J ) 2007; 83(2):141-148.
 (26)  Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory 
arthritis: I. frequency of different outcomes. Rheumatology (Oxford) 2005; 44(8):995-1001.
 (27)  Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T et al. Ongoing disease activity and 
changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. 
Arthritis Rheum 2011; 63(9):2809-2818.
 (28)  Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular juvenile 
idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009; 
48(8):972-977.
 (29)  Bertilsson L, Andersson-Gare B, Fasth A, Petersson IF, Forsblad-D’elia H. Disease course, 
outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort 
followed for 17 years. J Rheumatol 2013; 40(5):715-724.
 (30)  Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in 
select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52(11):3554-3562.
28 Chapter 1
 (31)  Prelog M, Schwarzenbrunner N, Tengg E, Sailer-Hock M, Kern H, Zimmerhackl LB et al. Quan-
titative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission. Clin 
Rheumatol 2009; 28(4):385-389.
 (32)  Knowlton N, Jiang K, Frank MB, Aggarwal A, Wallace C, McKee R et al. The meaning of 
clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling 
in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 
2009; 60(3):892-900.
 (33)  Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M et al. Phagocyte-specific 
S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted 
treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann 
Rheum Dis 2012; 71(12):1991-1997.
 (34)  Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am 
Med Assoc 1949; 140(8):659-662.
 (35)  van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. 
J Rheumatol 2000; 27(1):261-263.
 (36)  Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM. Carpal length in children--a 
useful measurement in the diagnosis of rheumatoid arthritis and some concenital malfor-
mation syndromes. Radiology 1978; 129(3):661-668.
 (37)  van Rossum MA, Zwinderman AH, Boers M, Dijkmans BA, van Soesbergen RM, Fiselier TJ et 
al. Radiologic features in juvenile idiopathic arthritis: a first step in the development of a 
standardized assessment method. Arthritis Rheum 2003; 48(2):507-515.
 (38)  van Rossum MA, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ et 
al. Development of a standardized method of assessment of radiographs and radiographic 
change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthri-
tis Rheum 2005; 52(9):2865-2872.
 (39)  Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N et al. Develop-
ment and validation of a clinical index for assessment of long-term damage in juvenile 
idiopathic arthritis. Arthritis Rheum 2005; 52(7):2092-2102.
 (40)  Hemke R, van Rossum MA, van Veenendaal M, Terra MP, Deurloo EE, de Jonge MC et al. 
Reliability and responsiveness of the Juvenile Arthritis MRI Scoring (JAMRIS) system for the 
knee. Eur Radiol 2013; 23(4):1075-1083.
 (41)  Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N et al. Assessing current 
outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. 
Arthritis Rheum 2008; 59(11):1571-1579.
 (42)  Susic GZ, Stojanovic RM, Pejnovic NN, Damjanov NS, Soldatovic II, Jablanovic DB et al. Anal-
ysis of disease activity, functional disability and articular damage in patients with juvenile 
idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol 2011; 29(2):337-344.
 (43)  Bertilsson L, Andersson-Gare B, Fasth A, Forsblad-D’elia H. A 5-year prospective population-
based study of juvenile chronic arthritis: onset, disease process, and outcome. Scand J 
Rheumatol 2012; 41(5):379-382.
General introduction 29
 (44)  Lipinska J, Brozik H, Stanczyk J, Smolewska E. Anticitrullinated protein antibodies and ra-
diological progression in juvenile idiopathic arthritis. J Rheumatol 2012; 39(5):1078-1087.
 (45)  Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM et al. Radiologic outcome 
and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol 
2003; 30(4):832-840.
 (46)  Kotaniemi K, Savolainen A, Karma A, Aho K. Recent advances in uveitis of juvenile idiopathic 
arthritis. Surv Ophthalmol 2003; 48(5):489-502.
 (47)  Rosenberg AM. Uveitis associated with childhood rheumatic diseases. Curr Opin Rheumatol 
2002; 14(5):542-547.
 (48)  Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr 
Opin Ophthalmol 2003; 14(6):395-398.
 (49)  Twilt M, Swart vd Berg M, van Meurs JC, ten Cate R, van Suijlekom-Smit LW. Persisting uveitis 
antedating psoriasis in two boys. Eur J Pediatr 2003; 162(9):607-609.
 (50)  American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology: 
Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. 
Pediatrics 1993; 92(2):295-296.
 (51)  Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with 
juvenile rheumatoid arthritis. Pediatrics 2006; 117(5):1843-1845.
 (52)  Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. Prevalence and complications of 
uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: 
suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007; 
46(6):1015-1019.
 (53)  Cabral DA, Petty RE, Malleson PN, Ensworth S, McCormick AQ, Shroeder ML. Visual prognosis 
in children with chronic anterior uveitis and arthritis. J Rheumatol 1994; 21(12):2370-2375.
 (54)  de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 
87(7):879-884.
 (55)  Chia A, Lee V, Graham EM, Edelsten C. Factors related to severe uveitis at diagnosis in 
children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol 2003; 
135(6):757-762.
 (56)  Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T et al. Evidence-
based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated 
with juvenile idiopathic arthritis. Rheumatol Int 2012; 32(5):1121-1133.
 (57)  Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R et al. Abatacept for severe anti-
tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis 
Care Res (Hoboken ) 2010; 62(6):821-825.
 (58)  Lindsley CB. Pharmacotherapy of juvenile rheumatoid arthritis. Pediatr Clin North Am 1981; 
28(1):161-177.
30 Chapter 1
 (59)  Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM et al. 2011 
American College of Rheumatology recommendations for the treatment of juvenile idio-
pathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of 
arthritis and systemic features. Arthritis Care Res (Hoboken ) 2011; 63(4):465-482.
 (60)  Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y et al. 2013 update of the 
2011 American College of Rheumatology recommendations for the treatment of juvenile 
idiopathic arthritis: recommendations for the medical therapy of children with systemic 
juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic 
medications. Arthritis Care Res (Hoboken ) 2013; 65(10):1551-1563.
 (61)  de Oliveira SJ, Albuquerque Pedrosa FT, Bicalho do NC, Corrente JE, Saad MC. Probability 
of remission of juvenile idiopathic arthritis following treatment with steroid joint injection. 
Clin Exp Rheumatol 2013.
 (62)  Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. In-
creased adenosine release at inflamed sites diminishes leukocyte accumulation in an in 
vivo model of inflammation. J Clin Invest 1993; 92(6):2675-2682.
 (63)  Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions 
of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008; 
47(3):249-255.
 (64)  Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I et al. Methotrex-
ate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, 
placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The 
Cooperative Children’s Study Group. N Engl J Med 1992; 326(16):1043-1049.
 (65)  Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J et al. Randomized, placebo-
controlled, crossover trial of low-dose oral methotrexate in children with extended oligo-
articular or systemic arthritis. Arthritis Rheum 2000; 43(8):1849-1857.
 (66)  Pohjankoski H, Latva K, Kautiainen H, Saila H, Klaukka T, Virta L et al. First-year purchases of 
disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland. Clin 
Exp Rheumatol 2011; 29(5):878-881.
 (67)  Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF et al. Disease-modifying 
antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional 
analysis of the CARRA Registry. J Rheumatol 2012; 39(9):1867-1874.
 (68)  Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J et al. Methotrexate 
withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized 
clinical trial. JAMA 2010; 303(13):1266-1273.
 (69)  Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ et al. Etanercept 
in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Col-
laborative Study Group. N Engl J Med 2000; 342(11):763-769.
 (70)  Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G. A combination of etaner-
cept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot 
study. Ann Rheum Dis 2001; 60(4):410-412.
General introduction 31
 (71)  Haapasaari J, Kautiainen H, Hannula S, Pohjankoski H, Hakala M. Good results from combin-
ing etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin 
Exp Rheumatol 2002; 20(6):867-870.
 (72)  Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D et al. Safety and 
efficacy of combination of etanercept and methotrexate compared to treatment with 
etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from 
the German JIA Registry. Ann Rheum Dis 2009; 68(4):519-525.
 (73)  Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG et al. Ef-
ficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic 
arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER 
study. Ann Rheum Dis 2013.
 (74)  Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF et al. Tumour necrosis 
factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results 
from the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford) 2013; 
52(4):712-717.
 (75)  Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC et al. Long-term efficacy and 
safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: 
interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis 
Rheum 2003; 48(1):218-226.
 (76)  Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ et al. The Ger-
man etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 
63(12):1638-1644.
 (77)  Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD et al. Long-term safety and 
efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. 
Arthritis Rheum 2006; 54(6):1987-1994.
 (78)  Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL et al. Safety and efficacy of up to 
eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. 
Arthritis Rheum 2008; 58(5):1496-1504.
 (79)  Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP et al. Long-term 
follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the 
Dutch national register. Ann Rheum Dis 2009; 68(5):635-641.
 (80)  Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A et al. Long-term safety 
and effectiveness of etanercept in children with selected categories of juvenile idiopathic 
arthritis. Arthritis Rheum 2009; 60(9):2794-2804.
 (81)  Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR et al. Duration 
of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic 
arthritis patients. Rheumatology (Oxford) 2011; 50(1):189-195.
 (82)  Zuber Z, Rutkowska-Sak L, Postepski J, Dobrzyniecka B, Opoka-Winiarska V, Kobusinska K 
et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit 
2011; 17(12):SR35-SR42.
32 Chapter 1
 (83)  Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M et al. Factors associ-
ated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011; 
306(21):2340-2347.
 (84)  Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A et al. Factors as-
sociated with achievement of inactive disease in children with juvenile idiopathic arthritis 
treated with etanercept. J Rheumatol 2013; 40(2):192-200.
 (85)  Baszis K, Garbutt J, Toib D, Mao J, King A, White A et al. Clinical outcomes after withdrawal 
of anti-tumor necrosis factor alpha therapy in patients with juvenile idiopathic arthritis: a 
twelve-year experience. Arthritis Rheum 2011; 63(10):3163-3168.
 (86)  Postepski J, Kobusinska K, Olesinska E, Osinska V, Opoka-Winiarska V. Clinical remission 
in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int 2013; 
33(10):2657-2660.
 (87)  Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM et al. Treat-
ment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or 
adalimumab? Rheumatology (Oxford) 2013; 52(9):1674-1679.
 (88)  Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab 
in the management of juvenile idiopathic arthritis. J Rheumatol 2013; 40(10):1749-1755.
 (89)  Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifi-
ers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis 
Rheum 2013; 42(6):597-618.
 (90)  Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA et al. Abatacept in children 
with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled with-
drawal trial. Lancet 2008; 372(9636):383-391.
 (91)  Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA et al. Long-term safety and 
efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 
62(6):1792-1802.
 (92)  Brunner H, Ruperto N, Zuber Z, Cuttica RJ, Xavier R, Calvo I et al. A4: Efficacy and Safety of 
Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data 
From CHERISH. Arthritis Rheumatol 2014; 66 Suppl 11:S5-S6.
 (93)  Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K et al. Childhood arthritis and 
rheumatology research alliance consensus treatment plans for new onset polyarticular 
juvenile idiopathic arthritis. Arthritis Care Res (Hoboken ) 2014 Jul;66(7):1063-72
 (94)  Tynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M et al. Aggressive combination 
drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multi-
centre randomised open-label clinical trial. Ann Rheum Dis 2011; 70(9):1605-1612.
 (95)  Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS et al. Trial of early 
aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 
64(6):2012-2021.
General introduction 33
 (96)  Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treat-
ment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheuma-
tologists in the United States and Canada. J Rheumatol 2007; 34(9):1918-1924.
 (97)  Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V et al. Prognostic factors in juvenile 
rheumatoid arthritis: a case-control study revealing early predictors and outcome after 
14.9 years. J Rheumatol 2003; 30(2):386-393.
 (98)  Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp 
Rheumatol 2003; 21(5 Suppl 31):S89-S93.
 (99)  Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflamma-
tory arthritis: II. predictors of outcome in juvenile arthritis. Rheumatology (Oxford) 2005; 
44(8):1002-1007.
 (100)  Selvaag AM, Lien G, Sorskaar D, Vinje O, Forre O, Flato B. Early disease course and predictors 
of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year 
prospective study. J Rheumatol 2005; 32(6):1122-1130.
 (101)  Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S et al. Predictors of early 
inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, 
prospective inception cohort study. Arthritis Rheum 2009; 61(8):1077-1086.
 (102)  Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best 
Pract Res Clin Rheumatol 2009; 23(5):599-608.
 (103)  Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011; 377(9783):2138-
2149.
 (104)  Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular 
vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011; 10(8):482-489.
 (105)  Kamphuis S, Hrafnkelsdottir K, Klein MR, de Jager W, Haverkamp MH, van Bilsen JH et al. 
Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive 
distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health. Arthritis 
Res Ther 2006; 8(6):R178.
 (106)  de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M et al. CD4+CD25bright 
regulatory T cells actively regulate inflammation in the joints of patients with the remitting 
form of juvenile idiopathic arthritis. J Immunol 2004; 172(10):6435-6443.
 (107)  Kamphuis S, Kuis W, de Jager W, Teklenburg G, Massa M, Gordon G et al. Tolerogenic im-
mune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic 
arthritis. Lancet 2005; 366(9479):50-56.
 (108)  Mijnheer G, Prakken BJ, van Wijk F. The effect of autoimmune arthritis treatment strategies 
on regulatory T-cell dynamics. Curr Opin Rheumatol 2013; 25(2):260-267.
 (109)  Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-
producing T cells are enriched in the joints of children with arthritis, but have a reciprocal 
relationship to regulatory T cell numbers. Arthritis Rheum 2008; 58(3):875-887.
34 Chapter 1
 (110)  Hemdan NY, Birkenmeier G, Wichmann G, Abu El-Saad AM, Krieger T, Conrad K et al. 
Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010; 9(11):785-
792.
 (111)  Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocili-
zumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Im-
munol 2005; 28(3):231-238.
 (112)  Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S et al. Efficacy and safety of tocili-
zumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-
blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371(9617):998-1006.
 (113)  Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C et al. A multicentre, randomised, 
double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra 
in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 
2011; 70(5):747-754.
 (114)  Glass DN, Giannini EH. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis 
Rheum 1999; 42(11):2261-2268.
 (115)  Baum J, Fink C. Juvenile rheumatoid arthritis in monozygotic twins: a case report and review 
of the literature. Arthritis Rheum 1968; 11(1):33-36.
 (116)  Moroldo MB, Tague BL, Shear ES, Glass DN, Giannini EH. Juvenile rheumatoid arthritis in 
affected sibpairs. Arthritis Rheum 1997; 40(11):1962-1966.
 (117)  Prahalad S, Ryan MH, Shear ES, Thompson SD, Glass DN, Giannini EH. Twins concordant for 
juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43(11):2611-2612.
 (118)  Savolainen A, Saila H, Kotaniemi K, Kaipianen-Seppanen O, Leirisalo-Repo M, Aho K. 
Magnitude of the genetic component in juvenile idiopathic arthritis. Ann Rheum Dis 2000; 
59(12):1001.
 (119)  Saila H, Savolainen A, Tuomilehto-Wolf E, Tuomilehto J, Leirisalo-Repo M. Type of onset 
of juvenile idiopathic arthritis in monozygotic twins can be phenotypically different. J 
Rheumatol 2000; 27(9):2289-2290.
 (120)  Moroldo MB, Chaudhari M, Shear E, Thompson SD, Glass DN, Giannini EH. Juvenile rheuma-
toid arthritis affected sibpairs: extent of clinical phenotype concordance. Arthritis Rheum 
2004; 50(6):1928-1934.
 (121)  Saila HM, Savolainen HA, Kotaniemi KM, Kaipiainen-Seppanen OA, Leirisalo-Repo MT, Aho 
KV. Juvenile idiopathic arthritis in multicase families. Clin Exp Rheumatol 2001; 19(2):218-
220.
 (122)  Prahalad S, Zeft AS, Pimentel R, Clifford B, McNally B, Mineau GP et al. Quantification of 
the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum 2010; 62(8):2525-
2529.
 (123)  Graham TB, Glass DN. Juvenile rheumatoid arthritis: ethnic differences in diagnostic types. 
J Rheumatol 1997; 24(9):1677-1679.
General introduction 35
 (124)  Schwartz MM, Simpson P, Kerr KL, Jarvis JN. Juvenile rheumatoid arthritis in African Ameri-
cans. J Rheumatol 1997; 24(9):1826-1829.
 (125)  Oen K. Comparative epidemiology of the rheumatic diseases in children. Curr Opin Rheu-
matol 2000; 12(5):410-414.
 (126)  Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis 
with autoimmune diseases and related conditions. Arthritis Rheum 2009; 60(3):661-668.
 (127)  Cardenas-Roldan J, Rojas-Villarraga A, Anaya JM. How do autoimmune diseases cluster in 
families? A systematic review and meta-analysis. BMC Med 2013; Mar 18;11:73.
 (128)  Pachman LM, Hayford JR, Hochberg MC, Pallansch MA, Chung A, Daugherty CD et al. New-
onset juvenile dermatomyositis: comparisons with a healthy cohort and children with 
juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40(8):1526-1533.
 (129)  Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial 
autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis 
Rheum 2002; 46(7):1851-1856.
 (130)  Huang CM, Yang YH, Chiang BL. Different familial association patterns of autoimmune 
diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid 
arthritis. J Microbiol Immunol Infect 2004; 37(2):88-94.
 (131)  Pohjankoski H, Kautiainen H, Kotaniemi K, Korppi M, Savolainen A. Diabetes, coeliac 
disease, multiple sclerosis and chronic arthritis in first-degree relatives of patients with 
juvenile idiopathic arthritis. Acta Paediatr 2012; 101(7):767-771.
 (132)  Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366(9491):1121-1131.
 (133)  Naidoo N, Pawitan Y, Soong R, Cooper DN, Ku CS. Human genetics and genomics a de-
cade after the release of the draft sequence of the human genome. Hum Genomics 2011; 
5(6):577-622.
 (134)  Forre O, Dobloug JH, Hoyeraal HM, Thorsby E. HLA antigens in juvenile arthritis. Genetic 
basis for the different subtypes. Arthritis Rheum 1983; 26(1):35-38.
 (135)  Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WE et al. Juvenile idiopathic 
arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 
(Oxford) 2002; 41(10):1183-1189.
 (136)  Hollenbach JA, Thompson SD, Bugawan TL, Ryan M, Sudman M, Marion M et al. Juvenile id-
iopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis 
Rheum 2010; 62(6):1781-1791.
 (137)  Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J et al. Dense genotyping of 
immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic 
arthritis. Nat Genet 2013; 45(6):664-669.
 (138)  Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthri-
tis. Pediatr Rheumatol Online J 2008 Jul 21;6:11
36 Chapter 1
 (139)  Angeles-Han S, Prahalad S. The genetics of juvenile idiopathic arthritis: what is new in 
2010? Curr Rheumatol Rep 2010; 12(2):87-93.
 (140)  Hinks A, Barton A, Shephard N, Eyre S, Bowes J, Cargill M et al. Identification of a novel 
susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. 
Arthritis Rheum 2009; 60(1):258-263.
 (141)  Thompson SD, Marion MC, Sudman M, Ryan M, Tsoras M, Howard TD et al. Genome-wide 
association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at 
chromosomal region 3q13. Arthritis Rheum 2012; 64(8):2781-2791.
 (142)  Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P et al. Autoimmune-associated 
lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37(12):1317-
1319.
 (143)  Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al. A functional 
variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 
2004; 36(4):337-338.
 (144)  Vang T, Liu WH, Delacroix L, Wu S, Vasile S, Dahl R et al. LYP inhibits T-cell activation when 
dissociated from CSK. Nat Chem Biol 2012; 8(5):437-446.
 (145)  Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC et al. A 
missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phospha-
tase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75(2):330-
337.
 (146)  Viken MK, Amundsen SS, Kvien TK, Boberg KM, Gilboe IM, Lilleby V et al. Association analy-
sis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and 
other autoimmune diseases. Genes Immun 2005; 6(3):271-273.
 (147)  Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE et al. Association between the 
PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: 
further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005; 52(6):1694-
1699.
 (148)  Ellis JA, Chavez RA, Pezic A, Ponsonby AL, Akikusa JD, Allen RC et al. Independent replica-
tion analysis of genetic loci with previous evidence of association with juvenile idiopathic 
arthritis. Pediatr Rheumatol Online J 2013; 11(1):12.
 (149)  Kaalla MJ, Broadaway KA, Rohani-Pichavant M, Conneely KN, Whiting A, Ponder L et al. 
Meta-analysis confirms association between TNFA-G238A variant and JIA, and between 
PTPN22-C1858T variant and oligoarticular, RF-polyarticular and RF-positive polyarticular 
JIA. Pediatr Rheumatol Online J 2013; 11(1):40.
 (150)  Dimopoulou DG, Zervou MI, Trachana M, Myrthianou E, Pratsidou-Gertsi P, Kardassis D et 
al. Investigation of juvenile idiopathic arthritis susceptibility loci: results from a Greek 
population. Hum Immunol 2013; 74(9):1194-1198.
 (151)  Fousteri G, Liossis SN, Battaglia M. Roles of the protein tyrosine phosphatase PTPN22 in 
immunity and autoimmunity. Clin Immunol 2013; 149(3):556-565.
General introduction 37
 (152)  Bottini N, Peterson EJ. Tyrosine Phosphatase PTPN22: Multifunctional Regulator of Immune 
Signaling, Development, and Disease. Annu Rev Immunol 2014; 32:83-119.
 (153)  Du J, Qiao Y, Sun L, Wang X. Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug 
target for treatment of autoimmune diseases. Curr Drug Targets 2014; 15(3):335-346.
 (154)  Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the 
shared genetics of immune-related diseases. Nat Rev Genet 2009; 10(1):43-55.
 (155)  Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H et al. System-








The TRAF1/C5 reGion 
is a risk facTor for 
PolyarThriTis in 
JuvenIle IDIoPAThIC ArThrITIs 
Annals of the Rheumatic Diseases 2008 Nov;67(11):1578-80
H.M. Albers *1, F.A.S. Kurreeman*1, J.J. Houwing- Duistermaat1, 
D.M.C. Brinkman1, S.S.M. Kamphuis2, H.J. Girschick3, C. Wouters4, 
M.A.J. van Rossum5, W. Verduyn1 , R.E.M. Toes1, T.W.J. Huizinga1, 
M.W. Schilham1, R. ten Cate1.
*) contributed equally 
1) Leiden University Medical Center, Leiden, the Netherlands
2) Erasmus Medical Center- Sophia Children’s Hospital, Rotterdam, the Netherlands
3) University of Wuerzburg, Wuerzburg, Germany
4) University Hospital Gasthuisberg, Leuven, Belgium
5) Academic Medical Center- Emma Children’s Hospital and Reade, location Jan van 




Juvenile Idiopathic Arthritis (JIA) is a chronic disorder in which both genetic and envi-
ronmental factors are involved. Recently we identified the TRAF1/C5 region (located 
on chromosome 9q33-34) as a risk factor for Rheumatoid Arthritis (RA) (pcombined= 1.4 x 
10-8). In the present study the association of the TRAF1/C5 region with the susceptibil-
ity to JIA was investigated.
Methods
A case-control association study was performed in 338 Caucasian JIA patients and 
511 healthy individuals. We genotyped SNP rs10818488 as a marker for the TRAF1/
C5 region.
results
The A-allele was associated with the susceptibility to Rheumatoid Factor (RF) negative 
polyarthritis with an 11% increase in allele frequency (OR 1.54, 95% CI 1.09- 2.18; p= 
0.012).  This association was stronger when combining subtypes with a polyarticular 
phenotype (OR 1.46, 95% CI 1.12- 1.90; p= 0.004). In addition, we observed a trend to-
wards an increase in A-allele frequency in patients with extended oligoarthritis versus 
persistent oligoarthritis (49%, 38% respectively); p=0.055. 
conclusion
Apart from being a well replicated risk factor for RA, TRAF1/C5 also appears to be a risk 
factor for the RF negative polyarthritis subtype of JIA and, more generally, seems to be 
associated with subtypes of JIA characterized by a polyarticular course. 
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inTroducTion
Juvenile Idiopathic Arthritis (JIA) is defined as arthritis of unknown etiology that 
persists for at least 6 weeks and begins before the age of 16 years. It is the most com-
mon chronic inflammatory rheumatic disease in childhood.1 In 1997 the International 
League of Associations for Rheumatology (ILAR) formulated criteria for the classifica-
tion of 7 different subtypes of JIA based on clinical and laboratory features.2,3 
Although the pathogenesis and etiology are still poorly understood, JIA is thought to 
be an autoimmune disease in which genetic and environmental factors play a role. 
Evidence for the importance of a genetic component includes the ethnic variability 
in the incidence of different subtypes of JIA, a female preponderance, an increased 
sibling recurrence rate (λs) of 15 and the association with HLA- and non-HLA genes 
(like PTPN22).3-5 Still little is known about which genetic factors are involved in the 
susceptibility to JIA and the severity of JIA. Identification of these genetic factors 
could help to understand the pathogenesis of JIA and could be of use to identify 
patients with an unfavorable prognosis in an early stage. 
Recently we identified the TRAF1/C5 region (located on chromosome 9q33-34) as 
a genetic risk factor for RA, using a candidate gene approach.6 A similar finding was 
made in a genome-wide study in RA.7 TRAF1 is encoding the TNF-receptor-associated 
factor 1 and C5 is encoding the complement component 5. Inspired by these results 
we have studied whether variability in the TRAF1/C5 region also affects the suscep-
tibility to JIA. 
MaTerials and MeThods
A case-control association study was performed in 338 Caucasian JIA patients from 
pediatric rheumatology centers in the Netherlands (54%), Belgium (24%) and Ger-
many (22%). Genotype frequencies of 511 healthy unrelated Dutch adult controls 
were available out of the 524 controls previously described by Kurreeman et al. due to 
random genotyping failure.6 All JIA patients (72% female, 28% male) were diagnosed 
according to the revised ILAR criteria.2 The inclusion of patients focused on persistent 
(39%) and extended (14%) oligoarthritis and RF-negative (22%) and RF-positive (5%) 
polyarthritis because of their relative homogeneous phenotypes. Patients included 
had a follow-up of at least two years. Informed consent from all patients and/or parents 
and approval from each institutional review board were obtained. DNA was isolated 
from blood samples (20%) or mouthswabs (80%).
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One tagging SNP (rs10818488) was genotyped as it revealed the strongest as-
sociation in RA and none of the other tagging SNPs in the 65kb block provided 
additional information.[6] Rs10818488 is highly linked with rs3761847 (r2= 1, data 
from HAPMAP) and rs2900180 (r2= 0.66), which were associated with RA as well.7 
Rs10818488 was genotyped using a PCR-RFLP method as described.6 Each 96-wells 
plate contained 2 positive and 2 negative controls. 8% of the samples were run in 
duplicate and we observed a concordance rate > 98%. 
Differences in genotype frequencies between cases and controls were assessed 
using the Cochran-Armitage Trend test. Allelic odds ratios (OR) with 95% confidence 
interval (CI) as well as the genotype-specific odds ratios were computed. Case and 
control genotype frequencies were in Hardy –Weinberg-equilibrium. Statistical 
analysis was performed with SPSS 14.0. A p-value of <0.05 was considered statisti-
cally significant.
resulTs
JIA is a heterogeneous disease consisting of several subtypes. As it is best to inves-
tigate genetic risk factors in well-defined phenotypic groups, we have analyzed the 
genotypes of the rs10818488 SNP in the different subtypes of JIA as well as in the 
overall group of JIA-patients as shown in Table 1. 
Frequencies in patients with persistent oligoarthritis, systemic JIA and in the overall 
JIA patient-group did not differ from those in controls. In extended oligoarthritis and 
RF positive polyarthritis (the equivalent of RA) a trend towards an increased A-allele 
frequency was observed (49%, 50% resp. vs 41% in controls). However, although 
we do observe an 8-9% increase in the A allele, we possess limited power to detect 
significant differences.  In RF negative polyarthritis patients we found a significant 
increase in the A-allele by 11% (Allelic OR 1.54, 95% CI 1.09- 2.18) when compared 
to controls. Homozygotes for the susceptibility allele (AA) had an OR of 2.51 (95% 
CI 1.23- 5.14) compared to the homozygotes of the protective allele (GG), whereas 
heterozygotes had an OR of 1.50 (95% CI 0.81- 2.77). Gender was not a significant 
covariate when performing a regression analysis (p=0.124). 
Since extended oligoarthritis, RF negative polyarthritis and RF positive polyarthritis 
have a considerable phenotypic overlap and share a polyarticular course of dis-
ease, we also analyzed these subtypes grouped together to determine whether the 
TRAF1/C5 region predisposes to a polyarticular disease course. The A-allele was 
significantly increased in this combined group (51% in cases, 41% in controls), with 
























































































































































































































































































































































































































































































































































1.29- 3.90) and a p-value (Cochran-Armitage Trend test) of 0.004 which remains 
significant after bonferonni correction (p<0.013). 
Since persistent and extended oligoarthritis are clinically similar at disease onset, 
but differ in their course and outcome, we tested the hypothesis that these two 
subtypes would also differ in their genetic predisposition. Intriguingly, we detected 
a borderline significant difference between these two subtypes when compared 
directly to each other (Allelic OR 1.57, 95% CI 0.98- 2.51; p=0.055). 
Together, these data indicate that the A-allele predisposes predominantly to sub-
types of JIA characterized by a polyarticular course, indicating that this allele does 
not associate with JIA as such, but rather with a particular phenotype of JIA.  
discussion
In this study we report for the first time an association between the TRAF1/C5 region 
and JIA. The A-allele of rs10818488 was significantly associated with the susceptibility 
to RF negative polyarthritis. However, patients with RF negative polyarthritis have a 
considerable phenotypic overlap with patients with extended oligoarthritis and RF posi-
tive polyarthritis, in having a polyarticular course of disease. Intriguingly, rs10818488 
seems to be associated with this polyarticular phenotype and this difference remained 
significant after bonferroni correction for multiple tests (p<0.013).  
Although we cannot formally exclude the possibility that population- stratification 
may play a role in this study, we did not observe any statistically significant differ-
ences in the minor allele frequencies of the patients from the Netherlands, Belgium 
and Germany.  Additionally, analyzing the Dutch population independently did not 
alter the results (e.g. RF negative polyarthritis vs controls: Allelic OR 1.66 (95% CI 
1.10- 2.51), genotypic OR (AA vs GG) 3.05 (95% CI 1.25- 7.44).
At the clinical level, it is also important to make a distinction between persistent 
oligoarthritis and extended oligoarthritis in order to predict the probability of the 
development of a polyarticular disease course and adjust the medical treatment 
accordingly. Comparison of patients with persistent and extended oligoarthritis 
revealed a borderline significant difference in A-allele frequency. This may indicate 
that the TRAF1/C5 region may eventually be helpful in predicting the development 
of an extended course in patients with oligoarthritis. Extended studies of this poly-
morphism may confirm its relevance as a predictive marker.
It is presently unclear how the association between the TRAF1/C5 region and disease 
susceptibility can be explained biologically. The associated polymorphism is highly 
linked to the TRAF1 gene as well as the 3’ untranslated region of the C5 gene. Acti-
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vated complement-component-5 acts as a strong chemoattractant for neutrophils, 
and a deregulated activity may contribute to the perpetuation of inflammation. In 
JIA, complement activation is occasionally observed, especially in active polyarthri-
tis.8 On the other hand, TNF-receptor-associated factor-1 (TRAF-1) plays an essential 
role in the intracellular TNF-signaling pathway and is possibly a negative regulator 
of TNF-signalling.9 Evidence for the importance of TNF in JIA is suggested by the 
effectiveness of treatment directed against TNF-alpha, especially in subtypes with a 
polyarticular course.10 However, future research will be necessary to confirm the ge-
netic association and investigate functional consequences of the associated allele 
and could reveal further insight in the pathogenesis of polyarticular disease in JIA.
Apart from being a well replicated risk factor for RA, TRAF1/C5 also appears to be a 
risk factor for the RF negative polyarthritis subtype of JIA and, more generally, seems 
to be associated with subtypes of JIA characterized by a polyarticular course.
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Juvenile Idiopathic Arthritis (JIA) is characterized by chronic arthritis and an autoim-
mune etiology. In several autoimmune diseases, amongst which rheumatoid arthritis, 
an association has been found with the 4q27 locus. In this study the possible role of 
the 4q27 locus in JIA has been investigated.
Materials & Methods
A case-control association study was performed in a total of 655 Caucasian JIA patients 
and 791 healthy controls in two independent sample sets.  The rs6822844 marker in 
the 4q27 locus was genotyped.
results
In the first and largest sample set a 5% decrease in T-allele frequency was observed in 
patients compared to controls (allelic OR 0.72, 95% CI 0.55- 0.95; p= 0.019), together 
with a decrease of 2.5% in T-allele frequency in the second sample set (allelic OR 0.81, 
95% CI 0.61- 1.09; p=0.169). The combined dataset generated an OR of 0.76 (95%CI 
0.62- 0.93; p= 7.08*10-3). When analyzing the different JIA subtypes individually, a 
significant decrease was seen in the subtypes with a polyarticular course of disease 
(extended oligoarthritis; p= 0,019 and RF negative polyarthritis; p=0,038). 
conclusion
The 4q27 locus, previously reported to be associated with rheumatoid arthritis, type 1 




Juvenile Idiopathic Arthritis (JIA) is a group of heterogeneous disorders characterized 
by chronic arthritis diagnosed in children less than 16 years of age.1 Seven different 
subtypes can be distinguished according to the ILAR classification.2 The subtypes oli-
goarthritis (persistent and extended) and rheumatoid factor (RF) negative polyarthritis 
are considered the most homogeneous subtypes with shared phenotypic features. Sys-
temic JIA has a more distinct phenotype resembling an autoinflammatory syndrome. 
Although the precise etiology is still unknown, JIA is considered to be an autoimmune 
disease.
Genetic studies in autoimmune diseases have revealed the presence of shared 
common autoimmune susceptibility loci.3 In JIA, associations have been described 
with the MHC locus, PTPN22 and TRAF1/C5.4-6 The 4q27 locus, a region of strong 
linkage disequilibrium (LD) including the genes encoding interleukin 2 (IL2) and 
interleukin 21 (IL21), has been associated with celiac disease, rheumatoid arthritis, 
type 1 diabetes and psoriatic arthritis.7-9 To answer the question whether the 4q27 
locus is also associated with JIA we genotyped  rs6822844, which can be used as 
a proxy for the 4q27 haplotype that is associated with autoimmune disease,8 in JIA 
patients and controls. 
MaTerial & MeThods
Patient population
A case-control association study was performed in two independent sample sets 
consecutively. These sample sets consisted of Caucasian JIA patients, recruited from 
pediatric rheumatology centers in the Netherlands (n=327), Belgium (n= 96), Germany 
(n=95) and Switzerland (n=137) and healthy Dutch adult controls, who were randomly 
selected by the section Immunogenetics and transplantation Immunology of the 
Leiden University Medical Center, the Netherlands. The first sample set contained 328 
JIA patients and 465 healthy controls, and the second sample set consisted of 327 JIA 
patients and 326 controls. All JIA patients (69% female, 31% male) were diagnosed 
according to the revised ILAR classification.2 The inclusion of patients focused on the 
oligoarthritis (persistent and extended) and rheumatoid factor (RF) negative polyar-
thritis subtypes, because of their homogeneous phenotypes. The overall JIA patient 
group included 44% persistent oligoarthritis, 13% extended oligoarthritis, 24% RF 
negative polyarthritis, 3% RF positive polyarthritis, 11% systemic JIA patients and 5% 
patients with other JIA subtypes. Because of the small sample size in the RF positive 
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polyarthritis patients and JIA patients with “other” subtypes, these groups were ex-
cluded from further subanalysis. All patients had a self-reported European Caucasian 
ethnicity. Written informed consent was obtained from all patients and/or parents and 
the institutional review boards from all participating centers approved the study.
dna and genotyping
DNA was collected by means of a blood sample (12% of cases and all controls) or 
a mouthswab (88% of cases). Genotyping was performed using MassArray matrix-
assisted laser desorption ionization time-of-flight mass spectrometry, according to the 
protocols recommended by the manufacturer (Sequenom, San Diego, California, USA). 
Each 384-well plates contained 8 positive controls (CEPH DNA), 8 negative controls 
and 10% duplicates. The error rate was less than 1%. Random genotyping failure oc-
curred in 3% cases and in 1% controls. 
statistical analysis
Because of the adherence to an additive model and the lack of evidence for a recessive 
model, we compared cases and controls using allelic odds ratios (OR) with 95% confi-
dence interval (CI). The common OR of the two independent sample sets combined was 
calculated using the Mantel-Haenszel test. There was no heterogeneity between the 
two sample sets (Breslow-Day test p<0.05). Case and control genotype frequencies did 
not deviate from Hardy Weinberg equilibrium. All statistical analysis was performed 
with SPSS 14.0. A p-value of <0.05 was considered statistically significant.
resulTs
To test for association of the 4q27 region with JIA, rs6822844 was typed in two inde-
pendent sample sets of patients and controls, consecutively. In the first and largest 
sample set the T-allele frequency was significantly decreased from 20% in controls 
to 15% in patients (allelic OR 0.72, 95%CI 0.55- 0.95; p=0.019). The same trend in 
decrease in T-allele frequency from 18% to 15% was observed in the second sample 
set, although did not reach statistical significance (allelic OR 0.81, 95% CI 0.61- 1.09; 
p=0.169). The common OR of sample set 1 and 2 combined showed a positive associa-
tion with JIA (p=7.08x10-3) (Table 1). 
As it is important to investigate genetic risk factors in homogeneous, well-defined 
phenotypic groups, we also analyzed association in the different JIA subtypes (Table 
2). Although a trend towards a decreased T-allele frequency was observed in persis-
tent oligoarthritis and systemic JIA, only the subtypes with a polyarticular course of 
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disease (extended oligoarthritis; p= 0,019 and RF negative polyarthritis; p=0,038) 
showed a significant decrease in T allele frequency.
discussion
This study shows for the first time a positive association of the 4q27 locus (rs6822844) 
in JIA, where a protective effect of the T-allele was observed. When testing the dif-
ferent JIA subtypes individually, a decrease in T-allele frequency was observed in all 
subtypes. Interestingly, only in the JIA subtypes that share a polyarticular phenotype 
this decrease was significant. A similar observation was made for the recently identi-
fied association with the TRAF1/C5 region indicating a common genetic constitution 
underlying the polyarticular phenotype.4 
table 1. Genotype and allele frequencies (rs6822844) in JIA patients and controls in two indepen-
dent sample sets
n Genotype 






GG GT TT T
Set 1 Controls 460 293 (63.7) 152 (33.0) 15 (3.3) 182 (19.8)
JIA 
patients
311 224 (72.0) 80 (25.7) 7  (2.3) 94 (15.1) 0.72   (0.55- 0.95) 0.019*
Set 2 Controls 323 218 (67.5) 95 (29.4) 10 (3.1) 115 (17.8)
JIA 
patients
324 233 (71.9) 85 (26.2) 6  (1.9) 97 (15.0) 0.81   (0.61- 1.09) 0.169
Combined data sets 0.76   (0.62- 0.93) 7.08 
x10-3 *
* p-value <0.05 considered significant 
º in the combined dataset the Mantel-Haenszel OR is used.
table 2. Analysis of allele-frequencies in the different subtypes of JIA in the overall cohort of cases 
and controls
Diagnosis• n T-allele allelic or (95% ci) p
Control 783 0.190
Persistent oligoarthritis 275 0.165 0.85  (0.65- 1.10) 0.207
Extended oligoarthritis 83 0.114 0.55  (0.34- 0.91) 0.019*
RF negative polyarthritis 151 0.139 0.69  (0.49- 0.98) 0.038*
Systemic JIA 69 0.152 0.77  (0.47- 1.24) 0.280
* p-value <0.05 considered significant 
• Diagnosis according to the revised ILAR classification (2)
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With patients originating from different European countries, population stratifica-
tion cannot completely be ruled out. However no significant variance in allele- fre-
quency in control populations from Western Europe has been reported7;8 and the 
allele- frequency observed in our control population was very similar to previously 
reported frequencies. In addition, when comparing the allele-frequencies in the 
cases originating from the different European countries, no significant difference 
was found (p=0,77). Moreover, the underrepresentation of the minor T-allele and 
the 4q27 effect size is similar as described in other autoimmune diseases such as 
RA and T1D.8 
The 4q27 locus consists of a large region of strong linkage disequilibrium (LD) encod-
ing the genes KIAA1109, TENR, IL2 and IL21. Both IL2 and IL21 are likely candidates 
for association with susceptibility to JIA, as both cytokines are involved in immune 
activation and regulation pathways. 
The IL2 pathway, in which the interaction between IL2 and the IL2-receptor-alpha 
(IL2RA) is central, is involved in T-cell proliferation and regulation.10 Mice deficient 
in Il2, have T-cells with impaired proliferation and effector function in vitro and 
develop lethal autoimmunity.11 Not only the 4q27 locus, but also the IL2RA locus 
has been associated with several autoimmune diseases,12;13 indicating an important 
role of the IL2-pathway in immune regulation and maintenance of self-tolerance.     
IL21 is involved in a wide range of immunological processes. IL21 appears to play 
a role in autoimmunity by both influencing the cellular immune response through 
inhibition of suppression by CD4+ regulatory T- cells and generating Th17 cells, as 
well as by influencing the humoral response.14 
Further analysis of the immunologic pathways involved in JIA may be helpful in 
identifying the causal gene in this locus. Moreover, sequencing, fine-mapping 
and extensive testing of variants of this region will be required to narrow down the 
region of association and identify the associated gene as well as functional testing 
of all the linked variants associated with disease.
In conclusion, like rheumatoid arthritis, type 1 diabetes, celiac disease and psoriatic 
arthritis, also JIA is associated with the 4q27 locus. The identification of the 4q27 
locus as a risk factor for JIA contributes to the collected evidence that one of the 
genes in this region plays a role in autoimmune diseases in general. In addition, our 
data indicate that the 4q27 locus contributes to the genetic susceptibility to JIA and 
warrants further research into the biological pathways explaining this association. 
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Juvenile idiopathic arthritis (JIA) is considered a complex genetic autoimmune disease. 
We investigated the association of genetic variants previously implicated in JIA, auto-
immunity and/or immunoregulation, with susceptibility to JIA.
Methods
A genetic association study was performed in 639 JIA patients and 1613 healthy con-
trols of North-West European descent. Ninety-three single nucleotide polymorphisms 
(SNPs) were genotyped in a candidate gene approach. Results of the entire JIA patient 
group (all subtypes) were compared to results obtained, alternatively, with a clinically 
homogeneous patient group including only oligoarticular and rheumatoid factor (RF) 
negative polyarticular JIA patients (n=493). Meta-analyses were performed for all SNPs 
that have been typed in other Caucasian JIA cohorts before.
results
SNPs in or near PTPN22, VTCN1, the IL2-IL21 region, ANKRD55, and TNFA were con-
firmed to be associated with JIA (p<0.05), strengthening the evidence for involvement 
of these genes in JIA. In the majority of these replicated SNPs, effect sizes were larger 
when analysing a homogeneous patient cohort than when analysing all subtypes. We 
identified two novel associations with oligoarticular and RF negative polyarticular JIA: 
CD226 rs763361 (OR 1.30, 95%-CI 1.12-1.51, p=0.0006) and CD28 rs1980422 (OR 
1.29, 95%-CI 1.07-1.55, p=0.008). Meta-analyses including reported studies confirmed 
the association of both SNPs with susceptibility to JIA (OR 1.16, p=0.001 and OR 1.18, 
p=0.001, for rs763361 and rs1980422 respectively).
conclusions
The CD226 gene has been identified as novel association with JIA, and a SNP near CD28 
as a suggestive association. Both genes are probable candidate risk factors since they 
are involved in costimulation of T cells. 
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inTroducTion
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in 
childhood. Prevalence numbers vary from 4 to 400 per 100,000 children.1 JIA compris-
es a heterogeneous group of conditions that share chronic arthritis with onset before 
the age of sixteen. Seven distinct subtypes have been defined by the International 
League of Associations of Rheumatologists (ILAR) based on clinical characteristics and 
laboratory parameters.2 However, phenotypic overlap between subtypes does exist, 
particularly between oligoarthritis (persistent and extended) and rheumatoid factor 
(RF) negative polyarthritis. These subtypes are only distinguished on the basis of the 
number of affected joints at onset and during the course of the disease.3 A proportion 
of these patients have circulating antinuclear antibodies (ANA) and are specifically at 
risk for developing JIA-associated uveitis.3
The pathogenesis of JIA is not well understood. It is considered an autoimmune 
disease in which a deregulated T cell response towards an, as yet unidentified, 
self-antigen causes joint inflammation.4 In most subtypes, synovial inflammation, 
which eventually leads to bone erosion, is associated with an overproduction of pro-
inflammatory cytokines, such as TNF-α and IL-17.5-9 JIA is a complex trait in which 
both genetic and environmental factors seem to be involved. Ethnic differences in 
epidemiologic studies,1,10 as well as an increased risk of JIA for relatives of patients 
(sibling recurrence risk ratio λS of 12),11-13 form evidence for genetic contribution to 
the risk of JIA. 
It has become increasingly clear that autoimmune diseases cluster in individuals 
and families.14,15 In line with this, genetic variations have been identified that are 
associated with more than one autoimmune disease, like rheumatoid arthritis (RA), 
type 1 diabetes mellitus, autoimmune thyroid disease, inflammatory bowel disease, 
systemic lupus erythematosus, multiple sclerosis, and also JIA.16-20 These results 
imply the existence of general genetic susceptibility to autoimmune diseases.
Identification of genetic risk variants could contribute to understanding of disease 
pathways, improve diagnosis of (subtypes of) JIA, and ultimately improve prognosis 
by providing new targets for therapy. Both candidate gene and genome-wide as-
sociation studies (GWAS) have been performed to elucidate the genetic basis of 
JIA. Compared to more common autoimmune diseases, until recently JIA cohorts 
were small and heterogeneous. Only few genetic associations had been replicated, 
such as PTPN22 and the major histocompatibility complex (MHC) region.21,22 Other 
(suggestive) JIA susceptibility loci have been reported, but not confirmed, such as 
ANKRD55 on 5q11.22 Nevertheless, replication of these loci is essential to exclude 
false positive associations. Therefore we investigated in a Caucasian JIA cohort 
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genetic loci previously implicated in JIA. Additionally, we investigated the associa-
tion of genetic loci implicated in autoimmunity and/or immunoregulation with JIA. 
Analyses were performed in both a large but relatively heterogeneous JIA patient 
cohort (including all subtypes), and a smaller but phenotypically more homoge-
neous patient group (including only the persistent and extended oligoarticular and 
RF negative polyarticular subtypes).
MeThods
subjects
DNA was available from 639 JIA patients with all subtypes, recruited through seven 
collaborating paediatric rheumatology referral centres in The Netherlands, Belgium, 
Germany, and Switzerland. All patients were of self-reported or parent-reported North-
West European Caucasian descent. JIA cases were classified according to the revised 
ILAR criteria.2 The patient group contained 263 patients with persistent oligoarthritis, 
88 with extended oligoarthritis, and 142 with RF negative polyarthritis, resulting in a 
homogeneous group of 493 patients (Table 1). 
DNA samples from healthy Caucasian controls were collected from three sources. 
See online supplementary methods for a detailed description of the control panels. 
Of the 93 markers that were successfully typed in the JIA patients, 40 were typed in 
869 controls and 53 in 1319 controls (supplementary Tables S1, S2).
All patients and controls provided informed consent. The institutional review boards 
of all participating centres approved this study.
Genotyping
We genotyped single nucleotide polymorphisms (SNPs) adopting a candidate gene ap-
proach. The choice for specific genes and/or SNPs was based on previous reports sug-
gesting involvement in JIA, other autoimmune diseases and/or immunoregulation. 93 
SNPs located in 57 genes/loci passed quality control, listed in supplementary Table S2. 
See online supplementary methods for a detailed description of genotyping methods.
statistical analysis
Allele frequencies were compared between JIA cases and controls. Allelic odds ratios 
(OR) and 95% confidence intervals (CI) were calculated using the allelic case-control 
association test in PLINK.23 These ORs correspond to the genotypic ORs of an additive 
model. We differentiated between loci that have been associated with JIA before (‘JIA 
replication loci’; 36 of 93 successfully typed SNPs) and loci that have not been impli-
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cated in JIA before (57 SNPs) (supplementary Table S2). For analysis of ‘replication loci’ 
we included patients with all JIA subtypes, to conform to reported studies that revealed 
these JIA loci. Because there was a prior probability that these loci would be associated 
with JIA in our study too, a p value < 0.05 was considered significant for these SNPs. 
We also performed the association analyses including only the most homogeneous JIA 
subtypes (persistent and extended oligoarthritis and RF negative polyarthritis, n=493). 
For the other 57 SNPs we analysed these 493 homogeneous JIA patients by compar-
ing them as a group to controls. To adjust for multiple testing, a Bonferroni correction 
should be applied to the results for these 57 SNPs, leading to a significance threshold 
table 1
Patient characteristics of the JIA cohort











Persistent oligoarthritis 263 (41)
Extended oligoarthritis 88 (14)
RF negative polyarthritis 142 (22)
RF positive polyarthritis 22 (3)
Systemic JIA 73 (11)
Psoriatric arthritis 4 (<1)
Enthesitis related arthritis 3 (<1)






AID in 1st degree relative 69 (16)
 AID in 1st or 2nd degree relative 169 (38)
RF: rheumatoid factor; ANA: antinuclear antibodies; AID: autoimmune disease
a) Family history known of 442 patients
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of p < 0.001. Additionally, we performed ILAR subtype-specific case-control analyses 
(within the homogeneous patient group) for all 93 SNPs, and also compared all ANA 
positive patients within this group to controls (supplementary Table S3).
Meta-analyses were performed for all SNPs that have been investigated in JIA before 
(supplementary Tables S4, S5). We included reported genetic association studies 
in Caucasian case-control cohorts (including a mixed set of JIA subtypes), in which 
the same SNPs have been typed. We excluded studies for which data necessary to 
calculate allelic ORs were not available. Not all JIA replication loci were included for 
meta-analyses because of these inclusion and exclusion criteria. In case of overlap-
ping individuals in reported studies, we only included the study with the largest 
JIA cohort. For meta-analyses of rs1980422 near CD28 and rs763361 in CD226, we 
performed analyses in homogeneous (oligoarticular and RF negative polyarticular) 
JIA patients.18,24,25  Because of the small number of studies included in the meta-
analyses, a fixed-effects model was used in a Mantel-Haenszel test. 
All statistical analyses were performed with use of the software PLINK v1.07 (http://
pngu.mgh.harvard.edu/purcell/plink/).23
resulTs
replication of JIA loci
Thirty-six SNPs that have been previously reported to be associated with JIA were 
investigated in our entire JIA cohort consisting of 639 patients with all seven different 
subtypes. To conform to reported studies, all ILAR subtypes were included. Nine of 
36 reported SNPs were confirmed to be associated (p < 0.05): VTCN1 rs10923217, 
KIAA1109 rs4505848, IL21 rs1398553, ANKRD55 rs6859219, TNFA rs1799724, 
rs1800750, rs361525, and rs1800610, and MIF rs755622 (Table 2). Because we 
propose to perform association studies only in a patient cohort as homogeneous 
as possible, additional analyses were limited to only oligoarthritis and RF negative 
polyarthritis (n=493). Although limiting the patient group led to fewer cases, all 
associations were still significant (Table 2). By performing analyses in the smaller, 
more homogeneous JIA cohort, the reported JIA SNPs PTPN22 rs2476601 and TNFA 
rs1800629 were additionally confirmed. In the majority of these replicated associa-
tions, analysis in the more homogeneous patient cohort led to larger effect sizes. For 
all SNPs that had been investigated in Caucasian JIA cohorts before, a meta-analysis 
was performed. For 23 of 36 replication loci, appropriate data for meta-analyses were 
available, of which PTPN22 rs2476601, VTCN1 rs10923217, rs6669320, rs10923223 
and rs12046117, PTPRC rs10919563, AFF3 rs1160542, CCR5 rs333, TNFA rs1799724, 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TNFAIP3 rs6920220, TNPO3 rs10488631, IL2RA rs2104286, and CLEC16A rs6498169 
were significant (supplementary Table S4).
novel JIA loci
An additional 57 SNPs, not reported to be associated with JIA before, located in or near 
autoimmune loci, were investigated in the homogeneous patient cohort. One SNP was 
strongly associated with JIA, CD226 rs763361 (OR 1.30, 95% CI 1.12-1.51, p=0.0006).
This SNP has not been reported to be associated with JIA before and represents a novel 
association (Table 3). The effect is particularly prominent in the persistent oligoarthritis 
patients (OR 1.39, p=0.0008) (supplementary Table S3). CD226 rs763361 has been 
investigated before in two other Caucasian JIA cohorts and a non-significant trend of 
this SNP towards association with JIA (all subtypes) was reported (p=0.1318; p=0.05925). 
We performed a meta-analysis combining the results from our study and the published 
data. To limit clinical heterogeneity between study cohorts, only patients with oligo-
articular and RF negative polyarticular JIA were included in this meta-analysis. The 
meta-analysis revealed a combined association of this CD226 variant with JIA, OR 1.16, 
p=0.001 (supplementary Table S5, Figure S1).
Rs1980422 near CD28 was revealed as a suggestive association (OR 1.29, 95% CI 
1.07-1.55, p=0.008) which was not significant after correction for multiple testing 
(Table 3). The effect of this SNP is particularly prominent in ANA-positive patients 
(OR 1.52, p=0.0004) (supplementary Table S3). This SNP was investigated before 
in a GWAS in Caucasian (oligoarticular and RF-negative polyarticular) JIA patients 
and a trend towards association was reported (p=0.04).24 Also for this SNP we per-
formed a meta-analysis combining the results of the present and the reported study, 
which resulted in a combined association of rs1980422 with JIA, OR 1.18, p=0.001 
(supplementary Table S5, Figure S1). 
table 3











(95% ci) P (allelic)
2 204610396 CD28 rs1980422 C 0.22 0.27 1.29 
(1.07-1.55)
0.008079
18 67531642 CD226 rs763361 T 0.47 0.54 1.30 
(1.12-1.51)
0.0006295
Chr: chromosome; MAF: minor allele frequency; OR: odds ratio; CI: confidence interval
a Homogeneous subtypes include oligoarticular (persistent and extended) and RF negative polyarticular JIA patients. 
Only SNPs that are (suggestively) associated with p<0.05 are listed.
b Base-pair position is based on NCBI dbSNP build 136
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Pooling our results with published non-significant associations (24 of 57 SNPs) re-
vealed a potential novel association of PRKCQ rs4750316 with JIA (OR 0.90, p=0.01) 
(supplementary Table S5).
discussion
We investigated the role of 93 genetic markers previously associated with JIA or 
involved in autoimmunity or immunoregulation in a large Caucasian JIA cohort. We 
identified the CD226 gene as a novel association with JIA, and a SNP near CD28 as a 
suggestive association.
While this study was powered (>=80%) to detect associations with an effect size 
(OR) >= 1.4, for SNPs with a minor allele frequency >= 0.10 at an alpha of 0.05, 
replication is the golden standard in genetic association studies and essential to 
exclude false-positive results. Collecting a large, homogeneous patient cohort which 
generates sufficient power is challenging in JIA, given the relatively low prevalence. 
A recent large study in JIA with dense genotyping of immune-related disease loci, 
which was published whilst this study was in progress, has also shown that increasing 
sample size improves power to detect true JIA loci.22 Although meta-analyses have 
limitations in case of publication bias and clinical heterogeneity between cohorts, 
they are also valuable for evaluating potentially false-positive or false-negative 
associations. Pooling of our and published results provides additional evidence for 
associations of 13 SNPs in 9 loci previously implicated in JIA. Furthermore, pooling 
of non-significant results from several studies suggests association of rs4750316 
near PRKCQ with JIA, which is also an RA-locus.26,27 However, heterogeneity within a 
cohort (e.g. by including clinically different JIA subtypes) can be a pitfall leading to 
false-negative results.
We compared results obtained by analysing the entire JIA patient group in a case-
control study to, alternatively, only JIA patients with the two clinically most similar 
ILAR subtypes (persistent and extended) oligoarthritis and RF negative polyarthritis). 
Although limiting the inclusion to two JIA subtypes resulted in smaller patient num-
bers, the study had enough power to confirm well-established JIA loci, e.g. PTPN22 
and TNFA. In the majority of replicated SNPs, effect sizes were larger when analysing 
only the homogeneous cohort. This argues in favour of restricting analyses to a ho-
mogeneous patient cohort, as has also been performed in two recent large studies 
in JIA.22,24
The associated loci PTPN22 (rs2476601), VTCN1 (rs10923217), KIAA1109 
(rs4505848), IL21 (rs1398553), ANKRD55 (rs6859219), and TNFA (rs1799724, 
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rs1800750, rs1800629, rs361525, rs1800610) were replicated in this study 
strengthening their involvement in JIA. Four of these were confirmed in a meta-anal-
ysis: PTPN22 rs2476601, VTCN1 rs10923217, and TNFA rs1799724 and rs361525. 
An additional nine JIA replication SNPs, not confirmed by this study, were signifi-
cantly associated in the meta-analysis. All of these genes are also associated with 
RA and/or other autoimmune diseases and are probably involved in the regulation 
of the immune response. All genes except ANKRD55 have obvious roles in immune 
processes. It should be noted that the C allele of rs755622 in the promoter region 
of MIF (encoding the proinflammatory cytokine macrophage migration inhibitory 
factor) is associated with protection to JIA in our study, but this conflicts with results 
from other JIA cohorts that suggest association of the C allele with susceptibility.28-31 
The reason for these opposing results is not clear, but the minor allele frequency 
(MAF) of this SNP in our control cohort is comparable to the MAF in other North-West 
European control cohorts.29,32-34 Genetic studies of MIF in RA and inflammatory bowel 
disease have yielded similarly opposing results,29,35-40 indicating that the  role of this 
SNP in JIA and other autoimmune diseases is still unclear. The other investigated 
JIA loci, of which IL2RA and IL2RB reached genome-wide significance in a previous 
report, were not confirmed in our cohort, which might be due to insufficient power 
to detect modest risk loci.22 A SNP in IL2RA was significant in the meta-analysis, 
underlining the importance of combining data from different JIA cohorts.
One of the strongest replicated associations with JIA is rs6859219, located at locus 
5q11, in ANKRD55, an ankyrin repeat domain-containing gene with unknown func-
tion. This region has been recently identified by dense genotyping of immune-relat-
ed disease loci in JIA patients.22 Although nearby genes  IL6ST and IL31RA encode 
proteins involved in immunity, SNPs in these genes are not in linkage disequilibrium 
with the associated SNP in ANKRD55. Ankyrin repeat domains are common protein 
structures and mediate protein-protein interactions. Although the precise function 
of ANKRD55 is not known, it is specifically expressed in resting CD4+ T cells (http://
www.amazonia.transcriptome.eu), which is interesting when a role in autoimmunity 
is presumed. Rs6859219 was previously found to be associated with RA in a GWAS 
and with multiple sclerosis.41-43
In addition to the confirmation of previously identified associations, two novel 
susceptibility loci for the most common JIA subtypes were discovered. CD28 
rs1980422 is only weakly associated, but is interesting because of its location 
between two immune related genes: CD28 (approximately 10 kb away) and CTLA4 
or cytotoxic T-lymphocyte antigen-4 (approximately 129 kb away), a gene that is 
associated with multiple autoimmune diseases including RA, with conflicting results 
in JIA.18,21,29,44,45 There is minimal linkage disequilibrium between rs1980422 and 
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several SNPs in CTLA4. We also investigated the well-established general autoimmu-
nity SNP rs231775 in CTLA4, but this SNP was not associated with JIA in this study. 
Both gene products have opposing roles in T cell activation. CD28 is expressed on 
the T cell surface and involved in costimulation of T cells. CTLA4 is expressed by 
T cells upon activation by antigen presenting cells. It functions as an attenuator 
of T cell activation by competing with CD28 for shared ligands (CD80 and CD86). 
Rs1980422 near CD28 was associated with RA in a GWAS.46 In a recent GWAS in 
JIA, this SNP was tested, but not significantly associated with JIA after correction for 
multiple testing.24 Combining these results with ours in a meta-analysis resulted in 
a significant association. The CD28 region has not been identified as a significant 
JIA susceptibility locus in a recent, large association study in which the ImmunoChip 
was used, but interestingly, this ImmunoChip study as well as the JIA GWAS revealed 
a strong association of SNPs in the region of CD80, coding for a ligand of CD28, with 
JIA.22,24 The implication of three components of this costimulatory pathway, CD80, 
CTLA4 and CD28, in JIA and other autoimmune diseases is supportive for a role in 
autoimmune pathogenesis.
The most strongly associated novel SNP rs763361 is located in CD226, which 
encodes CD226 or DNAX accessory molecule 1 (DNAM-1). DNAM-1 is a type 1 
membrane protein belonging to the Ig-supergene family. It is mainly expressed on 
T and NK cells and is involved in the adhesion and costimulation of these cells via 
its ligands CD112 and CD155.47,48 The CD226 region has not been identified as a 
(genome-wide significant) JIA susceptibility locus in the large association study with 
use of the ImmunoChip, which also captures CD226.22 Nevertheless, a meta-analysis 
of our study with two previous candidate gene studies confirmed the association 
with JIA.18,25 Furthermore, recent genetic studies have reported an association of 
this non-synonymous SNP (Gly307Ser) with susceptibility to multiple autoimmune 
diseases, as type 1 diabetes mellitus, autoimmune thyroid disease, multiple sclero-
sis, rheumatoid arthritis, and systemic lupus erythematosus, denoting it as a general 
autoimmunity locus.49,50 A fine-mapping study of the 18q22 region, in which the 
SNP lies, was performed in type 1 diabetes mellitus and multiple sclerosis patients 
by exonic resequencing and tag SNP mapping.49 This study pointed out the SNP as 
a probable causal variant. However, this study cannot exclude other (rare) variants 
in linkage disequilibrium with rs763361 being the true causal variant. If rs763361 
would be correlated with altered expression and/or signaling, this could explain the 
contribution of this variant to autoimmunity. DNAM-1 deficient mice show impaired 
control of viral infections and less cytotoxic activity against tumors compared to 
wild type mice, suggesting a form of immunodeficiency when CD226 function is im-
paired.51,52 In another report in which the role of CD226 in experimental autoimmune 
CD226 (DNAM-1) 71
encephalomyelitis (EAE, a model for multiple sclerosis) was studied, application of 
a monoclonal antibody against CD226 led to delayed onset and reduced severity 
of EAE.53 This is suggestive for a role of CD226 in the development of autoimmune 
disease. By contrast, it is apparently contradictory that individuals that were ho-
mozygous for a CD226 haplotype associated with susceptibility to systemic lupus 
erythematosus expressed lower CD226 transcript levels and lower surface proteins 
on T cells and NK cells.50 Replication in independent, homogeneous cohorts and 
additional fine-mapping and functional studies are needed to clarify the pathogenic 
implications of variation in these loci.
In summary, our data generate renewed interest for a role in JIA of two biological 
pathways that aid priming of T cells: the costimulatory mechanism involving CD28, 
CTLA4 and CD80/CD86, and the CD226 gene, encoding the accessory molecule 
DNAM-1, which is a novel JIA susceptibility locus. This does not only contribute 
to knowledge of JIA pathogenesis, but targeting these T cell stimulating processes 
might also be of therapeutic interest.
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1130 controls were healthy blood bank donors (758 randomly selected by the Im-
munogenetics and Transplantation Immunology (ITI) section of the Department of 
Immunohematology and Bloodtransfusion, and 372 by the Laboratory for Diagnostic 
Genome Analyses (LDGA) at Leiden University Medical Center, all from the region of 
Leiden, The Netherlands), 372 controls were anonymized individuals that requested 
genetic counselling at the LDGA regarding a monogenic disease in their families, but 
tested negative for this single genetic defect, and 111 controls were recruited via 
participating patients and their families (but unrelated) (supplementary Table S1). Due 
to limited availability of DNA, genetic markers were genotyped in different control 
cohorts. Of the 93 markers that were successfully typed in the JIA patients, 40 were 
typed in 869 controls and 53 in 1319 controls (supplementary Tables S1, S2).
DNA and genotyping
DNA was isolated from buccal swabs or a blood sample. We performed genotyping 
of 112 SNPs in 65 genes/loci by iPLEX MassARRAY according to the manufacturer’s 
recommendations (Sequenom, San Diego, California, USA). Only SNPs exceeding a 90% 
call rate and no evidence for deviation from Hardy-Weinberg equilibrium in the control 
population (p > 0.005) were used for further analysis. 93 of 112 SNPs (83%) located in 
57 genes/loci passed quality control, listed in supplementary Table S2. SNP call rates 
per individual exceeded 90%.
Supplementary Table S1
Control subjects
set source n Type of control subjects 
1 ITI 464 Healthy blood donors 
2 ITI 294 Healthy blood donors 
3 LDGA 372 Healthy blood donors 
4 LDGA 372 Healthy relatives of monogenic disease patients 
5 JIA families 111 Healthy unrelated acquaintances of JIA patients 
ITI: Immunogenetics and Transplantation Immunology section; LDGA: Laboratory for Diagnostic Genome Analyses




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SupplementaryTable S6. References of studies analysed for meta-analysis (supplementary Tables 
S4 and S5)
Cimaz 20071 Cimaz R, Cazalis MA, Reynaud C et al. IL1 and TNF gene polymorphisms in patients with 
juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 2007; 66(7):900-904.
Cinek 20042 Cinek O, Vavrincova P, Striz I et al. Association of single nucleotide polymorphisms within 
cytokine genes with juvenile idiopathic arthritis in the Czech population. J Rheumatol 2004; 
31(6):1206-1210.
Cinek 20063  Cinek O, Hradsky O, Ahmedov G et al. No independent role of the -1123 G>C and+2740 A>G 
variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in 
two Caucasian populations. Diabetes Res Clin Pract 2007; 76(2):297-303.
Crawley 19994 Crawley E, Kay R, Sillibourne J et al. Polymorphic haplotypes of the interleukin-10 5’ flanking 
region determine variable interleukin-10 transcription and are associated with particular 
phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42(6):1101-1108.
Dimopoulou 20135 Dimopoulou DG, Zervou MI, Trachana M et al. Investigation of juvenile idiopathic arthritis 
susceptibility loci: results from a Greek population. Hum Immunol 2013; 74(9):1194-1198.
Donn 20016 Donn RP, Barrett JH, Farhan A et al. Cytokine gene polymorphisms and susceptibility to 
juvenile idiopathic arthritis. British Paediatric Rheumatology Study Group. Arthritis Rheum 
2001; 44(4):802-810.
Donn 20027 Donn R, Alourfi Z, De BF et al. Mutation screening of the macrophage migration inhibitory 
factor gene: positive association of a functional polymorphism of macrophage migration 
inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46(9):2402-2409.
Ellis 20138 Ellis JA, Chavez RA, Pezic A et al. Independent replication analysis of genetic loci with 
previous evidence of association with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 
2013; 11(1):12.
Hinks 20059 Hinks A, Barton A, John S et al. Association between the PTPN22 gene and rheumatoid 
arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an 
autoimmunity gene. Arthritis Rheum 2005; 52(6):1694-1699.
Hinks 200910 Hinks A, Ke X, Barton A et al. Association of the IL2RA/CD25 gene with juvenile idiopathic 
arthritis. Arthritis Rheum 2009; 60(1):251-257.
Hinks 2009 II11 Hinks A, Barton A, Shephard N et al. Identification of a novel susceptibility locus for juvenile 
idiopathic arthritis by genome-wide association analysis. Arthritis Rheum 2009; 60(1):258-
263.
Hinks 201012 Hinks A, Eyre S, Ke X et al. Overlap of disease susceptibility loci for rheumatoid arthritis and 
juvenile idiopathic arthritis. Ann Rheum Dis 2010; 69(6):1049-1053.
Hinks 2010 II13 Hinks A, Eyre S, Ke X et al. Association of the AFF3 gene and IL2/IL21 gene region with 
juvenile idiopathic arthritis. Genes Immun 2010; 11(2):194-198.
Hinks 2010 III14 Hinks A, Martin P, Flynn E et al. Association of the CCR5 gene with juvenile idiopathic arthritis. 
Genes Immun 2010; 11(7):584-589.
Hinks 2010 IV15 Hinks A, Martin P, Flynn E et al. Investigation of type 1 diabetes and coeliac disease 
susceptibility loci for association with juvenile idiopathic arthritis. Ann Rheum Dis 2010; 
69(12):2169-2172.
Hinks 201116 Hinks A, Martin P, Flynn E et al. Subtype specific genetic associations for juvenile idiopathic 
arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic 
arthritis. Arthritis Res Ther 2011; 13(1):R12.
Hinks 201217 Hinks A, Cobb J, Sudman M et al. Investigation of rheumatoid arthritis susceptibility loci 
in juvenile idiopathic arthritis confirms high degree of overlap. Ann Rheum Dis 2012; 
71(7):1117-1121.
Hinks 201318 Hinks A, Martin P, Thompson SD et al. Autoinflammatory gene polymorphisms and 
susceptibility to UK juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2013; 11(1):14.
CD226 (DNAM-1) 101
Kaalla 201319 Kaalla MJ, Broadaway KA, Rohani-Pichavant M et al. Meta-analysis confirms association 
between TNFA-G238A variant and JIA, and between PTPN22-C1858T variant and 
oligoarticular, RF-polyarticular and RF-positive polyarticular JIA. Pediatr Rheumatol Online J 
2013; 11(1):40.
Lindner 200720 Lindner E, Nordang GB, Melum E et al. Lack of association between the chemokine receptor 5 
polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis. BMC Med 
Genet 2007; 8:33.
McDowell 199521 McDowell TL, Symons JA, Ploski R et al. A genetic association between juvenile rheumatoid 
arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38(2):221-228.
Miterski 200422 Miterski B, Drynda S, Boschow G et al. Complex genetic predisposition in adult and juvenile 
rheumatoid arthritis. BMC Genet 2004; 5:2.
Mourão 200923 Mourao AF, Caetano-Lopes J, Costa P et al. Tumor necrosis factor-alpha -308 genotypes 
influence inflammatory activity and TNF-alpha serum concentrations in children with juvenile 
idiopathic arthritis. J Rheumatol 2009; 36(4):837-842.
Ozen 200224 Ozen S, Alikasifoglu M, Bakkaloglu A et al. Tumour necrosis factor alpha G-->A -238 and G-->A 
-308 polymorphisms in juvenile idiopathic arthritis. Rheumatology (Oxford) 2002; 41(2):223-
227.
Pazár 200825 Pazar B, Gergely P, Jr., Nagy ZB et al. Role of HLA-DRB1 and PTPN22 genes in susceptibility to 
juvenile idiopathic arthritis in Hungarian patients. Clin Exp Rheumatol 2008; 26(6):1146-1152.
Prahalad 200826 Prahalad S, Bohnsack JF, Whiting A et al. Lack of association of functional CTLA4 
polymorphisms with juvenile idiopathic arthritis. Arthritis Rheum 2008; 58(7):2147-2152.
Prahalad 200927 Prahalad S, Hansen S, Whiting A et al. Variants in TNFAIP3, STAT4, and C12orf30 loci 
associated with multiple autoimmune diseases are also associated with juvenile idiopathic 
arthritis. Arthritis Rheum 2009; 60(7):2124-2130.
Schmeling 200628 Schmeling H, Wagner U, Peterson A et al. Tumor necrosis factor alpha promoter 
polymorphisms in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 
24(1):103-108.
Seldin 200529 Seldin MF, Shigeta R, Laiho K et al. Finnish case-control and family studies support PTPN22 
R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no 
effect in juvenile idiopathic arthritis. Genes Immun 2005; 6(8):720-722.
Skinningsrud 201030 Skinningsrud B, Lie BA, Husebye ES et al. A CLEC16A variant confers risk for juvenile 
idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid 
arthritis. Ann Rheum Dis 2010; 69(8):1471-1474.
Suppiah 200531 Suppiah V, O’doherty C, Heggarty S et al. The CTLA4+49A/G and CT60 polymorphisms and 
chronic inflammatory arthropathies in Northern Ireland. Exp Mol Pathol 2006; 80(2):141-146.
Thompson 201032 Thompson SD, Sudman M, Ramos PS et al. The susceptibility loci juvenile idiopathic arthritis 
shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum 
2010; 62(11):3265-3276.
Thompson 201233 Thompson SD, Marion MC, Sudman M et al. Genome-wide association analysis of juvenile 
idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. Arthritis 
Rheum 2012; 64(8):2781-2791.
Viken 200534 Viken MK, Amundsen SS, Kvien TK et al. Association analysis of the 1858C>T polymorphism 
in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes 
Immun 2005; 6(3):271-273.
Zeggini 200235 Zeggini E, Thomson W, Alansari A et al. Tumour necrosis factor receptor II polymorphism and 
juvenile idiopathic arthritis. Rheumatology (Oxford) 2002; 41(4):462-465.
Zeggini 2002 II36  Zeggini E, Thomson W, Kwiatkowski D et al. Linkage and association studies of single-
nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. 
Arthritis Rheum 2002; 46(12):3304-3311.
102 Chapter 4
Supplementary Figure S1 Meta-analysis of novel JIA susceptibility loci
a. Meta-analysis of CD226 rs763361, restricted to oligoarticular and RF negative JIA patients of Caucasian origin
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 Juvenile Idiopathic Arthritis is a heterogeneous disease involving chronic arthritis. The 
clinical course is characterized by a fluctuating pattern of active and inactive disease. 
We have described in detail the clinical course in different JIA subtypes in the first two 
years after diagnosis and studied its relation to disease activity in the following years. 
Methods
Detailed clinical data on different parameters describing the disease activity in se-
quential time periods covering the first two years after diagnosis were retrieved from 
the charts of 311 JIA patients and compared between subtypes. In a cohort of 146 
patients the relation of these different clinical variables to the course of disease in the 
following three years was evaluated.
results 
The percentage of time with active disease in the first two years differed significantly 
between subtypes. In all subtypes a broad spectrum of activity was observed. The time 
with active disease in the first two years was the most significant factor associated with 
the duration of active disease in the following years. 
conclusion
In this study, different percentages of time with active disease have been observed 
between JIA subtypes in the first two years. The cumulative duration of activity varied 
widely within each subtype. Regarding the prognosis of the individual patient, the 
clinical course in the first two years appears to be predictive of the clinical course in 
the following years. Patients that have less time with active disease in the first two 
years are not likely to develop unremitting clinical course later on. 
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inTroducTion
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders characterized 
by chronic inflammation of the joint. Seven different subtypes have been defined by 
the International League of Associations for Rheumatology (ILAR) based on clinical and 
laboratory parameters.1 Within JIA, persistent oligoarthritis, extended oligoarthritis and 
rheumatoid factor (RF) negative polyarthritis are the most homogeneous subtypes with 
a large phenotypic overlap.2 Although the remission rate is the highest in persistent 
oligoarthritis,3 the precise clinical course of the different subtypes is still unclear.   
Prediction of the clinical course of the disease could be helpful for choosing the 
optimal treatment strategy for an individual patient. However, at this moment no 
clinically useful prognostic factors are known.4;5 The outcome of JIA regarding dis-
ease activity and remission has frequently been studied in the different subtypes, 
but unfortunately different studies have used a large variety of definitions of remis-
sion and thereby generated data that are difficult to compare.3-6 Several years ago a 
preliminary definition of remission has been formulated, defining different states of 
inactivity; inactive disease, clinical remission on medication and clinical remission 
off medication.7 Furthermore, almost all studies in JIA concerning outcome have 
used a cross-sectional study design, while Wallace et al clearly showed that JIA is 
a disease with fluctuating disease activity that can best be described by analysis 
of sequential time periods.8 By using sequential time periods, the cumulative time 
with active or inactive disease can be determined and used as outcome measure.8;9 
Already different studies have shown that a prolonged disease activity is related 
to a poor outcome regarding radiographic damage.10;11 Moreover it seems to be im-
portant to distinguish between different states of activity, because reaching a state 
of minimal disease activity (MDA) is related to less damage to the joint (amongst 
others) compared to not reaching MDA.12  
In this study we will describe the clinical course of the first two years after diagnosis 
in different subtypes of JIA by analyzing sequential episodes of disease activity. 
Moreover, we have studied the different parameters of disease activity assessed in 
the first two years after diagnosis in relation to the clinical course in the following 




A cohort of 640 JIA patients, with oligoarthritis, polyarthritis and systemic JIA, origi-
nating from 7 different pediatric rheumatology referral centers in the Netherlands, 
Belgium, Germany and Switzerland and who were diagnosed after 1 January 1991, was 
observed retrospectively. For this study patients were excluded when no clinical data 
on disease activity were available (n= 144), when the follow-up was less than 2 years 
(n=158), if re-classified  with psoriatic arthritis, JIA with enthesitis and undifferentiated 
JIA (n=6) and if an ongoing uveitis was present with only a mild course of arthritis (n=3). 
This resulted in a JIA cohort of 311 patients that were included in the analysis of the 
clinical course of the first two years after diagnosis. In order to identify prognostic fac-
tors for the clinical course in the following years, only patients with a follow-up of >= 5 
years were included (n=146), excluding 165 patients with a follow-up of >2 years and < 
5 years. All patients were diagnosed or (re)classified according to the ILAR classification 
and had a self- or parental-reported Caucasian ethnicity.1 The characteristics of the JIA 
patient cohort are listed in Table 1. 
The ethical review boards of all participating centers gave their approval to this 
study and informed consent was obtained from all patients and/or parents.  
table 1. Patients’ characteristics#
n        (%)
Total JIA population 311
Subtype:
Persistent oligoarthritis 124 (39.9)
Extended oligoarthritis 56 (18.0)
RF- negative polyarthritis 91 (29.3)
RF- positive polyarthritis 9 (2.9)
Systemic JIA 31 (10.0)
Female 214 (68.8)
Follow-up (year) (median; min-max) 4.8 2.0- 15.9
Age at onset (year) (median; min-max) 4.1 0.6- 15.5
ANA positive 163 (52.4)
negative 109 (35.0) 
other*/ unknown 38 (12.2)
Uveitis positive 47 (15.1)
negative 225 (72.3)
unknown 32 (10.3)
#) Parameters listed in numbers and percentages unless otherwise indicated
*) If antinuclear antibodies are not consistently present or detected
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clinical data
Each patient’s chart was reviewed retrospectively and the disease activity (according 
to different parameters) at all visits during the complete disease course was evaluated. 
We assumed that the patient stayed in the same state of disease activity until the next 
visit. Patients visited the pediatric rheumatologists with an interval of 6 months or less 
in case of inactive disease and with an interval of 3 months or less when disease was 
active. Due to the retrospective nature of this study, the follow-up of the patients has 
not been uniform; patients with a remitting course of disease had fewer visits to the 
pediatric rheumatologist than patients with an unremitting course of disease. However, 
when patients in an inactive state developed complaints the subsequent visit was usu-
ally placed forward. Therefore, in individual patients, mainly the state of active disease 
might be over-estimated.   
Different parameters were used indicating disease activity; state of disease activity 
(active or inactive disease), the subjective physicians’ global assessment of disease 
activity (categorized as: 0 = inactive disease, 1 = mild, 2 = moderate, 3 =  severe, 4 
= very severe disease) and the number of joints with arthritis (categorized as: 0 = no 
joints, 1 = monoarthritis (1 joint) , 2 =  oligoarthritis (>=1 – 4 joints), 3 = polyarthritis 
(>=4- <=10 joints), 4 = severe polyarthritis (> 10 joints). No joint score was used 
for systemic JIA, because of the systemic features that are involved in JIA.  Inactive 
disease was defined as absence of active arthritis, no systemic features, normal ESR 
(when available) and a physicians’ global assessment indicating inactivity (category 
0). The activity of JIA-associated uveitis was not incorporated in the definition of 
inactivity, because of missing data about the detailed ophthalmologic follow-up. 
However, to minimize the possible bias this could cause, we excluded patients (n=3) 
that had a known ongoing uveitis with only short periods of arthritis. 
Furthermore, data on the use of different medication (yes/no) in the first two years 
were reviewed and grouped as: the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) alone; intra-articular steroids (IAS) alone or combined with NSAIDs ; sul-
fasalazine (SSZ) alone or in combination with NSAIDs; the use of Methotrexate (MTX) 
(started <= 6 months (early) or >6 months (late) after diagnosis) combined with any 
other (or no other) drugs besides Etanercept;  Etanercept in combination with MTX 
and any other (or no other) drugs; other types or combinations of treatment. 
Beside data on disease activity and medication, also data on the presence or ab-
sence of antinuclear antibodies (ANA), age at onset and gender were collected.  
Parameters of activity
In order to evaluate the clinical course of the different subtypes, for each patient the 
first two years after diagnosis were analyzed. For this period, the percentage of time 
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with active disease was calculated together with the percentage of patients that had 
reached clinical remission within these first two years. Clinical remission (yes/no) was 
defined as the presence of an episode of inactivity lasting >= 6 months. Additionally, 
the mean physicians’ global assessment and the mean joint score were calculated for 
each individual patient for the time the disease was active in the first two years (later 
referred to as the physicians’ global assessment and joint score). The percentage of 
time with active disease that was evaluated as mild by the physicians (category 1) was 
used as measure for mild active disease. These different parameters of disease activity 
were compared between the different subtypes.
To study the prognostic value of different clinical parameters assessed in the first 
two years, the percentage of time with active disease in the following three years 
(third, fourth and fifth year (3-5) after diagnosis) was calculated to determine the 
clinical course later on in the disease. The percentage of time with active disease 
during the years 3-5 was used to define remitting and unremitting clinical course. 
Remitting clinical course was defined as: percentage of time with active disease 
between 0 and 35%, whereas unremitting clinical course was defined as: percent-
age of time with active disease >=65%. Patient with active disease during more 
than 35% and less than 65% of the time were considered as having an intermediate 
clinical course. Following the same definition, patients were also categorized into 
remitting, intermediate and unremitting course according to their percentage of 
active disease in the first two years after onset.
statistical analysis
When analyzing the parameters of activity in the first two years in different subtypes, 
non-parametric tests (Kruskal Wallis, Mann-Whitney U test) were used because of the 
non-normal distribution of different variables in the overall population and some sub-
types. Comparing the different parameters in patients with a remitting and unremitting 
clinical course, a Pearsons’ Chi-square or Mann-Whitney U test were used depending 
on the tested variable. A p-value of <0.05 was regarded as statistically significant.
Positive and negative predictive values were calculated for the remitting and unre-
mitting category comparing the clinical course in the first two years after onset with 
the clinical course in the years 3-5 in order to estimate the predictive value of the 
clinical course in the first two years. Data were analyzed using SPSS 16.0.
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resulTs
Percentage of time with active disease in the first two years
The percentages of time with active disease in the first two years after diagnosis in the 
overall JIA cohort as well as in the individual subtypes are listed in Table 2 and shown 
in Figure 1. The median percentage of time with active disease in the overall JIA cohort 
is 57%, meaning that half of the patients have more than 14 months of active disease 
(cumulative) during the first two years. The percentage of time with active disease is 
significantly different between the subtypes (p=0.031). Analyzing the three subtypes 
with the most phenotypic overlap (persistent oligoarthritis, extended oligoarthritis and 
rheumatoid factor (RF) negative polyarthritis), the lowest median percentage of time 
with active disease is observed in patients with persistent oligoarthritis (47%) com-
pared to extended oligoarthritis (70%; p <0.001) and RF- negative polyarthritis (58%; 
Figure 1. The percentage of time with active disease in the first two years after diagnosis in the dif-
ferent subtypes.
Systemic	  










































p*<0.001	   p*=0.025	  
p*=0.004	  
0.6	  
♦ median percentage of time with active disease per subtype of JIA
*) p-value of Mann- Whitney U test comparing two subtypes (persistent oligoarthritis vs extended oligoarthritis, 
extended oligoarthritis vs RF-negative polyarthritis, persistent oligoarthritis vs RF-negative polyarthritis)
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p=0.004), whereas the median percentage of time with active disease in extended 
oligoarthritis is the highest and significantly different from RF-negative polyarthritis 
(p=0.025). In patients with systemic JIA the median percentage of active disease is 
comparable to patients with RF-negative polyarthritis (61%; p=0.67). Patients with RF-
positive polyarthritis have the highest median percentage of time with active disease 
(85%), but because of the small sample size (n=9) no reliable conclusion can be drawn 
from these data. 
Clinical remission in the first two year
When an episode of inactive disease lasted >= 6 months, this was regarded as an 
episode of clinical remission. The percentage of patients within the different subtypes 
who reached clinical remission in the first two years is listed in Table 2. Patients with ex-
tended oligoarthritis have a significantly lower percentage of clinical remission (36%) 
compared to both persistent oligoarthritis (69%; p< 0.001) and RF-negative polyarthri-
tis (60%; p= 0.004). No difference between persistent oligoarthritis and RF-negative 
polyarthritis patients was observed (p=0.22). In systemic JIA, 58% of the patients have 
reached clinical remission in the first two years. Inherent to the high percentage of time 
with active disease, the percentage of clinical remission is low (11%) in RF-positive 
polyarthritis. Only 84 patients had a continuous period of inactive disease for >= 12 
months in these first two years and 34 patients (of which 68% persistent oligoarthritis 
patients) were off medication for >= 12 months in that episode.
Physicians’ global assessment of disease activity, percentage of mild active 
disease and the joint score in the first two years
The physicians’ global assessment (reviewed at times when the disease was active in 
the first two years) in the overall JIA cohort and in the different subtypes is listed in 
Table 3. No significant differences in the median physicians’ global assessment of dis-
ease activity were observed when comparing only persistent oligoarthritis, extended 
oligoarthritis and RF-negative polyarthritis (p=0.58). This means that although the 
cumulative time of active disease is different in these three subtypes, the physician 
evaluates the severity of disease activity similar at times when the disease is active. 
No association between the percentage of time with active disease and the physician’s 
global assessment is observed in the analysis of the total JIA cohort (data not shown). 
The percentage of time in which the physicians’ global assessment is evaluated as 
mild (category 1) is also listed in Table 3. No significant differences in percentages 
of mild active disease are observed comparing JIA subtypes.
Due to the ILAR classification that is based on differences in the number of affected 
joints, the median joint score during active disease in the first two years is signifi-
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cantly different between the subtypes (Table 3). Patients with an extended oligo-
arthritis have a significant higher median joint score than persistent oligoarthritis 
patients, although both subtypes have <= 4 joints involved in the first 6 months. 
This indicates that extended oligoarthritis not only affects more than 5 different 
joints during the disease course, but that on the average more joints are active at 
the same time. 
These data show that the clinical course, indicated by the percentage of time with 
active disease in the first two years after diagnosis, is different in the JIA subtypes. 
Especially the clinical course of persistent oligoarthritis is significantly different from 
extended oligoarthritis, which seem to be two separate entities. However within 
each subtype an individual patient can have a wide range of activity varying from 
only a short time of active disease to ongoing disease activity.  This already shows 
that the subtype JIA on itself is not valid as a prognostic factor for the individual 
patient. 
Prognostic factors for the clinical course in years 3-5 after diagnosis 
In patients with a follow-up of >= 5 years (n=146) the percentage of time with active 
disease was evaluated during the years 3-5 (third, fourth and fifth year) after diagno-
sis and patients were categorized into a remitting (0-35% time with active disease), 
intermediate (35-65%) or an unremitting clinical course (65-100%). The different 
parameters of disease activity measured in the first two years, the use of medication 
in the first two years together with subtype, age at onset, gender and ANA status were 
table 2 The percentage of time with active disease and the percentage of patients that have reached 
clinical remission in the first two years after diagnosis in the overall JIA cohort and the different 
subtypes. 
Percentage of time with active 
disease 
clinical remission °
median (range) p1 % p 2
Overall JIA cohort (n=311) 0.57 (0.02-1.0) 0.031    (1-5) 0.58 < 0.001 (1-5)
1.Persistent oligoarthritis (n=124) 0.47 (0.06- 1.0) <0.001 (1vs 2) 0.69 <0.001  (1 vs 2)
2.Extended oligoarthritis (n=56) 0.70 (0.02- 1.0) 0.025   (2 vs 3) 0.36 0.004    (2 vs 3)
3.RF- negative polyarthritis (n=91) 0.58 (0.14- 1.0) 0.004   (1vs 3) 0.60 0.218    (1 vs 3) 
4.RF- positive polyarthritis (n=9) 0.85 (0.49- 1.0) 0.11
5.Systemic JIA (n=31) 0.61 (0.05- 1.0) 0.67     (3 vs 5) 0.58 0.269    (1 vs 5)
°) percentage of patients that have reached clinical remission in the first two years after diagnosis
1) p-value of Kruskal-Wallis test in all subtypes (1-5) or Mann- Whitney U test comparing two subtypes (persis-
tent oligoarthritis vs extended oligoarthritis, extended oligoarthritis vs RF-negative polyarthritis, persistent 
oligoarthritis vs RF-negative polyarthritis) indicated by numbers (in brackets).
2) p-value of Pearson-Chi-square comparing the percentage of clinical remission in all subtypes (1-5) and com-
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table 4. Patients’ characteristics and comparison of the different clinical and demographic param-
eters between patients with a remitting course and an unremitting course #
n remitting course* unremitting course* p
All JIA subtypes• 146 62 (42.5) 44 (30.1)
Subtypeº 0.4181
  Persistent oligoarthritis 43 25 (58.1) 10 (23.3)
  Extended oligoarthritis 44 15 (34.1) 14 (31.8)
  RF negative polyarthritis 39 15 (38.5) 12 (30.8)
  RF positive polyarthritis 4 0   (0) 4   (100)
  Systemic JIA 16 7 (43.8) 4 (25.0)
Age at onset (years), median (range) 146 2.94 (0.62-12.64) 4.17 (1.23- 14.2) 0.2032
Gender female 108 46 (42.6) 33 (30.6)
male 38 16 (42.1) 11 (28.9) 0.961
ANA† positive 83 37 (44.6) 22 (26.5) 0.4371
negative 34 12 (35.3) 13 (38.2)
Percentage active disease in  first two years, 
median (range)
106 45.8 (6.22- 100) 100 (47.4- 100) <0.0012§
Clinical remission (>= 6 months) in first 2 
years (yes/no)
69 45 (65.2) 8 (11.6) <0.0011§
Clinical remission off mediation (>= 12 
months) in the first 2 years (yes/no)
10 9 (90) 0 <0.0011§
Physicians’global assessment in first two years, 
median (range)&
122 1.70 (1.0- 3.0) 1.74 (1.0- 2.72) 0.3732
Percentage mild active disease 119 0.34 (0- 1.0) 0.37 (0- 1.0) 0.9412
Medication in first two years:
  NSAIDs only 35  21 (60.0) 8 (22.9) 0.0521
  IAS 3 29 19 (65.5) 4 (13.8) 0.0171§
  SSZ3 9 3 (33.3) 1 (11.1) 0.1711
  MTX4 47 14 (29.8) 19 (40.4) 0.0741§
  MTX early 13 5 (38.5) 6 (46,2) 0,396&
  MTX late 34 9 (26.5) 13 (38,2)
  Etanercept5 6 1 (16.7) 4 (66.7) 0.1201
  Systemic glucocorticoids6 39 11 (28.2) 17 (43.6) 0.0421§
NSAIDs= non-steroidal anti-inflammatory drugs, IAS= intraarticular steroids, SSZ= sulfasalazine, MTX= methotrex-
ate
#) Parameters listed in number (percentage) unless otherwise indicated. 
*) Remitting and unremitting course based on the disease activity in the years 3-5 after diagnosis.
•) According to the revised ILAR classification (1)
º) Patients with RF-positive polyarthritis not included in the analysis of subtypes because of the low number of 
patients. 
1) p-value of Pearson’s Chi-square
2) p-value of Mann Whitney U test
†) Analysis of ANA only in persistent oligoarthritis, extended oligoarthritis and RF- negative polyarthritis.
§) p-value of <0.05 statistical significant
&) calculated over the time when disease was active
3) monotherapy or combined with NSAIDs 
4) monotherapy or combined with other drugs besides Etanercept
&) Difference between MTX early and late
5) always combined with MTX 
6) monotherapy or combined with other drugs
118 Chapter 5
compared between the group of patients with a remitting and unremitting clinical 
course in years 3-5 in order to evaluate their relation to the clinical course (Table 4). 
A remitting clinical course during the years 3-5 was observed in 42.5% of the 
patients compared to 30.1% of patients with an unremitting disease course. No 
differences in age at onset, gender and ANA status were observed between patients 
with a remitting course and those with an unremitting course. When analyzing 
the different subtypes, the patients with RF-positive polyarthritis were excluded 
because of their small sample size. No difference in the percentage of remitting and 
unremitting clinical course was observed between the remaining subtypes. When 
the use of medication in the first two years was analyzed, it appeared that patients 
who had received only intra-articular steroids (combined with NSAIDs) as treatment 
showed more often a remitting clinical course (p=0.017), while patients that were 
treated with systemic glucocorticoids had a higher percentage of unremitting clini-
cal course (p=0.042). 
Most important, already in the first two years after diagnosis the percentage of time 
with active disease was significantly lower and the percentage of patients reach-
ing clinical remission significantly higher in patients who had a remitting clinical 
course in the following years (years 3-5) (p<0.001).  During the first two years, there 
were no differences in physicians’ global assessments or percentage of time periods 
with mild active disease observed between the patient groups with a remitting or 
unremitting course in year 3-5. This might indicate that reaching a state of inactive 
disease instead of a diminished disease activity should be the goal of treatment in 
JIA.
Predictive value of the percentage of active disease during the first 2 years
Figure 2 shows the percentage of time with active disease in the first 2 years plotted 
against the activity in the years 3-5. A significant correlation between the two variables 
is observed both in the overall JIA population as well as in each subtype (p <0,05; data 
not shown). The percentage of active disease in the first two years was categorized into 
remitting, intermediate and unremitting course (following the same definition as used 
for years 3-5), and compared to the clinical course in years 3-5 (Figure 2 and Table 5). 
Furthermore the positive and negative predictive values of having a remitting or unre-
mitting course in the first two years after diagnosis in relation to the course in years 3-5 
are listed in Table 5. The positive predictive value of having a remitting disease in the 
first two years of disease was 90.9%, whereas the negative predictive value of having 
an unremitting clinical course in the first two years is 91.3%.  
Analyzing the clinical variables assessed in the first two years and their associa-
tion with activity of the longer term (years 3-5) resulted in a significant association 
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Figure 2. The percentage of time with active disease in the first 2 years after diagnosis plotted 
against the percentage of time with active disease in the three following years (n=146).
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between the time with active disease in the first 2 years and the duration of active 
disease in the following three years. Patients with a remitting course in the first two 
years are not likely to develop a more severe course, whereas patients categorized 
as having no unremitting course are not likely to develop an unremitting course. 
It seems that the disease activity (category) in the first two years can be used as 
predictive factor for the disease in the following years. 
table 5. Categorized clinical course of first two years against the clinical course of the following 
three years
Activity first 2 years Activity  year 2-5 Positive 
predictive value
negative 
predictive valueremitting intermediate unremitting
Remitting 20 (90.9) 2 (9.1) 0 (0) 90.9 66.1
Intermediate 28 (59.6) 13 (27.7) 6 (12.8)
Unremitting 14 (18.2) 25 (32.5) 38 (49.4) 49.4 91.3
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discussion
This study shows that the clinical course, indicated by the percentage of time with 
active disease in the first two years after diagnosis, is different in the JIA subtypes. 
Patients with extended oligoarthritis seem to have the most severe clinical course with 
respect to time with active disease and not achieving remission, compared to patients 
with persistent oligoarthritis and RF-negative polyarthritis and should be regarded as 
a separate entity. This higher percentage of active disease in extended oligoarthritis 
might be due to less aggressive treatment; significant less patients with extended oli-
goarthritis received methotrexate in the first two years (38%), compared to RF- nega-
tive polyarthritis patients (65%; p=0.002). This suggests that extended oligoarthritis 
patients should be treated more aggressively and/or earlier in their clinical course. 
The observed disease activity in the RF-positive polyarthritis patients is the high-
est of all, but because of the small number of patients included in this study, no 
conclusions can be drawn concerning this subtype. The percentage of time with 
active disease in the different subtypes in this cohort of JIA patients is similar to the 
percentages of active disease that are described by Wallace et al and Oen et al.8;9 
These similarities suggest that the percentage of active disease is representative for 
the different subtypes and a reproducible measure for sequential disease activity 
during the course of the disease.
In the systemic JIA subtype it is already known that a broad spectrum of disease 
activity with a monocyclic or intermittent course as well as an unremitting disease 
courses exists. Moreover, in all subtypes a broad spectrum of disease activity is 
observed in individual patients, varying from a small percentage of time with active 
disease to no inactive episodes at all. For the individual patient it would be more 
relevant to identify clinical prognostic factors that are associated with a remitting or 
unremitting clinical course. 
In this study different clinical parameters have been tested for their association with 
the clinical course in the years 3-5 after diagnosis. We have chosen assess these 
different parameters in the first two years after diagnosis. We assumed that a mini-
mum of two years are required after diagnosis to treat the patient with the optimal 
medication and evaluate its effectiveness and therefore this period might give a 
good representation of the disease activity after onset in the individual patient. 
In all subtypes the percentage of active disease in the first 2 years after diagnosis 
is strongly associated with the clinical course in the following three years and can 
reliably be used to identify patients with a remitting or a non-unremitting clinical 
course. We have defined the clinical course based on the percentage of time with 
active disease; patients with an unremitting course having active disease 65-100% 
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of the time, thus only a short time with disease quiescence. It should be noted that 
no detailed information about the activity of a JIA-associated uveitis was available, 
so patients with inactive disease could be having an active uveitis. However, patients 
with only mild arthritis and an ongoing severe uveitis were excluded from the study. 
In contrast to the study of Oen et al, in this study no associations between subtype, 
ANA status and age at onset and the clinical course were observed.13 Association 
with the types and symmetry of joints involved at disease onset was not studied 
because of the lack of detailed data on joint involvement. 
Our data show that in the overall JIA population up to 30% of the patients have an 
unremitting clinical course in the years 3-5 after diagnosis, indicating that the treat-
ment regime used in this patient cohort is not sufficient to induce long lasting dis-
ease quiescence. However patients included in this study having a follow-up of >= 5 
years were diagnosed before May 2003 and only 6 patients used Etanercept and no 
patients used other biologicals. In the last years more patients have efficiently been 
treated with Etanercept and other biologicals like IL1-receptor antagonist or anti 
IL-6.14 Future studies should be performed to evaluate the clinical disease course of 
patients treated with these drugs. 
In conclusion, differences in percentages of active disease between JIA subtypes have 
been observed, but more important; within each subtype individual patients can have 
both a remitting or unremitting clinical course. For the individual patients the clinical 
course in the first two years after diagnosis is clearly related to  the clinical course in 
the following three years. Studies in rheumatoid arthritis show that reaching sustained 
remission early in the course of disease by using a more aggressive initial treatment 
is related to an improved radiographic outcome and less joint damage.15-17 This study 
shows that a lower percentage of active disease in the first two years is related to a mild 
course of disease afterwards. Also in JIA, reaching a state of clinical remission early 
in the course of disease should be the aim for treating patients and therefore a more 
aggressive initial treatment might be necessary. Future studies are needed to identify 
prognostic factors that could already be determined at disease onset and could reli-
ably point out the patients that are at risk of an unremitting disease course and should 
be treated with early aggressive treatment.
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The course of disease in Juvenile Idiopathic Arthritis (JIA) is unpredictable with episodes 
of activity and remission. In order to identify predictive factors, 93 SNPs, JIA subtype, 
age at onset and ANA status were studied in relation to disease course.
Methods
Genetic and clinical parameters were analysed in a cohort of 272 Caucasian patients 
with persistent oligoarthritis (n=129), extended oligoarthritis (n=57) and rheumatoid 
factor negative polyarthritis (n=86). Categories of disease course (remitting (n=65), 
intermediate (n=96) and unremitting (n=111)) were designed based on the cumulative 
time spent in active disease in the first two years. 
results
Univariate analysis revealed association of the course of disease with JIA subtype
(p=5.7*10-5) and three SNPs; VTCN1 rs10923223 (p=4.4*10-5), VTCN1 rs12046117 
(p=0.017) and CDK6 rs42041 (p=0.038). In a subsequent multivariate ordinal lo-
gistic regression analysis, VTCN1 rs10923223 (OR 0.41, 95%-CI 0.26-0.63) and JIA 
subtype (OR 3.8, 95%-CI 2.0-7.2; OR 2.5, 95%-CI 1.4-4.2, for extended oligoarthritis 
and RF-negative polyarthritis versus persistent oligoarthritis, respectively) were the 
strongest independent factors for course of disease.
conclusion
This study provides evidence that VTCN1, encoding B7-H4, is associated with course 
of disease in selected subtypes of JIA. VTCN1 might be useful in predicting the course 
of disease.
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inTroducTion
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders characterized 
by chronic inflammation of the joint(s). JIA is thought to be an autoimmune disease in 
which the immune response is deregulated.1 Clinical course and outcome are of great 
importance to patients, parents and physician. In outcome studies using a variety of 
criteria for remission, an overall remission rate of 40% has been reported. The high-
est remission rate was consistently observed in persistent oligoarthritis compared to 
extended oligoarthritis and rheumatoid factor (RF)-negative polyarthritis.2-4 Because 
the course of disease is unpredictable and fluctuating in all JIA subtypes with episodes 
of active and inactive disease, the cumulative time spent in a state of active disease 
is an accurate measure for the disease activity over time.4-6 Since it is unethical to 
study patients who do not receive treatment, course of disease is inevitably defined for 
patients receiving treatment if and when necessary. The percentage of active disease in 
the first years is not only predictive for the course of disease in the following years,2, 6 
but a prolonged disease activity is also related to damage to the joints or functional 
impairment.7 The aim of treatment is to minimize the time spent in active disease.
No clinical parameters or biomarkers are available at disease onset to predict the 
course of disease.8 Genetic markers would be ideal as predictive factors, already 
present at disease onset and not influenced by disease activity or medication. 
Recently, a number of genetic susceptibility factors for JIA (e.g. HLA, PTPN22, PTPN2 
and IL2RA) have been described and replicated by means of genome-wide and 
candidate gene association studies.9-11 Some of these genetic risk factors are also 
involved in other autoimmune diseases.  
The aim of this study was to identify genetic factors associated with severity of 
JIA. The relationship between single nucleotide polymorphisms (SNPs) in candidate 
genes involved in immunoregulation and autoimmunity and the percentage of ac-
tive disease in the first two years after diagnosis was investigated. 
MaTerials and MeThods
Patient population
Two hundred and seventy-two Caucasian JIA patients with persistent oligoarticular, 
extended oligoarticular and RF-negative polyarticular JIA of whom both DNA and clini-
cal data were available, were studied. Patients, recruited from eight centers throughout 
North-Western Europe, were diagnosed between 1991 and 2006 and had a follow-up 
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of at least two years. Informed consent was obtained from all patients and/or parents 
and the review boards of the participating centers approved this study (Table 1).
clinical data
All hospital visits during the first two years after diagnosis have been retrospectively 
evaluated to determine the state of disease activity at each visit. Inactive disease was 
defined as the absence of clinically active arthritis, the lowest possible physician’s 
global assessment and an ESR <20 mm/hr (following a modified definition of clinically 
inactive disease).12 The cumulative time spent in active disease in the first two years 
was determined and formed the basis for the categories of disease course:6 remitting 
(<= 35% active disease), intermediate (35-65% active disease) and unremitting (>= 
65% active disease) (Table 1). 
Genetic factors
112 SNPs in 65 genetic regions were genotyped, because of their association with 
JIA, other autoimmune diseases and/or their role in immunoregulation (Supplementary 
Table S1). 
statistical analysis
The three categories representing course of disease were used as outcome parameter. 
Univariate analysis was performed with the clinical parameters JIA subtype, age at 
onset and ANA status using Chi-square and Kruskal-Wallis tests, and with the genetic 
parameters comparing the genotype distribution of each SNP between the categories 
of disease course with a linear by linear trend test. The linkage disequilibrium of as-
sociated SNPs (p<0.05) was studied using parental data (Haploview).13 
Parameters with a p-value <0.05 in the univariate analysis were analyzed by multi-
variate ordinal logistic regression. Odds ratios and 95% confidence intervals (CI) are 
presented. A p-value <0.001 was considered significant after Bonferroni correction 
for multiple testing (57 successfully typed genes/loci). ROC curves were plotted for 
two models with different parameters predicting course at disease onset (Supple-
mentary Table S2 and Figure S1). A case-control analysis was performed with the 
SNPs that were associated with course of disease (p<0.05), to evaluate their role in 
susceptibility to JIA (Supplementary Table S3). Data were analyzed using IBM SPSS 
Statistics 20.
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   The Netherlands 138 (50.7)
   Belgium 45 (16.5)
   Germany 49 (18.0)
   Switzerland 40 (14.7)
Subtype
   Persistent oligoarthritis 129 (47.4)
   Extended oligoarthritis 57 (21.0)
   RF negative polyarthritis 86 (31.6)
Gender
   Female 190 (69.9)
   Male 82 (30.1)
ANA
   Positive 153 (56.3)
   Negative 86 (31.6)
   Inconclusive/unknown 33 (12.1)
Course of diseasec
   Remitting course 65 (23.9)
   Intermediate course 96 (35.3)
   Unremitting course 111 (40.8)
Medicationd
   Intra-articular steroids (n=166) 63 (38.0)
   Sulfasalazine (n=218) 73 (33.5)
   Methotrexate (n=238) 97 (40.8)
   Etanercept (n=233) 4 (1.7)
median range
Percentage of active diseasee  
   Total cohort
   Remitting course
   Intermediate course









Age at onset 3.98 (0.6-16.2)
a) Written informed consent from patients and parents was obtained after a personalised informative letter from 
the local investigator and the coordinating centre, in their native language. The majority of patients partici-
pated by taking a buccal swab at home and sending this to the coordinating centre. They authorised storage 
and analysis of their DNA for this and further JIA related research. 
b) Paediatric rheumatologists in the participating centres (The Netherlands n=5, Belgium n=1, Germany n=1, and 
Switzerland n=1) are all members of the Paediatric Rheumatology European Society (PRES).
c) Remitting clinical course: percentage of active disease in the first two years <= 35%; intermediate clinical 
course: percentage of active disease in the first two years >35 and <65%; unremitting clinical course: percent-
age of active disease in first two years >=65%.
d) Treatment was started in the first two years after diagnosis. Notable is that not of all patients the detailed data 
on use of medication are known (n).
e) Percentage of active disease in the first two years after diagnosis.
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resulTs
93 of 112 SNPs (83%) located in 57 genes/loci were successfully genotyped in 272 
patients (Supplementary Table S1). This cohort consisted of 65 patients with a remit-
ting course of disease, 96 patients with an intermediate course, and 111 patients with 
an unremitting course (Table 1).
In univariate analysis JIA subtype, but not ANA status or age at onset, was signifi-
cantly associated with the course of disease; the persistent oligoarthritis patients 
had more intermediate and remitting disease course, whereas the majority of ex-
tended oligoarthritis and RF-negative polyarthritis patients followed an unremitting 
table 2. Univariate analysis of clinical and genetic parameters with the categories representing dis-
ease course as outcome parametera.
remitting intermediate unremitting p
subtype
    Persistent oligoarthritis 45 (0.35) 48 (0.37) 36 (0.28)
    Extended oligoarthritis 6   (0.11) 17 (0.30) 34 (0.60)
    RF-negative polyarthritis 14 (0.16) 31 (0.36) 41 (0.48) 5.7*10-5 b 
ANA
    Positive 21 (0.24) 28 (0.33) 37 (0.43)
    Negative 33 (0.22) 59 (0.39) 61 (0.40) 0.65b
Age at onset (median, range) 4.0 (1.0-15.0) 3.2 (0.6- 14.9) 4.3 (1.0- 16.2) 0.49c
Gene snp Genotype Remitting Intermediate Unremitting pd
CDK6 rs42041 00 31 (49.2) 55 (59.8) 69 (65.1)
01 27 (42.9) 32 (34.8) 33 (31.1)
11 5 (7.9) 5 (5.4) 4 (3.8) 0.038
MAF (G) 0.29 0.23 0.19
VTCN1 rs10923223 00 33 (51.6) 63 (67.0) 88 (79.3)
01 26 (40.6) 29 (30.9) 22 (19.8)
11 5 (7.8) 2 (2.1) 1 (0.9) 4.4*10-5
MAF (C) 0.28 0.18 0.11
VTCN1 rs12046117 00 40 (62.5) 64 (69.6) 88 (79.3)
01 23 (35.9) 27 (29.3) 22 (19.8)
11 1 (1.6) 1 (1.1) 1 (0.9) 0.017
MAF (T) 0.20 0.16 0.11
LCK rs695161 00 22 (33.8) 27 (28.4) 28 (25.7)
01 33 (50.8) 53 (55.8) 51 (46.8)
11 10 (15.4) 15 (15.8) 30 (27.5) 0.051
MAF (C) 0.41 0.45 0.51
a) Only the SNPs of interest with a p-value <0.1 are shown.  
b) p-value of Pearson Chi-square test
c) p-value of Kruskal-Wallis test
d) p-value of linear by linear association (trend test) with one degree of freedom
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disease course (p=5.7*10-5) (Table 2). Comparing the genotype distribution in the 
three categories reflecting course of disease revealed three SNPs that were asso-
ciated (p<0.05). Two of these SNPs were located in the VTCN1 gene, rs10923223 
(p=4.4*10-5) and rs12046117 (p=0.017) and a third association was found with 
CDK6 rs42041 (p=0.038) (Table 2). The minor alleles of the three SNPs were associ-
ated with a remitting course. None of the other investigated SNPs were associated, 
except a trend towards association with LCK rs695161 (p=0.051). Because two of the 
associated SNPs (rs10923223 and rs12046117) were located in the VTCN1 gene, the 
linkage disequilibrium was studied. The two SNPs were highly correlated (D’=0.97; 
r2=0.77). Therefore we have included only VTCN1 rs10923223 in further analyses. 
In multivariate ordinal regression analysis, JIA subtype (extended oligoarthritis 
and RF-negative polyarthritis, with persistent oligoarthritis as reference; extended 
oligoarthritis OR 3.8, 95%-CI 2.0-7.2, p=6.3*10-5; RF-negative polyarthritis OR 2.5, 
95%-CI 1.4-4.2, p=9.0*10-4) and the genetic factors VTCN1 rs109232203 (OR 0.41, 
95%-CI 0.26-0.63, p=5.8*10-5) and CDK6 rs42041 (OR 0.66, 95%-CI 0.44-0.97, 
p=0.036) were independently associated with course of disease (Table 3). The ad-
dition of VTCN1 rs10923223 and CDK6 rs42041 to a model predicting course of 
disease at diagnosis in which only subtype at onset is included, increases the AUC 
of an ROC curve from 0.57 to 0.67 (Supplementary Table S2 and Figure S1).
discussion
In this study we describe that genetic variations in VTCN1 (rs10923223 and rs12046117) 
and in CDK6 (rs42041) are associated with the course of disease in JIA. Our data show 
a protective effect of the minor allele of all three SNPs on the course of disease. This 
effect is independent of the association that exists between the JIA subtype and the 
course of disease. Because CDK6 is involved in cell-cycling, the association of disease 
table 3.  Multivariate ordinal logistic regression of associated clinical (subtype) and genetic param-
eters (VTCN1, CDK6).
b or 95%ci p
subtype
Persistent oligoarthritis vs. extended 
oligoarthritis
1.33 3.8 2.0-7.2 6.3*10-5
Persistent oligoarthritis vs. RF-negative 
polyarthritis
0.90 2.5 1.4-4.2 9.0*10-4
VTCN1 rs10923223 -0.90 0.41 0.26-0.63 5.8*10-5
CDK6  rs42041 -0.42 0.66 0.44-0.97 0.036
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course with CDK6 rs42041 is not unlikely. However, this association is not significant 
after correction for multiple testing. 
Interestingly, the association of VTCN1 with the course of disease is in line with the 
described function of the encoded protein. VTCN1, V-set domain containing T cell 
activation inhibitor 1, encodes B7-H4, a member of the B7 co-signaling molecule 
family expressed on antigen presenting cells.14,15 Ligation of B7-H4 has an inhibitory 
effect on T-cell proliferation and production of cytokines.14,15 Because of its inhib-
iting effects on immune responses B7-H4 has been associated with prognosis in 
cancer and autoimmunity.16,17 
In B7-H4 deficient mice an exacerbation of collagen induced arthritis was observed.18 
An agonistic soluble B7-H4Ig suppressed the progression of collagen induced ar-
thritis and improved the progression of experimental autoimmune encephalomyeli-
tis.18,19 Targeting of this inhibitory B7-H4 pathway might be of therapeutic interest, 
similar to the CTLA4 fusion protein (Abatacept) in rheumatoid arthritis. 
In our cohort no significant association of VTCN1 with the susceptibility to JIA was 
observed (Supplementary Table S3), but instead an association of the minor allele 
of rs10923223 with a less severe course of disease (Table 2). It is conceivable that 
the minor allele is associated with a gain of function of VTCN1, leading to a stronger 
inhibitory signal to activated T cells. This hypothesis implies that VTCN1 does not 
contribute to initiation but rather to the course of the disease. At present it is very 
difficult to predict the course of disease at the moment of diagnosis. The addition 
of VTCN1 and CDK6 to the predictive model for disease course increased the AUC 
(Supplementary Table S2 and Figure S1). Although the total predictive power is still 
limited it suggests that genetic information may contribute to prognosis in the case 
of JIA.
It is remarkable that the well-established JIA loci PTPN22, 4q27 (IL2-IL21), 5q11 
(ANKRD55) and TNFA were not associated with course of disease, although they were 
associated with susceptibility in our cohort as well (Reinards et al. manuscript in 
preparation).9-11, 20 This suggests that genes involved in the development of disease 
are not necessarily involved in the progression of disease. Replication of our data 
remains necessary since patient numbers are relatively small when comparing cat-
egories of disease course. However, if association of VTCN1 with course of disease 
will be confirmed, these data support the development of therapeutic tools based 
on interfering with this receptor ligand interaction in JIA and maybe other auto-
immune diseases. 
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suPPleMenTary daTa 
roc curve
To give more insight into the predictive value for disease course of the parameters that 
can be used at disease onset (when persistent oligoarthritis cannot be distinguished 
from extended oligoarthritis yet), a ROC curve was plotted. The predictive value of an 
ordinal logistic regression model with subtype at onset (oligoarthritis versus polyar-
thritis at presentation) as only parameter was plotted (Figure S1a), followed by a model 
of the subtype at onset together with the genetic parameters with an independent 
effect in the multivariate analysis (Figure S1b). 
control population
A case-control analysis was performed with the SNPs that were associated with course 
of disease (p<0.05), to evaluate their role in developing JIA. 
The control population, used to determine allele frequencies of VTCN1 rs10923223 
and rs12046117 in healthy individuals, consisted of blood bank donors that were 
randomly selected by the Immunogenetics and Transplantation Immunology Section 
at Leiden University Medical Center, The Netherlands (n=758), or that were recruited 
via participating patients and their families (but unrelated) (n=111). Because there 
was not sufficient DNA for all of these controls to type all SNP’s, 744 additional indi-
viduals were included in case of CDK6 rs42041. These individuals were blood bank 
donors (n=372) or requested genetic counselling at the Laboratory for Diagnostic 
Genome Analyses, Leiden University Medical Center, regarding a monogenic disease 
in their families, but tested negative for this single genetic defect (n=372).
All controls were unrelated, of Caucasian descent, above the age of 18 years, and 
gave informed consent for anonymized (further) use of their (left over) DNA for 
scientific purposes, and for anonymized use of their DNA in a biobank.
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Supplementary Table S1
Genetic variants selected for association analysis with course of disease in JIA
chromosome Position*  Gene/region snP Minor allele
1 2553624 TNFRSF14-MMEL1 rs3890745 G
1 12091210 TNFRSF8-MIIP rs946461 T
1 12252955 TNFRSF1B rs1061622 G
1 32729702 LCK rs1004420 T
1 32743866 LCK rs695161 C
1 114377568 PTPN22 rs2476601 A
1 117685992 VTCN1 rs6673837 A
1 117690758 VTCN1 rs2358817 T
1 117711911 VTCN1 rs2358820 A
1 117730048 VTCN1 rs10923217 C
1 117730623 VTCN1 rs6669320 A
1 117746573 VTCN1 rs10923223 C
1 117751365 VTCN1 rs12046117 T
1 198700442 PTPRC rs10919563 A
1 206946897 IL10 rs1800896 C
1 207015957 IL19 rs2243191 T
1 207038686 IL20 rs1400986 T
2 100832155 AFF3 rs1160542 G
2 100835734 AFF3 rs10865035 A
2 103070568 IL18RAP rs917997 T
2 113537223 IL1A rs17561 A
2 113542960 IL1A rs1800587 A
2 113590390 IL1B rs1143634 A
2 113594867 IL1B rs16944 A
2 162856148 DPP4 rs2268894 C
2 191835596 STAT1 rs3771300 C
2 191843445 STAT1 rs13010343 A
2 191845725 STAT1 rs1547550 C
2 191855521 STAT1 rs7562024 T
2 204610396 CD28 rs1980422 C
2 204732714 CTLA4 rs231775 G
3 46414947 CCR5 rs333 del
3 58556841 FAM107A rs13315591 C
4 26108197 4p15 rs874040 G
4 123132492 KIAA1109 rs4505848 G
4 123348345 ADAD1 rs11732095 G
4 123514528 IL2-IL21 rs4492018 A
4 123548068 IL21 rs1398553 T
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Supplementary Table S1 (continued)
Genetic variants selected for association analysis with course of disease in JIA
chromosome Position*  Gene/region snP Minor allele
5 55438580 ANKRD55 rs6859219 A
5 96124330 ERAP1 rs30187 T
5 135287029 LECT2 rs31517 A
6 31540141 LTA rs2239704 A
6 31540313 LTA rs909253 G
6 31540784 LTA rs1041981 A
6 31542482 TNFA rs1799724 T
6 31542963 TNFA rs1800750 A
6 31543031 TNFA rs1800629 A
6 31543101 TNFA rs361525 A
6 31543827 TNFA rs1800610 A
6 31544189 TNFA rs3093662 G
6 57012930 ZNF451 rs3734738 A
6 106568034 PRDM1 rs548234 C
6 138006504 6q23 rs6920220 A
6 159482521 TAGAP rs394581 C
6 167534290 CCR6 rs3093023 A
7 75442759 CCL24 rs2302005 T
7 75442855 CCL24 rs2302004 C
7 92246744 CDK6 rs42041 G
7 128594183 TNPO3 rs10488631 C
9 34743681 CCL21 rs951005 C
9 139775146 TRAF2 rs7048473 C
9 139787453 TRAF2 rs2811761 G
9 139815053 TRAF2 rs10781522 G
9 139821068 TRAF2 rs3750512 C
10 6053163 IL2RA rs12722605 T
10 6099045 IL2RA rs2104286 G
10 6114660 IL2RA rs41295061 A
10 6393260 PRKCQ rs4750316 C
11 36525293 TRAF6 rs540386 T
11 71709272 IL18BP rs3814721 C
11 71710478 IL18BP rs2298455 C
11 71714078 IL18BP rs1541304 T
11 112035458 IL18 rs1946518 T
11 117869670 IL10RA rs2229113 A
12 6450945 TNFRSF1A rs767455 C
12 6451590 TNFRSF1A rs4149570 A
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Supplementary Table S1 (continued)
Genetic variants selected for association analysis with course of disease in JIA
chromosome Position*  Gene/region snP Minor allele
12 57968715 KIF5A rs1678542 C
16 11179873 CLEC16A rs12708716 G
16 11249329 CLEC16A rs6498169 G
16 27448401 IL21R rs3093341 G
16 67189486 TRADD rs11574518 T
17 32594568 CCL2-CCL7 rs8079244 C
17 40447401 STAT5A rs7217728 C
17 40461003 STAT5A rs2293154 A
18 67531642 CD226 rs763361 T
19 44515514 ZNF230 rs12753 A
20 43280231 ADA rs6031698 A
20 44746982 CD40 rs1883832 T
21 34640788 IL10RB rs2834167 G
22 24236392 MIF rs755622 C
22 37544245 IL2RB rs3218258 T
22 37544810 IL2RB rs3218253 T
22 37551607  IL2RB rs743777 G
*) Base-pair position is based on NCBI dbSNP build 136
112 SNPs in 65 loci have been genotyped by the iPLEX MassARRAY platform according to the manufacturer’s 
recommendations (Sequenom, San Diego, California, USA), of which these 93 SNPs in 57 loci passed quality 
control criteria. Only SNPs exceeding a 90% call rate were used for further analysis. SNP call rates per indi-
vidual exceeded 90%.
Supplementary Figure S1
ROC curves of predictive models for course of disease
AUC: 0.57	   AUC: 0.67	  
a.	  Only	  subtype	  at	  onset	  included	  
as	  predictor	  
b.	  3ubtype	  at	  onset	  and	  4ene5c	  
parameters	  included	  as	  predictors	  	  
AUC: area under the (solid) curve
The dashed line represents the reference.
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Supplementary Table S3
Genotype frequencies of the SNPs of interest in JIA cases compared to healthy controls
Gene snP  n Maf* Genotype   p#
     00 (%) 01 (%) 11 (%)  
VTCN1 rs10923223 Cases 269 0.17 184 (68) 77   (29) 8  (3)  
Controls 856 0.14 622 (73) 221 (26) 13 (2) 0.10
VTCN1 rs12046117 Cases 266 0.15 191 (72) 72   (27) 3   (1)  
Controls 848 0.13 640 (76) 197 (23) 11 (1) 0.30
CDK6 rs42041 Cases 261 0.23 155 (59) 92 (35) 14 (5)
  Controls 1274 0.26 713 (56) 465 (37) 96 (8) 0.19
*) MAF: minor allele frequency
#) p-value of linear-by-linear association (trend test with one degree of freedom)
Supplementary Table S2
Clinical and genetic parameters as predictors for course of disease plotted in a ROC curve
Figure Parameters included AUC*
S1a Subtype at onset# 0.57
S1b Subtype at onset#, VTCN1 rs10923223, and CDK6 rs42041 0.67
*) Area under the curve (AUC) reflecting the ability to distinguish between remitting, intermediate and 
unremitting disease
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 Methotrexate (MTX) is the most commonly used disease modifying antirheumatic drug 
in Juvenile Idiopathic Arthritis (JIA). At present no reliable prediction of individual re-
sponse to MTX can be made. Identification of clinical and genetic factors that influence 
the response to MTX could be helpful in realizing the optimal treatment for individual 
patients. 
Materials & methods
A cohort of 128 JIA patients treated with MTX was studied retrospectively. Eleven 
clinical parameters and genotypes of 6 single nucleotide polymorphisms in 5 genes 
related to the mechanism of action of MTX were compared between MTX responders 
and non-responders using a multivariate regression analysis.
results
The time from diagnosis to start MTX treatment, the physician’s global assessment at 
baseline and the starting dosage were significantly associated with the response to 
MTX at 6 months after initiation. Patients with a shorter time from diagnosis to start 
MTX and a higher disease activity according to the physician, but with a lower MTX 
dosage showed increased response. The effect of the starting dosage on MTX response 
seemed to be mainly due to the influence of the systemic JIA subtype. The time from 
diagnosis to start MTX treatment and physicians’ global assessment at baseline were 
highly correlated. Therefore, the precise effect size of each independent variable could 
not be determined.  
conclusion
In children with JIA, the time from diagnosis to start MTX appears to be an important 
factor for the MTX response. Our results suggest that earlier start of MTX treatment will 
lead to an increased response.  
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inTroducTion
Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic inflammatory 
disorder in childhood, with an incidence of around 10 per 100.000 children.1 JIA is 
defined as arthritis of unknown etiology that persists for more than 6 weeks and with 
an onset before the age of sixteen years. Seven different subtypes have been defined 
according to the criteria of the International League of Associations for Rheumatology 
(ILAR).2 
Methotrexate (MTX) is the most commonly used disease modifying antirheumatic 
drug (DMARD) in JIA, especially in the treatment of polyarticular JIA.3 The efficacy 
of MTX has been shown in randomized placebo controlled trials and in subsequent 
clinical use.4;5 The response rate of MTX, prescribed in a weekly standard dose of 
8.5-12.5 mg per body surface area (m2), is about 65% at 4-6 months after initiation 
of therapy.4;6-8 
The precise mechanism of action of MTX remains unclear, although it is thought that 
MTX inhibits the de novo synthesis of purine and pyrimidine, essential components 
of DNA and RNA.9;10 Thereby it inhibits the proliferation of cells, amongst which 
T-lymphocytes. Additionally it has been shown that the anti-inflammatory effects 
of MTX are mediated by an increased adenosine-release. More recently research 
groups have reported that genetically based differences contribute to MTX efficacy 
since polymorphisms in genes involved in the purine and pyrimidine synthesis have 
been associated with response to MTX in JIA and RA.11-13
However in JIA, reliable predictors for the response to MTX are yet unknown. Factors 
identifying JIA patients with a high likelihood to respond to MTX therapy would be 
very helpful for achieving the optimal treatment for individual patients in an early 
stage of the disease and thereby preventing damage to the joints on the long term. 
Therefore, the aim of this study is to identify clinical and genetic factors that are 
associated with the response to MTX in patients with JIA. 
MeThods & MaTerials 
Patient population
The patients in this analysis are a retrospectively observed cohort of children diag-
nosed with JIA that were recruited from 4 pediatric rheumatology referral centers in 
The Netherlands, Belgium and Germany. Clinical data were collected from 347 patients 
of which also DNA was available. Forty-four percent of these patients were treated with 
MTX (n=152) and 128 patients fulfilled the inclusion criteria for this study. Twenty-four 
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patients were excluded because: at start of MTX> 18 years (n=5), start MTX < 6 months 
ago (n=5), use of MTX because of JIA associated uveitis (n=3) and missing data about 
follow-up (n=11).  No statistical significant differences were found with regard to sub-
type, age at onset and gender between the 128 genotyped patients and the total group 
of patients receiving MTX (p>0.05). Patients with undifferentiated JIA (n=5), JIA with 
enthesitis (n=4) and psoriatic arthritis (n=1) were grouped together in the subgroup 
“other JIA”.  97 Per cent of the patients were of European white ethnicity based on 
self-report. Written informed consent was obtained from all patients and/or parents 
together with approval of each institution’s medical ethics board. 
clinical data
Demographic and clinical data, together with detailed information about the use of 
MTX and co-medication were collected from the patients’ chart. At the time point of 
start and at 6 months after initiation of MTX, the following parameters were scored: the 
physician’s global assessment of disease activity, the amount of joints with arthritis 
(defined by swelling, not due to bony enlargement, or if no swelling is present, limita-
tion of motion accompanied either by pain on motion and/or tenderness) (32 joint 
count) and the erythrocyte sedimentation rate (ESR). The physician’ global assessment 
was scored at a five point scale (1 no, 2 mild, 3 moderate, 4 severe and 5 very severe 
activity). In addition, the joint score was divided into categories with 0 no arthritis, 1 
monoarthritis (1 joint), 2 oligoarthritis (2-4 joints), 3 polyarthritis (5-10 joints), 4 severe 
polyarthritis (>11 joints) and in systemic JIA patients an additional category (5) was 
used when systemic features were present. 
Definition of response
The response to MTX was defined as follows: improvement in physician’s global assess-
ment of 1 or more categories together with an equal or improved joint score measured 
from baseline to 6 months after the start of MTX. The ESR was not incorporated in 
the definition of response because of the large number of missing data. Patients were 
considered non-responders to MTX if they did not fulfill the criteria of response. 
Pharmacogenetics
Six single nucleotide polymorphisms (SNPs) in 5 candidate genes, related to the 
mechanism of action of MTX, were selected taking the following criteria into consid-
eration: validated SNP, SNP -preferably- causing non-synonymous amino acid change, 
indications for clinical relevance from previous publications11-13 and a preferred 
minimal genotype frequency of approximately 10%. These SNPs were located in the 
genes adenosine monophosphate deaminase (AMPD1) (34C>T; rs17602729), amino-
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imidazole carboxamide ribonucleotide transformylase (ATIC) (347C>G; rs2372536), 
inosine triphosphate pyrophosphatase (ITPA) (94C>A; rs41320251) methylenetet-
rahydrofolate reductase (MTHFR) (677C>T; rs1801133 and 1298A>C; rs1801131) 
and in methylenetetrahydrofolate dehydrogenase (MTHFD1) (1958G>A; rs2236225). 
Genotyping was performed using real-time polymerase chain reaction (PCR) with Taq-
man technique according to protocols provided by the manufacturer (Taqman, Applied 
Biosystems, Foster City, CA, USA). 5-10% of samples were genotyped in duplicate. The 
mean for overall success rate was 96%. All 6 SNP genotype frequencies showed Hardy-
Weinberg equilibrium. 
statistical analysis 
Clinical variables considered relevant for the response to MTX at 6 months after initia-
tion were: subtype of JIA, age at start MTX, time from diagnosis to start MTX (time-to-start 
MTX in months), disease activity at start MTX (physician’s global score, joint score), ESR, 
starting dosage MTX (milligrams per body surface area per week), use of intra-articular 
steroids  and/or sulfasalazine (SSZ) and/or other DMARDs before MTX (yes/no), use of 
systemic steroids before MTX (yes/no), use of systemic steroids during MTX treatment 
(yes/no) and use of SSZ during MTX treatment (yes/no). These variables were com-
pared between responders and non-responders by the Student’s t-test, Mann-Whitney 
U test or Chi-square test depending on the tested variable. Differences in genotype 
distribution between responders and non-responders were tested in a two-by-two 
cross tabulation by carrier analysis with a two-sided Chi-square test. MTHFR 677C>T 
and MTHFR 1298A>C were only tested as number of copies of the MTHFR1298A-677C 
haplotype. With the sample size of 55 non-responders and 73 responders, an increase 
in frequency of 2 haplotype copies (MTHFR1298A-677C) from 12% to 34% could 
be detected with 80% power and 95% confidence. Variables with a p-value of < 0.1 
between responders and non-responders were considered relevant for influencing 
the response to MTX either by a true effect of by confounding.  Therefore, variables 
with p-value <0.1 were included in the multiple binary logistic regression analysis with 
response as dependent. Additionally the univariate odds ratios (with 95% confidence 
interval) of these variables were calculated to illustrate the confounding effect of the 
different variables. ESR was not included in the multivariate analysis because of the 
large number of missing data.  All statistical analyses were performed using SPSS 14.0. 




description of the patient population
The clinical and demographic characteristics for responders and non-responders are 
presented in Table 1. In our cohort (n=128) the response rate at 6 months after initia-
tion of MTX was 44% in persistent oligoarthritis,  69% in extended oligoarthritis, 61% 
in RF negative polyarthritis, 82% in RF positive polyarthritis and 32% in systemic JIA, 
whereas the response rate in the overall JIA population with these subtypes combined 
was 57% (Table 1).  In addition the comparison of the clinical and demographic charac-
teristics of the MTX responders and MTX non-responders is listed in Table 1. 
table 1.
Clinical and demographic characteristics of 128 JIA patients, according to their response to MTX# 
MTX non-responder  
% (n)
MTX responder          
% (n)       
p-value*
Total group of JIA patients 43   (55) 57   (73)
Diagnosis:1 0.050 P
   Persistent oligoarthritis 56   (10) 44   (8)
   Extended oligoarthritis 31   (8) 69   (18)
   RF negative polyarthritis 39   (17) 61   (27)
   RF positive polyarthritis 18   (2) 82   (9)
   Systemic JIA 68   (13) 32   (6)
   Other JIA• 50   (5) 50   (5)
Female:male 74:26 (41:14) 79:21  (58:15) 0.51 P 
Age at start MTX (years), mean (range; sd2) 7.9    (1.9- 15.9; 3.7) 7.7   (1.3- 17.4; 4.3) 0.82 t
Time-to-start-MTX in months, median (range ) 16.3  (0.0- 150) 9.5   (0.0- 94.8) 0.074 MW
Medication:
Starting dosage MTX (mg/m2) mean (range;sd) 10.4 (4.5- 23.7; 4.7) 8.6  (1.8- 16.5; 3.3) 0.018  t
SSZ,IAS or other DMARDs used before start MTX 
(yes/no)
58   (32) 56   (41) 0.82  P 
Systemic steroids used before start MTX (yes/no) 31   (17) 16   (12) 0.053  P 
SSZ used during MTX (yes/no) 33   (18) 32   (23) 0.88  P 
Steroids used during MTX (yes/no) 35   (19) 52   (38) 0.048  P 
Disease activity at start MTX:
ESR2 (mm/h), median (range) (n=67) 30   (7-137) 25  (2-107) 0.040  MW
Physician’s global assessment 0.000  lin
   1 Inactive 7    (4) 0     (0)
   2 Mild 16   (9) 4     (3)
   3 Moderate 55   (30) 56   (41)
   4 Severe 22   (12) 48   (28)
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Genetic analysis 
The genotype frequencies and the MTHFR haplotype frequencies in this population are 
presented in Table 2. Comparing MTX responders with non-responders in a haplotype-
carrier analysis, a statistically significant difference in number of MTHFR1298A-677C 
haplotype copies was found. Non-responders showed more frequently none or 1 copy 
of the MTHFR1298A-677C haplotype when compared to responders (p-value= 0.039). 
All other pharmacogenetic association analyses showed no significant differences.
   5 Very severe 0     (0) 1     (1)
Joint score 0.40  lin
  0 None 7     (4) 0     (0)
  1 Monoarthritis 2     (1) 4     (3)
  2 Oligoarthritis 35   (19) 31   (23)
  3 Polyarthritis 45   (25) 51   (37)
  4 Severe polyarthritis 0     (0) 11   (8)
  5 Systemic features 11   (6) 3     (2)
sd: standard deviation, SSZ: sulfasalazine, IAS: intra-articular steroid, DMARD: disease modifying anti rheumatic 
drug, ESR: erythrocyte sedimentation rate
#) all variables are presented as percentage (number of patients) unless indicated otherwise
•) other JIA consists of undifferentiated JIA (n=5), JIA with enthesitis (n=4) and psoriatic arthritis (n=1)
*) p-value of different statistical test comparing these clinical variables between the non-responders and re-
sponders.
1 Diagnosis JIA according to the revised ILAR criteria(2)
2 ESR not included in further analysis because of the large number of missing data 
P p-value of Pearson Chi-square
MW  p-value of Mann-Whitney U Test
t p-value of Student’s t-test
lin    p-value of linear-by- linear association
table 2. 





































































pº 0.183 0.748 0.279 0.503 0.039
*) The number of MTHFR1298A-677C haplotype copies
º) p-value of linear-by-linear association
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univariate and multivariate analysis of variables in relation to MTX response 
Variables with a p-value of <0.1 (Table 1 and 2) were considered of influence of the 
response to MTX and were analyzed univariately and thereafter included in a multivari-
ate regression analysis to correct for confounding effects (Table 3). 
In the multivariate regression analysis, the time-to-start MTX, the baseline physi-
cian’s global assessment and the starting dosage of MTX were significantly associ-
ated with the response to MTX at 6 months after initiation. No confounding effect of 
the included variables on the effect of time-to-start MTX on response was observed. 
Briefly, responders started earlier with MTX and had a higher disease activity at 
baseline based on the physician’s global assessment. What is more remarkable is 
that responders received a lower starting dosage. However, the starting dose MTX 
was highly influenced by the subtype of JIA (ANOVA p<0.001), especially by the 
systemic JIA patients who receive a higher starting dosage and have a decreased 
response. Repeating the multivariate analysis without the systemic JIA subtype re-
sulted in a significant association of the time-to-start MTX and baseline physician’s 
global assessment with MTX response (data not shown) and no effect of the starting 
dose on the MTX response was observed (OR 0.89, 95%CI 0.76- 1,05; p= 0.166). 
table 3 Univariate and multivariate regression analysis of clinical and genetic factors with MTX re-
sponse in JIA patients (n=118) as dependent variable. 
univariate analysis Multivariate analysis1
or (95% ci) p-value or (95% ci) p-value
JIA subtype* 0.069 0.441
   Persistent oligoarthritis 1.00 (reference)
   Extended oligoarthritis 2.81  (0.81- 9.80) 0.104 3.41  (0.62- 18.7) 0.159
   RF negative polyarthritis 1.99  (0.65- 6.03) 0.226 0.76  (0.18- 3.15) 0.700
   RF positive polyarthritis 5.63  (0.94- 33.8) 0.059 1.41  (0.16- 12.4) 0.757
   Systemic JIA 0.58  (0.15- 2.21) 0.422 0.68  (0.09- 5.12) 0.712
   Other JIA 1.25 (0.27- 5.89) 0.778 0.92  (0.14- 6.2) 0.933
Time-to-start-MTX (months) 0.98  (0.97- 0.996) 0.013 0.97  (0.95- 0.996) 0.021
Starting dosage MTX (mg/m2) 0.89  (0.81- 0.98) 0.023 0.84  (0.73- 0.97) 0.021
Steroid use during MTX (yes/no) 2.06 (1.00- 4.23) 0.050 2.34  (0.86- 6.34) 0.095
Steroid use before MTX (yes/no) 0.44  (0.19- 1.02) 0.056 0.43  (0.12-1.6) 0.205
Physician’s global assessment at 
start
2.6    (1.5- 4.7) 0.001 2.4    (1.1- 5.1) 0.026
MTHFR-haplotypeº 2.8 (1.03- 7.7) 0.043 2.3 (0.68- 7.7) 0.178
* JIA subtype as category with persistent oligoarthritis as reference subtype.
º 0 or 1 haplotype (MTHFR1298A-677C) copies versus 2 haplotype copies.
1 total R2 (Cox & Snell): 0.27
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Regarding the time-to-start MTX (Table 3), it is evident that the use of intra-articular 
steroids, SSZ and/or other DMARDs prior to MTX influences time-to-start MTX. Al-
though the use of prior treatment was not related to MTX response (Table 1), we 
analyzed whether the association of time-to-start MTX was independent of the 
use of prior treatment and a true effect for MTX response. Therefore the effect of 
time-to-start MTX on response was assessed including only patients with prior treat-
ments. This repeated multivariate analysis showed that the time-to-start MTX was 
still significantly associated to the response to MTX (OR 0.96, 95%CI 0.94-0.99; p= 
0.017). 
Finally, the time-to-start-MTX is strongly correlated to the physicians’ global as-
sessment at start MTX, meaning that patients with an increased disease activity are 
treated earlier. Interestingly, our data showed that the physicians’ global assessment 
at baseline also reflects the disease activity as measured from diagnosis to start 
MTX (data not shown). Although the precise effects size of time-to-start MTX and the 
physicians’ global assessment at baseline cannot be individually determined, from 
a clinical point of view it is important to observe that earlier treatment is related to 
increased response rates.  
discussion
In this retrospectively observed cohort of JIA patients, the time-to-start-MTX, the physi-
cian’s global assessment at baseline and the starting dosage are significantly associ-
ated with the response to MTX at 6 months. Patients with an earlier start of MTX and an 
increased disease activity show an increased response. Our finding that a lower starting 
dosage MTX is associated with increased response is mainly due to the systemic JIA 
patients, who receive a higher starting dose and show decreased response. 
Although treatment with intra-articular steroids, sulfasalazine and/or other DMARDs 
prior to MTX is an important determinant for the delay in starting MTX, only includ-
ing patients with prior treatments to MTX therapy still showed that an early start of 
treatment with MTX was  significantly associated with an increased response. This 
indicates that our data were not biased by population selection. 
Our data show that patients with an increased disease activity receive MTX earlier 
after diagnosis, which may partially reflect confounding by indication. Therefore, 
the independent effects of a higher physicians’ global assessment at baseline and 
the decreased time-to-start MTX on response cannot be determined in this analysis. 
The best evidence for these associations remains the replication in controlled trials 
with JIA patients.
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Because of the different treatment strategies and small numbers of patients in 
the different JIA subtypes, only associations with MTX response in the general JIA 
population were observed and no conclusion about the influences of response in 
individual subtypes can be drawn. 
With regard to the genetic parameters, only the MTHFR 1298A-677C haplotype 
showed a significant decrease in lower copy number in non-responders. This find-
ing is consistent with recent-onset rheumatoid arthritis where a higher number of 
haplotype copies was related to increased response to MTX.13 Remarkably, no other 
significant genetic associations with the response to MTX were detected. This may 
be due the small sample size resulting in an increased probability to obtain false 
negative findings (type 2 error). 
Our data analysis used a composite measure for response including the physi-
cian’s global assessment and the joint score. No frequent parent/ patient global 
assessment of overall well-being and information about limitation of joints could 
be retrospectively obtained from the patients’ chart. Although the definition of 
improvement as developed by Giannini et al.14 includes 6 core set variables, the 
two variables that were included in our definition of improvement are sensitive 
instruments for measuring change, with the subjective assessment of disease activ-
ity by the physician as the most responsive instrument.15 The independent factors 
are able to measure an improvement of 53-60%.16 Combined in our definition of 
improvement it generated a 57% response. Since improvement of the physician’s 
global assessment is part of our response definition and a higher physician’s global 
assessment at baseline is associated with response, the response rates in our cohort 
might be partly due to regression to the mean and an effect of unequal distance 
between the categories and will not fully reflect the true effect size of MTX. 
According to the distribution of subtypes, this retrospectively observed cohort is 
comparable to the clinical practice described by Brunner et al, indicating that no 
non-random exclusion of subtypes has occurred.3 In the different subtypes the 
response rates in this study are comparable to previous reported efficacy of MTX, 
except for persistent oligoarthritis.4-8 In the persistent oligoarthritis cohort of Brik et 
al an response rate of 90% has been reported in patients receiving  early treatment 
(maximum of 4.3 months), whereas our patients with persistent oligoarthritis had a 
response rate of 44% and were treated after a mean of 22.2 months (range 0-104 
months; sd 27.4).17 This difference in response rate underlines that also in persistent 
oligoarthritis early treatment with MTX may be an important factor for efficacy. 
In summary, in this JIA population, the time-to-start MTX is an important and in-
dependent factor for the response to treatment. Already in RA it has been shown 
that early treatment in the “widow of opportunity” is associated with an improved 
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clinical outcome and less radiographic damage.18 Although it is thought that JIA 
patients may show similar favorable effects of early treatment, our study is the first 
to illustrate that JIA patients have increased responses to MTX when treated earlier. 
Patients with a good clinical response to other DMARDs than MTX were not included 
in this study. Therefore, no conclusion about the effectiveness of MTX compared to 
other DMARDs or the association between time-to-start-MTX and other DMARDs in 
JIA can be drawn. 
In RA it has been shown that the onset of disease and immunologic events predate 
the symptoms by many years. The activation of RA is believed to be a multifactorial 
process that is followed by an ongoing progression of inflammation leading to bone 
damage already in the first year after diagnosis.19 Chronis arthritis in JIA patients 
probably has as similar early onset preceding the symptoms and a subsequent 
progression of inflammation. The increased response to early treatment with MTX, 
that is described in RA and shown in JIA in this study, might reflect the fact that MTX 
can suppress early stages of inflammation, but that the mechanism of action is less 
sufficient to control well-established chronic inflammation. 
It is clinically highly relevant that reducing the time-to-start MTX may lead to an 
increased response. Future prospective studies are needed to replicate these find-
ings and reveal the exact window of opportunity for JIA. More importantly future 
studies are needed to determine if an increased early response leads to less joint 
damage on the long-term.
In conclusion, our study shows the time-to-start-MTX appears to be an important 
factor for the MTX response. Our results suggest that earlier initiation of MTX treat-
ment will lead to an increased response.
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The aim of this thesis was to identify genetic factors associated with the susceptibility 
to JIA (part A) and to reveal clinical and genetic parameters involved in determining the 
course of disease and the response to treatment (part B).
PArT A. GeneTIC rIsk fACTors for JuvenIle IDIoPAThIC ArThrITIs
Genetics involved in JIA
Part of the evidence that genetic factors are involved in the pathogenesis of JIA, is the 
increased relative risk for family members of patients to develop JIA. It is reported 
that 1-5% of the JIA population is part of an affected sib pair.1,2 In our cohort of JIA 
patients, 7 sib pairs were included (2% of the total cohort) of which 2 were twins (Table 
1). Five out of 7 sib pairs had a similar JIA subtype with a comparable age at onset. It 
has been described that most of the (monozygotic) twins and sibpairs not only have 
a concordance in JIA subtype, but also in their course of disease,3 reflecting genetic 
factors that are involved in coping with ongoing inflammation. The concordance of the 
course of disease in our sibpairs, however, is not very obvious. 
table 1. Affected sib pairs included in the JIA cohort.
sib pair Gender diagnosis age at onset (yr) course of disease
1 F Persistent oligoarthritis Not known Not known
M RF-negative polyarthritis 2.5 Not known
2 M RF-negative polyarthritis 4.25 Unremitting
M RF-negative polyarthritis 2 Remitting
3 F RF-negative polyarthritis 13.75 Not known
(twin) F RF-negative polyarthritis 14.75 Not known
4 F Persistent oligoarthritis 2.25 Intermediate
F Persistent oligoarthritis 3.5 Remitting
5 F RF-negative polyarthritis 3.75 Remitting
M RF-negative polyarthritis 3.25 Intermediate
6 F Persistent oligoarthritis 3.75 Unremitting
(twin) F Persistent oligoarthritis 4 Unremitting
7 F Persistent oligoarthritis 1.75 Intermediate
M RF-negative polyarthritis 4.5 Unremitting* 
* limited follow-up of 16 months.
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Genetic association studies in JIA
Genetic association studies have been performed in many diseases in order to identify 
risk factors for developing disease and pathways involved in the pathogenesis. This 
research project was designed to perform genetic association studies in JIA.  The focus 
was on revealing associations with SNPs in non-HLA loci. Multiple SNPs have been 
studied in cases and controls of North-West European descent. The genes and genetic 
regions that are described in this thesis have been selected based on previously de-
scribed associations in JIA and other autoimmune diseases, and their involvement in 
immune regulation. Several associations have been identified in this JIA cohort;  these 
include newly discovered associations in JIA, in case of TRAF1/C5 (Chapter 2), the 4q27 
locus (Chapter 3) and the common autoimmune loci CD226 and CD28 (Chapter 4), as 
well as replications of previously described associations in JIA (Chapter 4).
Novel genetic associations in JIA
TRAF1/C5
The association of the TRAF1/C5 locus and autoimmunity was first described in RA 
as a result of a candidate gene study4 and an independent GWAS5 in the Caucasian 
population. Thereafter, more studies have been performed on the association between 
TRAF1/C5 and RA and other autoimmune diseases like systemic lupus erythematosus, 
alopecia areata and celiac disease in both Caucasians and other populations.6- 9 We 
were one of the first research groups to reveal the association between polyarticular JIA 
and TRAF1/C5 (Chapter 2). At almost the same time the association with TRAF1/C5 was 
described in a smaller cohort of 67 JIA patients.10 In other JIA cohorts the association 
has  been confirmed11-13 although an association has not been found in all studies.14 A 
meta-analysis should be performed including all published studies of TRAF/C5 in JIA to 
confirm this association.
The locus on chromosome 9, that is associated with several autoimmune diseases, 
contains two genes; TRAF1, encoding tumor necrosis factor receptor-associated fac-
tor 1 and C5, encoding complement factor 5. Both genes have a role in immunity and 
could be involved in the pathogenesis of JIA. Activated complement-component-5 
acts as a strong chemoattractant for neutrophils, and a deregulated activity may 
contribute to the perpetuation of inflammation. In JIA, complement activation is 
occasionally observed, especially in active polyarthritis.15 On the other hand, TNF-
receptor-associated factor-1 (TRAF-1) plays an essential role in the intracellular TNF-
signaling pathway and is possibly a negative regulator of TNF-signaling.16 Evidence 
for the importance of TNF-alpha in JIA is suggested by the effectiveness of treatment 
directed against TNF-alpha, especially in subtypes with a polyarticular course.17 
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However, additional research investigating the functional consequences of the as-
sociated allele is required and could provide further insights in the pathogenesis of 
polyarticular disease in JIA.
To explore the TRAF-1 pathways in more detail, additional genes involved in the 
TNF-signaling pathway have been incorporated in later genotyping (Chapter 4); 
these included TNFA, TNFRSF1A , TNFRSF1B , TNFAIP3, TNFRSF14-MMEL1, TNFRSF8-
MIIP, TRAF-2, TRAF-6, CD40 (=TNFRSF5).  An association has been replicated only for 
TNFA, and no other new associations were discovered or established associations 
replicated. Additionally we have investigated polymorphisms in complement-
related genes (C1QA, C1QB, C1QC, C1Qlocus, C3, CFB, C4BPA) in a smaller cohort 
but similarly did not find any association (unpublished data). 
4q27
The genetic association of the 4q27 region (also called the KIAA1109-TENR-IL2-IL21 
locus) with autoimmune immune disease was first described in celiac disease (GWAS)18 
which was shortly afterwards followed by an association with diabetes mellitus type I 
(GWAS)19 and RA.20 The association with RA was confirmed in both the Caucasian popu-
lation as well as in other ethnicities.  21, 22 As described in this thesis (Chapter 3) we 
were the first to describe the association of 4q27 (rs6822844) with JIA. The association 
of this locus with JIA has been replicated in different cohorts.  23-25 In addition to celiac 
disease, DM1, RA and JIA, this locus has been associated with further autoimmune 
diseases like psoriasis, psoriatic arthritis and ulcerative colitis. Therefore this locus can 
be considered a general autoimmune locus. 
The 4q27 locus contains the genes KIAA1109, TENR, IL2 and IL21 that are in strong 
linkage disequilibrium (LD). Two of the genes in this region are not likely to have a 
role in autoimmunity; the function of the protein coded by KIAA1109 is still unknown 
and the protein TENR (testis nuclear RNA-binding protein, also called adenosine de-
aminase domain-containing protein 1 (ADAD1)) has been described in mice as being 
transcribed exclusively in the testis and is suggested to have a role in testis-specific 
nuclear posttranscriptional processes. However, most interesting are the genes IL2 




The response to IL2 is mediated through the interaction with the IL2-receptor complex: 
IL2R-alpha (CD25), IL2R-beta (CD122) and IL2R-gamma (CD132). This IL2-receptor 
160 Chapter 8
complex can be trimeric (CD25/CD122/CD132), having a high affinity for IL2 and 
which is expressed by regulatory T-cells or can be  dimeric (CD122/CD132) having 
an intermediate affinity and which is more broadly expressed on T-cells, natural killer 
cells and monocytes. Stimulation of the receptor complex by IL-2 induces cytokine 
release (IL10 and others), through the  activation of STAT5.26 IL2 plays an important role 
in the proliferation and differentiation of T-cells27 and is crucial for the development 
and function of regulatory T-cells in the periphery. Regulatory T-cells suppress the 
excessive immune response to self-antigens (in autoimmunity) and foreign antigens 
(in infection). 
Immune complexes of IL2 and anti-IL2 monoclonal antibodies (IL2/JES6-1) can 
induce expansion of regulatory T-cells, binding the high-affinity receptor complex. 
Mice pre-treated with IL2/JES6-1 develop less collagen induced arthritis. In these 
mice expansion of regulatory T-cells was seen, causing suppressed levels of anti-
bodies to collagen type II and inhibition of T-helper-17 cells and IL17 production.28 
Although still under investigation as such, the IL2 immune complex might have a 
role in treating autoimmune diseases like RA and JIA.
Determining the serum levels of IL2 is not feasible because of its limited half-life, so 
study of the relation between polymorphisms in IL2 (4q27) and serum levels of IL2 
will not yield meaningful results.
IL2-receptor
Genetic polymorphisms in IL2RA/CD25 (located on 10p15), that is part of the high affin-
ity IL2-receptor,  have at first been associated with DM129 and thereafter with multiple 
other autoimmune diseases such as Graves’ disease,30 multiple sclerosis31 and RA.32 
An association with JIA has also been described.33, 25 IL2RA is therefore considered a 
general autoimmune locus. Although less investigated, association with IL2RB (CD122, 
located on 22q13) has been described in JIA25 and RA34 and has been associated with 
a more erosive form of arthritis.35 
More importantly, the genotype-phenotype correlation of polymorphisms in IL2RA 
has been studied, revealing variable surface levels of CD25 (on CD4+ memory cells), 
most likely reflecting a transcriptional difference depending on the underlying 
haplotype.36 In a recent study, the association between IL2RA polymorphisms and 
the function of regulatory T-cells was investigated. It was shown that the presence 
of a disease-associated IL2RA haplotypes lead to a diminished IL2 responsiveness, 
resulting in lower levels of FOXP3 expression by regulatory T-cells  and a reduction 
in their ability to suppress proliferation of autologous memory CD4+ cells.37
Concluding from these data, the IL2-pathway seems to play an important role in 
the pathogenesis of autoimmune disease (and thus JIA), partly through its effect on 
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regulatory T-cells. Genetic variation is not only associated with disease susceptibil-
ity, but also functional consequences of this genetic variation have been brought to 
light. 
Interleukin 21
IL21 binds to the IL21-receptor (IL21R) that is present on a variety of immune and 
non-immune cells.  Activation of the IL21R results in a pro-inflammatory and immune 
stimulatory response. Its plays a significant role in inducing the differentiation and 
expansion of T-helper-17 cells, which play a critical role in the pathogenesis of RA.38 
An increased level of IL21 is associated with increased disease activity in RA.39 In mice, 
blocking IL21 activity by IL21R Fc fusion protein (a potent neutralizing reagent for 
IL21) reduces collagen-induced arthritis and reverses the adjuvant-induced arthritis in 
Lewis rats.40 The autoimmune K/BxN mouse deficient of IL21R ((IL21R−/−) K/BxN) does 
not develop arthritis.41 
Underlining the role of IL21 in autoimmunity are the positive associations with 
genetic polymorphisms in IL21R. An association between SLE (rs3093301),42  Hashi-
moto’s thyroiditis (rs3093301 and rs2285452)43 and IL21R was described. Even 
more important are genetic associations that are related with an alteration of func-
tion. Genetic polymorphisms in IL21 have been studied in SLE in relation to serum 
levels of IL21. The A allele of rs2055979 was more frequently  present in patients 
compared to controls and this allele was associated with higher levels of IL21 within 
the patient group.44 However it should be mentioned that these polymorphisms are 
situated in the large LD block on 4q27 and might not only reflect change of function 
of the IL21 gene. 
These data strongly suggest that IL21 and IL21R are involved in the pathogenesis of 
autoimmune disease and targeting IL21 may have a role in treating RA, JIA and other 
autoimmune diseases.
To reveal more associations of the 4q27 locus and the IL2 and IL21 pathway genes, 
additional polymorphisms have been typed in a second round of genotyping. These 
polymorphisms, mainly included in Chapter 4, are summarized in Table2.
Common autoimmune susceptibility loci
Clustering of autoimmune diseases in JIA families 
Several studies have indicated a higher prevalence of autoimmunity in JIA families 
compared to controls.45-47 It is described that in 21.4% of the JIA families an autoim-
mune disease is present in first degree family members that is increased compared 
to the incidence in the normal population.45 Another study described that in 110 JIA 
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families, 81 families had at least one relative with an autoimmune disease (73.7%), 
compared to 33.3% in control families. Of all the JIA relatives, 12.6% had an autoim-
mune disease (predominantly Hashimoto thyroiditis), compared to 4.0% of relatives of 
the control population. 46 Huang et al showed comparable results, namely that 11.8% 
of the relatives of 110 JIA families (first, second and third degree family members) had 
an autoimmune disease.47 
We have performed a family survey by a questionnaire, asking about the prevalence 
of 11 autoimmune diseases in the family and indicating which family member was 
affected (first degree, second degree of more remote). The following autoimmune 
diseases were included: psoriasis, Bechterew’s disease, uveitis, RA, JIA,  inflammatory 
bowel disease (Crohn’s disease and ulcerative colitis), DM1, thyroid disease, multiple 
sclerosis, systemic lupus erythematosus, celiac disease. It should be mentioned that 
the diagnoses had not been medically verified and may contain misinterpretations, 
for example osteoarthritis recorded as RA. Of 412 JIA families information about 
the family history was available. A total of 301 cases of autoimmune disease were 
present in 223 families (54.1% of all JIA families). Autoimmune diseases were pres-
table 2. Additional polymorphisms in the 4q27 loci, IL2RA and IL21R
 Gene* rs or p
IL21/ADAD1 rs11732095 0.91 (0.68-1.23) 0.5508
IL21 rs1398553 1.22 (1.05-1.43) 0.0109
IL21 rs4492018 0.88 (0.73-1.05) 0.1495
IL21/KIAA1109 rs4505848 1.20 (1.03-1.41) 0.01901
IL2RA rs12722489 failed
IL2RA rs12722605 1.05 (0.85-1.30) 0.6622
IL2RA rs2104286 0.91 (0.76-1.10) 0.3382
IL2RA rs41295061 1.02 (0.79-1.32) 0.8834
IL2RA rs791589 failed
IL2RA# rs11594656 0,94 (0,79- 1,12) 0,486*
IL2RA# rs10795791 1.23 (1.062- 1.43) 0,0062*
IL2RB rs3218253 0.99 (0.84-1.17) 0.9164
IL2RB rs3218258 0.97 (0.82-1.15) 0.7135
IL2RB rs743777 0.95 (0.81-1.12) 0.5386
IL21R rs11074861 failed
IL21R rs3093341 0.80 (0.62-1.05) 0.1069
IL21R rs8057432 failed
*) Polymorphisms have been discussed in Chapter 4, except for IL2RA  rs11594656, rs10795791 and the SNP 
that have failed genotyping. 
#) IL2RA  rs11594656 and rs10795791 have been investigated in a smaller cohort and data have not been 
published. 
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ent in the first or second degree family member in 195 (47.3%) families and in only 
the first degree in 83 (12.9%) families (Table3). Psoriasis and RA were the main 
conditions present in family members. The distribution of the different autoimmune 
diseases is illustrated in Table 4. Unfortunately the total number of (unaffected) 
relatives in these families is not known.  
Replication of (common) autoimmune loci and JIA loci
In JIA several studies have been performed analyzing common autoimmune suscepti-
bility loci found in RA and other autoimmune diseases. 14,48,11,23,49,24,50,12,25 In Chapter 4 
table 3. Number of different autoimmune diseases present in 412 JIA families.
Number different 
aid
1st degree 1st and 2nd 
degree
In any relative
0 329 217 189
1 74 149 162
2 7* 37 46
3 2 8 13
4 0 1 2
AID positive 83 (12.9%) 195 (47.3%) 223 (54.1%)
*) the combination of psoriasis and RA in 3 families, other combinations were JIA and DM, Bechterew’s 
disease  and DM, RA and IBD, Bechterew’s disease and IBD.
table 4. Distribution of autoimmune disease in 412 JIA families.
1st degree 2nd degree > 2nd degree degree unknown Total (%)
Psoriasis 35 35 4 3 77 (25.6)
Bechterew’s disease 5 10 2 1 18 (6.0)
Uveitis 0 0 0 0 0
Rheumatoid arthritis 14 62 18 3 97 (32.2)
Juvenile idiopathic 
arthritis
13 9 5 2 29 (9.6)
Inflammatory bowel 
disease
8 11 2 1 22 (7.3)
Insuline dependent 
diabetes
7 12 4 2 25 (8.3)
Thyroid disease 9 12 1 2 24 (8.0)
Multiple sclerosis 1 3 0 0 4   (1.3)
Systemic lupus 
erythematosus
1 3 1 0 5   (1.7)
Celiac disease 0 0 0 0 0
Total (% of total) 93 (30.9) 157 (52.2) 37 (12.3) 4 (4.7) 301
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the replication of multiple common autoimmune loci in JIA is reported. Genes/loci that 
have been replicated are VTCN1, 4q27, TNFA, PTPN22 (the latter only in a more homo-
geneous cohort) and ANKRD55.  Although no significant association was identified in 
our case-control association study, a meta-analysis incorporating already published 
data of other cohorts revealed additional associations of SNPs in PTPRC, AFF3, CCR5, 
TNFAIP3, TNPO3, IL2RA and CLEC16A and JIA. The overlapping polymorphisms that have 
been investigated in our cohort and in the papers investigating common autoimmune 
susceptibility loci in JIA, are listed in Table 5. Unfortunately genotyping of some signifi-
cant polymorphisms in the highly interesting genes STAT 4 (rs7574865, rs8179673), 
TNFAIP3 (rs10499194) and IL2RA (rs12722489 and rs791589) have failed.  We did not 
include PTPN2, COG6, C12orf30, C3orf1, ANGPT or CD247 in our study.
ANKRD55
As more often is the case in discovery of new susceptibility loci (such as in PTPN22 and 
TRAF-1/C5), the association of ANKRD55 (rs6859219) with JIA was investigated at the 
same time in two different cohorts in various ways. While in the UK cohort, combined 
with the US and German cohort, dense genotyping was performed in regions of interest 
by Immunochip,25 at the same time a candidate gene approach was pursued in our 
cohort. In both studies an association with JIA was revealed. 
ANKRD55 was first discovered and replicated in a GWAS in RA51 and is also as-
sociated with multiple sclerosis.52 ANKRD55 is located at 5q11 and is an ankyrin 
repeat domain-containing gene with unknown function. Nearby genes are IL6ST and 
IL31RA (encoding proteins involved in immunity) but 13 haplotype-tagging SNPs in 
the IL6ST–IL31RA cluster were not in linkage disequilibrium with rs6859219.52
table 5. Sample sizes requirements for genetic association studies
MAF 10% 20% 30% 40%
cases controls cases controls cases controls cases Controls
OR
2.0 223 446 137 274 113 226 107 214
1.5 703 1406 415 830 332 664 304 608
1.3 1751 3502 1016 2032 798 1596 719 1438
Table shows number of cases and controls that need to be typed to detect associations at a sig-
nificance value of 0.05, power of 80%, for various minor allele frequencies, and odds ratios. A 
case:control ratio of 1:2 is assumed. OR: odds ratio; MAF: mino allele frequency
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(Common) autoimmune loci as novel associations in JIA 
Besides the replication of common autoimmune/JIA loci, we have also revealed novel 
associations with common autoimmune loci, which had not yet been discovered earlier 
in JIA.  We reported the association of CD226 with JIA (in the selected subtypes oligoar-
thritis and RF-polyarthritis) and a trend towards association of a locus near CD28. Both 
genes have been analyzed before in JIA, but with no significant association as outcome. 
We have performed a meta-analysis including these data, to generate an overall odds 
ratio, strengthening proof of association. Meta-analysis of CD226 showed an overall 
positive association for CD226 in JIA, underlining the role of this gene in JIA. In addi-
tion, CD28 also seems to be a novel association in JIA. 
Meta-analysis of our (non-significant) data with results from previous case-control 
association studies in JIA, that generated similar results lacking association, revealed 
a possible additional association with PRKCQ (rs4750316)
CD226
The association with autoimmunity of CD226 was first described in DM1,19 followed by 
the association with multiple autoimmune diseases such as multiple sclerosis, RA and 
autoimmune thyroiditis53 in both European and non-European patients.54 The strongest 
association is found with the non-synonymous SNP Gly307Ser (rs763361), although 
the function consequence of this polymorphism is not yet clear. CD226 (also known as 
DNAX accessory molecule 1, DNAM-1) is a 67-kDa type I membrane protein involved 
in the adhesion and co-stimulation of T-cells and NK cells. CD226 binds to two differ-
ent cell surface ligands; CD155 (poliovirus receptor) and CD112. CD226 might have 
a role in differentially regulating the proinflammatory (T-helper -1/T-helper-17)/anti-
inflammatory (T-helper-2) balance. 
We were the first to demonstrate a significant association with JIA (in the selected 
subtypes oligoarthritis (persistent and extended) and RF-negative polyarthritis), 
although this polymorphism has been studied before with various results. Ellis et 
al found a trend towards significance in their Australian cohort (including all JIA 
subtypes).12 CD226 was included in a Immunochip analysis,25 and already studied in 
a smaller (overlapping) UK cohort , using imputed data,23 but in these studies no as-
sociation with JIA was found. Analyzing the pooled data by means of a meta-analysis 
provided an overall odds ratio of 1.16 (p= 0.001115) that was significant.
CD28
The second novel susceptibility locus identified in our JIA cohort is CD28 (rs1980422), 
although after correction for multiple testing the significance was low. CD28 has been 
studied before by various methods; in a candidate gene approach,50 in a GWAS55 and 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was included in an Immunochip analysis.25 None of the other analyses provided any 
evidence of association. However when combining data from the GWAS with our data 
in a meta-analysis, the common odds ratio showed a positive association for CD28 
(rs1980422) with JIA.
Association with CD28 has been described in RA56,51 and in DM1.57 The polymor-
phism studied (rs1980422) is located between CD28 and CTLA4. CD28, like CTLA4, 
binds to their shared ligands CD80 and CD86 and has a costimulatory function on 
T-cell activation.  Interestingly, an association with CD80 has also been revealed in 
JIA recently.25 
Other loci studied
Besides common autoimmune loci we included a study of some genes involved in 
immune cell signaling, but they did not show any association. These genes are: LCK, 
LECT2, DPP4, ADA, ZNF230, ZNF451, CCR6 and CCL24.
limitations of genetic association studies 
Power and sample size
As is seen in the last decades of genetic association studies in JIA, the relative risk of 
the associated polymorphisms is only moderate to small. For example the odds ratio 
(OR) of our findings range from about 1.29 to  1.51 and the minor allele frequency 
(MAF) in controls of the investigated polymorphism is 0.1- 0.47 (TRAF1/C5: MAF 0.41, 
OR 1.46 (1.12- 1.90), 4q27: MAF 0.18-0.20, OR  0.76 (0.62- 0.93)(1/0.76 = 1.31), CD226: 
MAF 0.47, OR 1.30 (1.12-1.51), CD28: MAF 0.22, OR 1.29 (1.07-1.55), ANKRD55: MAF 
0.22, OR 0.74 (0.61-0.90) (1/0.74= 1.35), PTPN22: MAF 0.10, OR 1.32 (1.03-1.69), TNFA 
(rs1799724): MAF 0.10, OR 1.40 (1.09-1.79)).
Different cohort sizes that are needed to detect an association at a significance value 
of 0.05 and with a power of 80% detection are listed below (by Prahalad 2008)58 
(Table ..). As indicated, in our cohort of 639 cases and 1319 controls we hardly have 
power to detect a small OR in polymorphisms that have a low MAF.  
The size of our cohort is roughly comparable to other JIA cohorts that have been 
used for genetic studies in the last few years (Table 6). In order to increase power to 
detect associations with a small effect size, cohorts are being combined nowadays. 
Ideally, several large independent cohorts should be available to replicate genetic 
findings.
Besides the relative small number of JIA patients that are included in each JIA co-















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exist. This underlines once more the difficulty in creating a large patient cohort of a 
relatively rare disease. 
Phenotypic heterogeneity
JIA is a heterogeneous group of diseases characterized by chronic arthritis. Based on 
clinical features and laboratory parameters a classification into different subtypes 
has been made. Some of these subtypes have very distinct features, such as systemic 
JIA. More evidence arises that systemic JIA can be regarded as an autoinflammatory 
disease. JIA with enthesitis and psoriatic JIA each have specific characteristics. Only 
one category of psoriatic arthritis has some resemblance with early-onset ANA positive 
oligoarthritis. The subtypes oligoarthritis (persistent and extended) and RF-negative 
polyarthritis share the most clinical features and have a consistent overlap in genetic 
associations. Because of the phenotypic homogeneity of these subtypes, we have cho-
sen to perform our genetic association study of new JIA loci (Chapter 4) only in a group 
of patients with oligoarticular and RF-negative polyarticular JIA. The same approach 
has been followed in the US cohort55 that has also limited inclusion to these selected 
subtypes and in the most recent dense genotyping study with the Immunochip.25 
Between these subtypes (oligoarthritis and RF-negative polyarthritis) no consistent 
pattern of genetic association can be seen. In some cases the subtypes with a poly-
articular course (extended oligoarthritis and RF-negative polyarthritis) seem to have 
more similarities in their genetic associations, but this was not a consistent result for 
all associations (Chapter 4).
Ethnic/ geographical background 
In our cohort we have included patients form the Netherlands, Belgium, Germany and 
Switzerland, all with a self/parent reported Caucasian ethnicity. We have included only 
the patients with a North-West European background, taking the genetic variation due 
to immigration in Europe into account.  A low average level of genetic differentiation 
among Europeans has been described in 3000 Europeans with a close correspondence 
between genetic and geographic distances.61 Therefore we regard our cohort as having 
a similar genetic background.
When admixture within a study population exist population stratification can take 
place. For a proportion of the SNPs (52/93), we had the possibility to compare our 
control MAFs to results of another Dutch control cohort, which are comparable. This 
other Dutch cohort has been checked and corrected for population outliers.62 MAFs 
that were not publicly available have been obtained by personal communication. 
Because of the comparable MAFs of the control populations, we think it is unlikely 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































that potential population outliers in our control cohort have distorted our associa-
tion results.
When the genetic variation within a subpopulation differs from the rest of the (case 
or control) population, regardless of the presence of disease (or trait to be investi-
gated), it can cause false positive or false negative associations. In order to avoid 
population stratification, a TDT analysis (a family based study) can be conducted. 
In case of a TDT analysis, patient-parents trios are investigated and parents act as 
controls for their affected offspring.  
In our cohort, a TDT test was performed with the SNPs that were investigated in 
Chapter 4 (data not published) and the results are listed in Table 7. Three hundred 
twenty eight parent-patient trios were available for analysis in the cohort consist-
ing of oligoarthritis and RF-negative polyarthritis. In LTA (rs2239704) and TRAF6 
(rs540386) a significant overtransmission of the minor allele is demonstrated 
compared to the transmission expected based on Mendelian laws, indicating an 
association with disease.  However no association was found in the case-control 
association study with these SNPs. Remarkable is the trend toward association in the 
TDT analysis seen in PTPN22 (rs6673837), VTCN1 (rs6673837), CTLA4 rs231775), 
TNFA (rs1799724), TNFA (rs1800610) and CLEC16 (rs12708716); all SNPs that have 
been associated with JIA in previous studies. This shows that a TDT test generates 
similar results and can be additive to (or replace) a case-control association study. 
However it is challenging to create a cohort with the same number of patients that 
are needed for a case-control study, but with also (DNA of) both parents available.
What have genetic association studies brought us? 
Unfortunately, little is known about the genetic contribution to the susceptibility of 
JIA. It is estimated that 30% of the JIA risk can be explained by (common) genetic 
variations.25;55;63 In JIA the HLA-locus is estimated to explain 8-13% of the overall 
heritability.25;55;63 All other identified risk factors have only a small effect size. 
More is known about the genetic contribution to RA, a comparable autoimmune 
disease, also characterized by chronic arthritis. The genetic contribution to RA is 
estimated to be 65%.64;65 The contribution of the established risk loci to the total 
heritability to RA is thought to be 33-47%.51 The HLA-locus and PTPN22 are the 
most important genetic risk factors in RA.66;67 In RA, an additional 20% of disease 
risk could be explained by the thousands of additional SNPs embedded in GWAS 
results.68 
Although the contribution of each of the associated SNPs to the susceptibility to 
JIA is only modest and cannot be used to predict the occurrence of JIA in a healthy 
population, these genetic associations can generate more knowledge about the 
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immunological pathways involved in the pathogenesis of JIA and its overlap with 
other autoimmune diseases. Also these (modest) genetic associations can contain 
major lead points for developing new treatments and thereby possibly improving 
the outcome of disease in patients with JIA. 
PArT B. ClInICAl AnD GeneTIC fACTors InvolveD In The Course of 
disease and resPonse To TreaTMenT
Prognostic markers for clinical course
Genetic association studies have revealed some of the risk factors that are involved in 
developing JIA and have offered potential targets for new therapeutic options. How-
ever, the physician is dealing with an individual patient and has to inform the patient/
parents and decide about the optimal treatment, preferably taking into account the 
course that the disease will follow. It would be ideal if at onset of the disease, markers 
were available that could help in predicting the course of disease and response to 
treatment, possibly leading to tailor made therapy. 
To address the question of predictive factors, clinical parameters have first been 
investigated with regards to an association with the course of disease (Chapter 5). 
Subsequently genetic markers were studied for their ability to function as a prog-
nostic marker for predicting the course of disease in JIA (Chapter 6).
Clinical prognostic markers for the course of disease 
The clinical course of JIA has a fluctuating character with unpredictable episodes of 
active disease and disease quiescence. In order to capture these fluctuations, the se-
quential episodes of active and inactive disease have been studied and the percentage 
of time with active disease has been calculated for the first 2 (or 5 years) after disease 
onset (Chapter 5). 
In the first two years after diagnosis this percentage of time with active disease differs 
significantly between JIA subtypes (p=0.031); patients with persistent oligoarthritis 
have the lowest percentage of time with active disease (47%) and patients with ex-
tended oligoarthritis have the highest percentage of time with active disease (70%) 
in the first two years after onset (generating a p-value of <0.001 when comparing 
these two subtypes). Within this, only the cumulative time with active disease seems 
to be related to the JIA subtype, but not the physicians’ global assessment of the 
level of disease activity. The percentage of time with active disease in the different 
subtypes in this cohort of JIA patients is similar to the percentages of active disease 
that have been described previously in an independent JIA cohort,69;70 suggesting 
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that the percentage of time with active disease is representative for the different JIA 
subtypes and seems a reproducible measure for disease activity during the course 
of the disease. In our cohort, the percentage of time with active disease (divided 
arbitrarily into categories of course of disease; remitting, intermediate, unremitting) 
in the first two years is predictive for the course of disease in the following years. 
This can therefore be used as overall marker for predicting the subsequent course 
of disease. 
This parameter “percentage of time spent in active disease” differs from the param-
eter “reaching clinical remission (at least 6 months of inactive disease) on medica-
tion”, that has been proposed and validated in recent years.71 In our cohort of 272 
patients, 164 (60,3%) patients had inactive disease for >= 6 months during the 
first two years (on medication). Sixty five (39.6%) of these patients were classified 
as having a remitting disease course, 80 (48.8%) had an intermediate course of 
disease, but 19 (11.6%) patients were classified as having an unremitting disease 
course (Table 8). 
These 19 patients had an episode of inactive disease for 6 months, but were active 
for about 1 ½ year in their first two years after diagnosis and considered unremitting 
in our analysis. If reaching clinical remission (on medication) was used as parameter 
defining course of disease, these patients would have been classified as having 
a favorable course. Considering prognosis in terms of damage to the joint, every 
moment that a patient has (clinically) inactive disease is advantageous and thus is 
important. The aim of treatment is to minimize the time spent in a state of active 
disease, in order to prevent damage to the affected joints. According to Wallace et 
al 70 who studied the fluctuating pattern of the course of JIA, patients experience 
many episodes of inactive disease, that not always (only in 48%) lead to clinical 
remission.
The JIA subtype is related to the clinical course in the first two years, however the 
JIA subtype cannot be determined at onset. Oligoarthritis can evolve into extended 
table 8.  The cohort classified according to the different parameters indicating course of disease.
Remitting           course 
of disease
Intermediate course of 
disease
Unremitting course of 
disease
Clinical remission* 65 80 19 164 
No clinical remission 0 16 92 108 
65 96 111 272
*) Clinical remission (on medication) defined as a continuous period of inactive disease of at least 6 months with 
the use of medication (ref) that has taken place in the first two years after disease onset.
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oligoarthritis or be defined as persistent oligoarthritis only after 6 months (by 
definition). However once evolved into extended oligoarthritis, the course of disease 
(defined by the percentage of time with active disease in the first two years) is the 
least favorable compared to persistent oligoarthritis and RF-negative polyarthritis. 
This high percentage of time with active disease in extended oligoarthritis might 
be due to a less aggressive treatment or a delayed use of DMARDs.  Patients with 
extended oligoarthritis receive less methotrexate in the first two years (38%) com-
pared to those with RF-negative polyarthritis (65%). Extended oligoarthritis should 
be regarded as a separate entity and a more aggressive therapeutic approach might 
be beneficial. There seems to be a particular need for prognostic factors predicting 
the evolvement into extended oligoarthritis, that has great impact on the course that 
the disease will follow.  
Genetic prognostic markers for the course of disease
The same genetic markers as described in Chapter 4 were investigated in the cohort 
of 272 JIA patients of which the course of disease was determined. These genes/loci 
were selected based on their role in (general) autoimmunity and immunoregulation. 
Different categories of course of disease (remitting, intermediate, unremitting course), 
based on the percentage of active disease in the first two years after disease onset, 
were used as outcome parameter. Both univariate and multivariate analyses revealed 
VTCN1 (rs10923223) as a genetic marker associated with the course of disease, al-
though replication of these data is still essential (Chapter 6). A modest association has 
been found with CDK6 (rs42041), although not statistically significant. 
VTCN1
The gene VTCN1  (V-set domain containing T cell activation inhibitor 1) is located on 
chromosome 1 (1p13) and encodes B7-H4, a member of the B7 co-signaling molecule 
family.72 Binding to an as yet unknown receptor, B7-H4 has an inhibitory effect on 
T-cells by decreasing proliferation and cytokine production.72-74 The involvement of 
B7-H4 in tumor immunity has been described in multiple types of cancer.75 A higher 
expression of B7-H4 has been related to a more progressive disease and decreased 
survival, because of its potential inhibitory effect on T-cells involved in the anti-tumor 
response in (amongst others) renal cell carcinoma, ovarian cancer, melanoma, gastric 
and esophagus tumors.76 Important is the possible involvement in autoimmunity, 
where a loss of negative regulation might be crucial. In mice deficient of B7-H4, an 
increased severity of collagen induced arthritis is observed. Use of B7-H4Ig suppresses 
the progression of collagen induced arthritis, even in established arthritis.77 B7-H4 is 
expressed in the synovium, indicating a local influence of its inhibitory function.78 This 
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inhibitory B7-H4 pathway might be of therapeutic interest, (similar to the CTLA4 Ig 
results in RA).79 The genetic association of VTCN1 and several autoimmune diseases 
(JIA, RA and SLE) underline the importance of B7-H4 in autoimmunity.80-82 However as-
sociations with susceptibility in JIA have been inconsistent. A positive association has 
been discovered in a GWAS and replicated in an independent cohort study.80 Equally, 
in our candidate gene study (Chapter 4) a modest association was found. However in 
two other cohort studies no association with VTCN1 was detected.12;24 Of more clinical 
importance is that we describe, for the first time, the association of VTCN1 with the 
progression of JIA. The minor allele of especially rs10923223 is related to a more 
remitting disease. Possibly, this variation causes a gain of inhibitory function of B7-H4, 
leading to a better autoimmune regulation. Additional studies are needed to relate 
the genetic variation of VTCN1 to the co-inhibitory function of B7-H4. However our 
results contribute to the hypothesis that the B7-H4 pathway can be a new therapeutic 
target (for example agonistic B7-H4Immunoglobulinfusion proteins) in JIA. Finally, this 
polymorphism might be useful as a predictive factor for the course of disease in JIA.
CDK6
A modest association of CDK6 gene (rs42041) with a more remitting disease has been 
discovered, although not statistically significant after correcting for multiple testing. 
CDK6 (cyclin-dependent kinase 6) is a regulator of the cell cycle progression and as 
such might be involved in regulation of disease progression. It is therefore still a gene 
of interest and further investigation is needed to identify this gene as truly associated 
with the course of disease.
Combining clinical and genetic markers  
Both clinical and genetic parameters seem to be associated with the clinical course of 
JIA. When plotting the predictive value of the parameters that are available at disease 
onset in a ROC curve, we see almost no effect of JIA subtype alone, probably due to the 
fact that no differentiation can be made (at onset) between persistent oligoarthritis and 
extended oligoarthritis. However when adding genetic markers (VTCN1 rs10923223 
and CDK6 rs42041) the area under the curve increases. This suggests that a predictive 
model involving clinical and genetic parameters can be constructed and might be use-
ful for the physician to guide the individual (therapeutic) approach.  Additional studies 
in independent (prospective) cohort studies are needed to validate a predictive model. 
Pharmacogenetics
Besides predicting the course of disease, it is also beneficial for optimizing the individ-
ual therapeutic regime to be able to predict the response to treatment. Methotrexate 
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(MTX) has been the most important (non biological) disease modifying anti-rheumatic 
drug used in the last years. Variations in genes involved in the folate and adenosine 
pathways could be predictive for the response to MTX. Both clinical and genetic param-
eters have been studied in relation to the response to MTX.
Methotrexate
Clinical predictors for the response to MTX have been described in several reports, 
revealing an early start of treatment as the most consequently performing predic-
tive parameter.83-85 Consistent with previous (and following) reports, our study also 
revealed that the time to start of treatment is an important factor for the response to 
MTX (Chapter 7); early treatment seems to be more effective. 
In addition to clinical parameters, the genetic variation in genes involved in the 
cell entry, folate and adenosine pathway could also have a role in predicting the 
response to MTX treatment in JIA. In RA, the association of genetic polymorphisms in 
genes coding for folate pathway enzymes and genes involved in the adenosine path-
way and the response to treatment has been described.86;87 In JIA, a polymorphism 
in the methylenetetrahydrofolate reductase (MTHFR) gene (A1298C) has been as-
sociated with efficacy of MTX.88 Following this reported association, several studies 
have been performed yielding different results. SNPs in the SLC16A7 gene,89 inosine 
triphosphate pyrophosphatase gene (ITPA), 5-aminoimidazole-4-carboxamide ribo-
nucleotide transformylase gene (ATIC),90 ABCB1 rs1045642, ABCC3 rs4793665, and 
SLC19A1 rs105126691 were associated with response to MTX and also a possible 
effect of SNPs in methionine synthase reductase, multidrug resistance 1 (MDR-1/
ABCB1), multidrug resistance protein 1 (MRP-1/ABCC1) and proton-coupled folate 
transporter (PCFT)92 were reported. However other studies, including our report, 
have failed to detect any effect.93;94
Overall these reports show that the pharmacogenetics concerning the genes in-
volved in the cell entry, folate and adenosine pathways are far from elucidated. One 
of the major concerns with regards to these studies is the small patient cohorts, 
ranging from 58 to 287 patients (in total), that only have sufficient power to detect 
associations with a large effect. It is possible that associations with a relatively small 
effect have gone undetected, because of the lack of power.  Furthermore no official 
criteria defining response to treatment are available or were consistently used. A 
preliminary definition for improvement has been proposed,95 but not validated or 
widely implemented in studies involving response to MTX. Comparing different 
criteria evaluating response to MTX (by ACR and EULAR) demonstrated a good agree-
ment.96  
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On the one hand, the aim is to create a prediction model for response to MTX, involv-
ing genetic polymorphism, clinical parameters and biomarkers (such as MRP8/14)97 
that are associated with response to treatment. A prediction model could be helpful 
in choosing the optimal treatment strategy for the individual patient. At the other 
hand, by investigating the (change of) function of genetic polymorphisms that are 
associated with response to MTX, the working mechanism of MTX can be further 
elucidated, possibly leading to more specific lead points of treatment. 
limitations 
Even more than in studying genetic polymorphisms regarding susceptibility to JIA, the 
issue of small sample sizes (lacking power to detect associations with low risk) in as-
sociation studies with course of disease or response to treatment, is vast. To create a 
cohort of which detailed information about the course of disease is known, including 
information about all different episode of active and inactive disease in the first years 
after diagnosis, together with detailed use of medication, is challenging. Access to a 
detailed patient file is needed. Perhaps when electronic patient dossiers become fully 
available in the future, this would facilitate this process.  The same number of patients 
(per category that is investigated) is needed in these type of studies compared to 
investigating genetic risk factors for developing disease (see before). But in this type 
of studies the total patient cohort is divided into subgroups that are compared to each 
other, so at least twice the number of patients is needed. Replicating result of such 
studies is also more challenging, because of the (internationally and between centers) 
differences in approach towards defining course of disease and response to treatment. 
Compared to genetic association studies only concerning susceptibility to JIA, in-
vestigating genetic associations with the course of disease or response to treatment 
will yield results that are of interest to the clinician and could be beneficial with 
regards to informing the patient/ parents about the course of disease and treating 
the individual patient in the best way possible.
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Increasing the size of the JIA cohort 
Although it is not the most scientific challenging goal, it is of utmost importance for 
the power of the following studies (for example candidate gene studies or genotyping 
by Immunochip) to increase the size of the JIA cohort by collaborating with more Euro-
pean rheumatology referral centers. It has been discussed that only the three subtypes 
that have a phenotypic overlap, should be included with a similar genetic/ geographic 
background. Not only information about the subtype, but also detailed information 
about the course of disease and use of medication should be gathered. Collaborat-
ing with other JIA cohorts will increase the number of patients, however independent 
cohorts should still remain in order to allow for replication of the associations found. 
functional studies
The associations with JIA that have been revealed in this thesis are located either in 
loci with an unknown function (ANKRD55), or in loci with more than one gene which 
could be involved (in locus TRAF1/C5 the genes TRAF1 or C5 and in locus 4q27 the 
genes IL2 or IL21) and in loci/genes that are more likely to be directly involved in 
the pathogenesis or progression of JIA (VTCN1, CD226, CD28, PTPTN22, TNFA). Of all 
of these associations, the functional (non-synonymous) variant in PTPN22 seems the 
most obvious one of which the function should have shortly become clarified. How-
ever, after some years the functional consequences of PTPN22 (1858T) are still under 
investigation.1;2 This illustrates the difficulty in translating a genetic association to a 
functional difference that is related to disease or disease severity. 
Because of also its association with the course of disease and therefor its clinical 
relevance, the functional consequences of the different genetic variations in VTCN1 
should also be studied. In different studies, several polymorphisms in this gene are 
associated with the susceptibility of JIA. These seem to be indirect associations, 
with the causal variant not yet known. Because as yet no change in coding for 
amino-acids is known, a 3D image of an altered protein, to provide more insight 
in the consequences of such a different amino acid, cannot be prepared. However, 
the polymorphic gene can be expressed differently, thus the gene expression of 
the different genetic variations should also be studied, especially because a higher 
expression has been related to a more progressive disease in certain types of cancer. 
Because B7-H4 (the gene product of VTNC1) has an inhibitory effect on T-cells, the 
effect of the different VTCN1-gene products on T-cell stimulation should be studied 
by means of T-cell proliferation assays and levels of cytokine production. This should 
be done in healthy persons to rule out the influence of disease activity. Bypassing 
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the more subtle changes in function and ignoring the association of certain genetic 
variations, one might consider applying agonists or antagonists and evaluating the 
outcome of this extreme intervention, for example in collagen induced arthritis. 
More insight in the altered function of VTCN1 in patients with a more remitting 
course could be a lead point for developing drugs interfering in the VTCN1-pathway.
Not only in the case of VTCN1, but also of the other genes/ loci associated with 
JIA, functional consequences should be studied by means of expression studies, 
measuring levels of gene product and levels of proteins involved in the pathway of 
concern and in more functional studies such as proliferation assays. 
increasing the investigated pathways
In the work presented in this thesis the focus has been on replication of the genetic as-
sociations known in JIA and other autoimmune disease and investigating some genes 
that are part of a number of pathways that could be involved in JIA. Because ours is a 
new cohort of Caucasian JIA patients, reproduction in such an independent cohort is 
important for reinforcing the already known associations. At the same time replication 
of these associations shows that our cohort is comparable to others in the generation 
of similar results. The following step will then be to expand the number of pathways 
to be investigated. For example, the IL17/ IL23/ IL12/ IFN-gamma pathway also plays 
a major role in JIA. Associations of genes involved in this pathway and the susceptibil-
ity to and the severity of JIA should be studied. This could be done by means of a 
candidate gene study because of the limited number of genes involved. 
However more pathways involved in autoimmunity can be studied simultaneous by 
an Immunochip assay and this should be considered. The SNPs incorporated on the 
immunochip are dense selected tagging SNPs in specific genetic loci. 
Genome wide association study
In addition to studying selected genes or pathway, a study without prior hypothesis can 
be undertaken. In a genome wide association study (GWAS), polymorphisms throughout 
the entire genome may thus be identified. The advantage is that unexpected loci can 
be revealed. The disadvantage is the large number of patients that are needed (partly 
because of the low effect sizes that are expected). In JIA such a study has been under-
take twice. Surprising associations were revealed. In the first GWAS the associations 
with VTCN1 were brought to light and the second revealed 3q13 as a novel susceptibil-
ity locus that needs to be investigated in more detail to identify an associated gene. 
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Pharmacogenetics
To develop more insight in determinants of the response to treatment, genetic associa-
tions in genes involved in the specific pathways should be investigated. The pharma-
cogenetics of the MTX pathway has already been discussed. Nowadays treatment with 
anti-TNF has a big part in treating ongoing disease. Genes involved in the TNF-pathway 
should also be investigated in relation to response (comparing allele frequencies be-
tween responders and non-responders).  Ideally the response to drugs that are being 
developed based on genetic findings (such as might be the case in PTPN22 or VTCN1), 
should be studied in relation to the varying genetic background of a patient.  
Predictive model for the course of disease and response to treatment
Nevertheless, the most important still is the individual patient, which should be 
treated in the best possible way.  In this thesis many parameters have been raised and 
discussed that could be part of a predictive model for the course of disease in the indi-
vidual patient. These parameters are either clinical parameters (such as the subtype of 
JIA), or genetic factors (such as VTCN1, or additional genes that will be tested in future 
studies), but may also be biomarkers resulting from future functional studies. Similar 
models should be developed concerning the response to treatment (MTX or anti-TNF), 
similarly involving clinical and genetic parameters and possible biomarkers.
Association with specific characteristics of JIA
Many patients with predominantly oligoarticular JIA develop JIA-associated uveitis. 
Because this type of uveitis has few clinical symptoms, a stringent follow-up of eye-
involvement is required. Genetic associations with JIA-associated uveitis could be 
helpful in predicting uveitis. Genetic variations that are associated with the progres-
sion of uveitis are of clinical relevance for patients with uveitis.  However creating a 
study patient group with JIA-associated uveitis of sufficient size is already challenging, 
therefore to include sufficient patients to compare mild uveitis patients with progres-
sive uveitis patients seems hardly feasible.  
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Juvenile idiopathic arthritis (JIA) is a non-common disease in children that can persist 
into adulthood. JIA consist of a heterogeneous group of disorders characterized by 
chronic arthritis. Following the ILAR criteria several subtypes can be distinguished 
based on the number of joints that are affected at presentation and during the course 
of disease, and on some blood values. The JIA subtypes oligoarthritis (persistent and 
extended) and rheumatoid factor (RF) negative polyarthritis are the most common 
within the group of JIA. These subtypes share phenotypic features and have a simi-
lar course of disease. In all subtypes the course of disease follows an unpredictable 
pattern of episodes with active disease alternating with episode of inactive disease. 
Prolonged episodes of active disease will lead to (irreversible) damage of the joints. At 
this point, no reliable prediction can be made about the course that the disease will 
follow in the individual patient. 
The goal of treatment is to bring the ongoing arthritis to a halt shortly after disease 
onset to avoid damage to the joints. In recent years the treatment of JIA has shifted 
towards a more aggressive treatment with the use of potent anti-rheumatic medica-
tion in earlier stages of the disease. The level of response to medication differs 
between patients. No reliable prediction regarding the response to medication can 
be made, although this would be essential for choosing the optimal treatment for 
the individual patient.  
JIA is a complex disease
JIA is considered to be an auto-immune disease, although the precise pathophysiology 
is not clear. The immune reaction against an unknown agent causes an ongoing inflam-
mation of the joint, leading towards destruction of cartilage and bone. Several factors 
are believed to be involved in the pathogenesis of JIA. Besides environmental factors, 
also genetic factors seem to be important. Twin and family studies show that siblings 
of patients with JIA have a higher risk of developing (the same type of) JIA. In recent 
years several genetic studies have been performed trying to reveal an association 
between genetic variants (for example single nucleotide polymorphisms (SNPs)) and 
JIA by comparing the frequency of the variant in patient to the frequency in healthy 
persons.  If the frequency of the genetic variant varies significantly between patients 
and controls, the genetic variant is considered associated with the disease. Replication 
of an association in an independent JIA cohort makes an association stronger and is 
essential. Multiple associations have been replicated in independent JIA cohorts, like 
HLA, PTPN22, STAT4, TNFAIP3, IL2RA. It is estimated that 30% of the JIA risk can be 
explained by (common) genetic variations.
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aim of this thesis
The goal of this research project is to discover genetic associations with JIA. Genetic 
factors that are associated with the development of JIA can give more insight in the 
pathogenesis and might indicate lead points for new treatment strategies. Of more 
clinical relevance are the genetic factors that are associated with the course of disease 
or with the response to certain medication. These genetic associations might serve as 
a predictive tool, leading to a better understanding of the individual disease and more 
optimal individualized treatment.
In order to perform genetic association studies, a new and independent JIA cohort 
has been created including 639 patients from North-West Europe (the Netherlands, 
Belgium, Germany and Switzerland) of Caucasian origin. The focus has been on 
patients with oligoarthritis (persistent and extended) and RF-negative polyarthritis, 
because of their similar clinical phenotype. Several genetic polymorphisms (SNPs) 
have been studied in this JIA cohort. The frequencies of SNPs have been compared 
between JIA patients and healthy Caucasian (Dutch) individuals in order to discover 
association with the susceptibility to JIA. 
Additionally, detailed clinical information regarding the progression of disease 
and the use of medication has been collected for studying the association of ge-
netic polymorphisms with the course of disease or the response to medication. The 
percentage of active disease in the first two years has been selected as outcome 
measure regarding course of disease. Patient with a mild (remitting) disease (< 35% 
of the time with active disease in the first two years) were compared to patients with 
an intermediate (35-65% active disease) and with a severe (non-remitting) disease 
(>65% active disease) to study association with the course of disease.  Genetic 
association with response to methotrexate (MTX) was studied by comparing the 
frequency of selected genetic polymorphisms between MTX responders and MTX 
non-responders. The response to MTX was based on the improvement of the (sub-
jective) physician score combined with the decrease in number of affected joints 
after 6 months of treatment. 
For these genetic studies multiple genes and loci have been selected. Genes/loci 
have been selected based on a known association with JIA in order to replicate 
this association in a new and independent cohort. Also genes/loci have been se-
lected that have been associated with other autoimmune diseases, especially with 
rheumatoid arthritis that shares many features with JIA, in order to strengthen the 
hypothesis of a shared common auto-immune susceptibility. Furthermore, genes 
have been selected that are involved in immune-regulation following an educated 
guess. 
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Genetic associations with the susceptibility to JIA
In this cohort we have discovered new associations in JIA in the genes/loci TRAF1/C5 
(chapter 2), 4q27 (chapter 3), CD226 and CD28 (chapter 4). These genes have already 
been associated with other auto-immune diseases and might be part of a shared com-
mon auto-immune susceptibility. Also known JIA associations were replicated in our 
JIA cohort; VTCN1, 4q27, TNFA, PTPN22 and ANKRD55. By performing a meta-analysis 
involving our results and already published results, additional positive (overall) asso-
ciations were revealed with PTPRC, AFF3, CCR5, TNFAIP3, TNPO3, IL2RA and CLEC16A. 
TRAF1/C5 (chapter 2)
The genetic locus TRAF1/C5 includes both genes encoding TRAF-1 (TNF-receptor-asso-
ciated factor-1) and complement 5 (C5). Genetic information of this locus is transmitted 
in total to the next generation without recombination with its sister chromosome. This 
phenomenon is called linkage disequilibrium (LD). The positive association of JIA with 
this locus could reflect an association with TRAF1 as well as with C5 (or non-coding 
DNA). Both genes are likely to play a role in the pathogenesis of JIA. TRAF-1 is part of 
the TNF-pathway that seems to be of high importance in JIA, considering the effect 
of anti-TNF treatment in JIA. Complement 5 has a role in attracting neutrophils and 
dysregulation could be involved in the development of JIA. Following our result, the 
association of TRAF-1/C5 and JIA has been studied in other cohorts with conflicting 
results. Additional (more detailed) research of this locus is needed.  
4q27 (chapter 3)
The 4q27 locus has already been associated with multiple auto-immune diseases, but 
for the first time an association with JIA has been discovered in our cohort. The 4q27 
locus contains several genes of which two genes are highly likely to be involved in the 
pathogenesis of JIA. These genes encode interleukin 2 (IL2) and interleukin 21 (IL21) 
and are inherited together (LD). Interleukin 2 is involved in the proliferation and dif-
ferentiation of T-cells and in particular the regulatory T-cells.  These regulatory T-cells 
have a role in regulating or inhibiting the inflammatory response and dysfunction can 
lead to an excessive (auto)immune-response. Genetic variation in the gene coding the 
IL2-receptor (IL2RA) is associated with multiple autoimmune diseases, including JIA, 
underlining the importance of the IL2 pathway in autoimmunity. IL21 is involved in 
the differentiation and expansion of T-helper-17 cells. These T-helper-17 cells seem 
to play a central role in JIA and have a pro-inflammatory effect. In several autoimmune 
diseases the association with IL21-receptor has been described. In recent years the 
association of 4q27 and JIA has been replicated in several cohorts. 
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CD226 (DNAM-1)(chapter 4)
For the first time an association of CD226 and JIA is described in chapter 6. However 
CD226 has already been associated with other auto-immune diseases. CD226 (known 
as DNAX accessory molecule 1 or DNAM-1) is involved in the co-stimulation of T-cells 
and NK cells. Therefore, CD226 could have a role in the regulation of the balance 
between the pro- and anti-inflammatory immune response. In other JIA cohorts this 
association has been studied, but no association was found. However, performing a 
meta-analysis with our results and all published data, an overall positive association 
is revealed. 
Genetic association with the course of JIA (chapter 5 and 6)
For the first time genetic association with the course of disease, defined by the percent-
age of active disease in the first two years, has been studied in this cohort.  The same 
polymorphisms that were selected for studying the association with the susceptibil-
ity to JIA were used for discovering association with the course of disease. Detailed 
clinical data necessary for determining the clinical course of disease were available for 
272 patient with oligoarthritis (persistent and extended) and RF-negative polyarthritis 
(out of the 639 patient).  First the predictive value of several clinical parameters was 
determined (chapter 5). This showed that the JIA subtypes have a different course 
of disease; patients with persistent oligoarthritis have a favorable course with a low 
percentage of active disease in the first two years, whereas patients with an extended 
oligoarthritis have the highest percentage of active disease. Because the percentage of 
active disease in the first 2 years corresponded with the percentage of active disease 
in the three following years, this parameter was regarded a suitable outcome measure 
reflecting course of disease. 
When analyzing the association with course of disease, both clinical parameters 
(subtype) and genetic factors were included. Multivariate analysis showed that 
VTCN1 (rs10923223) is associated with the course of disease, regardless of JIA 
subtype (chapter 6). 
VTCN1 has already been associated with susceptibility to JIA and other auto-immune 
diseases (with varying results), but seems to have a prominent role in the progression 
of the inflammatory response in JIA. VTCN1 encodes B7-H4 that is involved in the 
co-stimulation of T-cells and inhibits the immune-response. Our data show that the 
minor allele is associated with a lower percentage of active disease in the first two 
years (remitting disease). This allele might enhance the function of VTCN1 leading 
towards a stronger inhibition of the immune response.  Additional studies concern-
ing the functional consequence of this VTCN1 variation will be essential. However 
until the precise role of VTCN1 will be clarified, the genetic association might be of 
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use in predicting the course of disease and helping the physician in choosing the 
optimal treatment strategy. Further prospective study should be conducted to verify 
the predictive value of VTCN1.
Genetic association and the response to methotrexate (chapter 7)
Both clinical and genetic factors have been studied in relation to the response to MTX 
in a cohort of 55 MTX non-responders and 73 MTX-responders. Several polymorphisms 
in genes involved in the folate and adenosine pathway have been selected. A multivari-
ate analysis showed that the time to start MTX (the time from diagnosis to start MTX) 
is associated with response to MTX; treatment in more early stages of the disease has 
a better response. No association with genetic factors was found. Because of the small 
group size the lack of association with genetic factors might be due to low power to 
detect smaller effects. 
These first genetic studies in this new (Caucasian) JIA cohort, including patients with 
similar phenotypic features, have led to discovery of new association (TRAF1/C5, 4q27, 
CD226 and CD28) and replication of known associations. Of clinical importance is the 
association of VTCN1 with the course of disease that might already be useful as factor 
predicting the course of disease and guiding the physician in the choice of treatment. 
Future plans following the results of this thesis will be to perform functional stud-
ies to elucidate the role of the VTCN1 polymorphism and its inhibitory effect on 
the immune-response.  Possibly, this might have therapeutic consequences.  Fur-
thermore the size of the cohort should be enlarged to enhance the power of our 
research. Especially increasing the cohort of patients with a known detailed course 







Juveniele idiopathische artritis (JIA), ofwel jeugdreuma, is een niet veel voorkomende 
ziekte bij kinderen, die kan blijven bestaan tot in volwassenheid. Het is een verzamel-
naam voor aandoeningen die gekenmerkt worden door een chronische gewrichtsont-
steking. Deze groep is volgens de ILAR classificatie onderverdeeld in meerdere subty-
pen op basis van het aantal gewrichten dat is aangedaan bij het begin van de ziekte, 
maar ook gedurende het ziektebeloop, en enkele laboratoriumwaarden. De subtypen 
oligoartritis (persisterend of extended) en reumafactor negatieve polyartritis zijn het 
meest voorkomend en zijn binnen de totale groep van jeugdreuma vergelijkbaar in hoe 
de ziekte zich gedraagt. 
Het beloop van de ziekte in alle subtypen bestaat uit onvoorspelbare episoden 
van ziekteactiviteit in verschillende gradaties, afgewisseld met inactieve ziekte. 
Hoe langer de ziekte actief is, hoe meer kans op beschadiging van de aangedane 
gewrichten. Op dit moment is niet te voorspellen wat de prognose van jeugdreuma 
is in de individuele patiënt. 
Therapie is erop gericht de ziekteactiviteit in een zo vroeg mogelijk stadium rus-
tig te krijgen om schade aan de gewrichten te voorkomen. In de laatste jaren is 
behandeling van jeugdreuma steeds agressiever geworden, met gebruik van meer 
potente antireumatische medicatie toegepast in een vroeger stadium van de ziekte. 
De respons op de verschillende soorten medicatie kan per patiënt verschillend zijn. 
Er zijn op dit moment ook nog geen goede voorspellers voor de respons op therapie, 
terwijl dat wel aanvullend zou zijn voor de keuze voor meest optimale individuele 
therapie. 
JIA als multifactoriële aandoening
JIA is een auto-immuunziekte, hoewel het precieze ontstaansmechanisme van de ziekte 
nog onduidelijk is. Ook waartegen de immuunreactie zich precies richt is niet bekend, 
maar wel is duidelijk dat de aanhoudende ontstekingsreactie in het gewricht zorgt voor 
schade aan het kraakbeen en het bot. Er wordt gedacht dat verschillende factoren een 
rol spelen in het ontstaan van jeugdreuma. Naast mogelijke omgevingsfactoren, lijkt 
een genetische aanleg belangrijk te zijn. In tweeling- en familie-studies wordt gezien 
dat jeugdreuma meer voorkomt bij de andere helft van een aangedane tweeling en ook 
bij broers en zussen van patiënten met jeugdreuma. 
Er zijn de afgelopen jaren veel studies verricht naar de associatie van genetische 
factoren en het ontstaan van jeugdreuma. Dit zijn vooral studies waarin de frequen-
tie van bepaalde genetische variaties (bv single nucleotide polymorphisms; SNPs) 
vergeleken wordt tussen patiënten met jeugdreuma en gezonde controle personen. 
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Als in patiënten met JIA de genetische variatie significant meer of minder voorkomt 
dan in controles, is de genetische variatie geassocieerd met JIA. Naast HLA, zijn 
meerdere genen (bv PTPN22, STAT4, TNFAIP3, IL2RA) bij herhaling en in onafhan-
kelijke JIA patiëntengroepen geassocieerd met jeugdreuma. Het totale aandeel dat 
genetische factoren hebben in de aanleg voor jeugdreuma is geschat op 30%. 
doel van dit proefschrift
Het doel van het onderzoek beschreven in dit proefschrift is om genetische associaties 
in JIA te onderzoeken. Genetische factoren die van invloed zijn op het ontstaan van 
JIA in een patiënt geven informatie over de pathogenese, maar kunnen ook belangrijke 
aanknopingspunten zijn voor nieuwe therapieën. Genetische factoren die geassocieerd 
zijn met het beloop van JIA of met de respons op bepaalde medicatie kunnen mogelijk 
voorspellende waarde hebben. Het is voor de behandelend (kinder)reumatoloog van 
klinisch belang om te kunnen voorspellen hoe de ziekte zich zal gedragen en wat de 
respons op therapie zal zijn. Informatie aan de patiënt en ouders kan hierdoor geopti-
maliseerd worden en de keuze voor therapie (en tijdstip van starten van therapie) kan 
geïndividualiseerd worden, met mogelijk een snellere remissie tot gevolg. 
Om deze studies uit te voeren is een nieuw en onafhankelijk JIA cohort gecreëerd, 
waarin 639 patiënten uit Noord-West Europa (Nederland, België, Duitsland en Zwit-
serland) met een caucasische etniciteit zijn geïncludeerd. Voornamelijk patiënten 
met oligoartritis (persisterend en extended) en reumafactor negatieve polyartritis zijn 
geselecteerd om de patiëntengroep een zo veel mogelijk overeenkomstig fenotype te 
geven. De frequentie van verschillende genetische polymorfismen (SNPs) is vergeleken 
tussen deze JIA patiënten en gezonde (caucasische) controles (afkomstig uit Nederland) 
om te kijken naar genetische associatie met het ontstaan van de ziekte. Van deze JIA 
patiënten is gedetailleerde informatie over het beloop van hun ziekte verzameld. Als 
maat voor de ernst van het beloop van de ziekte is er gekeken naar hoeveel procent 
van de tijd de patiënten een actieve ziekte hebben gehad in de eerste twee jaar na de 
diagnose. Patiënten met een mild beloop van de JIA (< 35% van de tijd actieve ziekte) 
zijn vergeleken met patiënten met een intermediair beloop van de ziekte (35-65% van 
de tijd actieve ziekte) en een meer ernstig beloop (>65% van de tijd actieve ziekte) om 
te kijken naar genetische associatie met het beloop van de ziekte. Binnen deze groep 
van JIA patiënten is er ook gekeken naar patiënten die methotrexaat (MTX) hebben 
gebruikt. Om te kijken naar betrokkenheid van genetische factoren op de respons op 
MTX werd de frequentie van geselecteerde SNPs in patiënten met een goede respons 
op MTX (gedefinieerd als een verbetering in subjectieve score door de behandelend 
kinderreumatoloog samen met een gelijk blijven of verbeteren van het aantal gewrich-
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ten wat aangedaan is in de eerste 6 maanden na het starten van MTX) vergeleken met 
patiënten die geen respons vertoonden op MTX. 
Voor de genetische studies naar associaties met het ontstaan van de ziekte en het 
beloop van de ziekte zijn meerdere genen/loci geselecteerd. Dit zijn aan de ene 
kant genen waarvan al een associatie bekend is met het ontstaan van JIA met als 
doel de associatie te repliceren in ons onafhankelijke cohort en zo de associatie 
mogelijk te versterken. Aan de andere kant zijn genen geïncludeerd die al geas-
socieerd zijn met (meerdere) auto-immuunziekten, waaronder reumatoïde artritis, 
wat veel overeenkomstige kenmerken heeft met JIA, en die deel uitmaken van een 
gemeenschappelijke genetische vatbaarheid voor autoimmuniteit. Daarnaast zijn 
ook genen geselecteerd die betrokken zijn bij de immuunregulatie. 
Genetische associaties met het ontstaan van JIA
In ons cohort hebben we een associatie gevonden met genen die nog niet eerder 
geassocieerd waren met JIA. Dit zijn de genen/loci TRAF1/C5 (hoofdstuk 2), 4q27 
(hoofdstuk 3), CD226 en CD28 hoewel de laatste met een lage significantie (beide 
beschreven in hoofdstuk 4). Dit zijn allemaal genen die al wel geassocieerd waren met 
andere autoimmuunziekten. Daarnaast zijn verschillende genen die al geassocieerd 
waren met JIA in ons cohort gerepliceerd; VTCN1, 4q27, TNFA, PTPN22 en ANKRD55. 
Meta-analyse van onze uitkomsten samen met studies die eerder gedaan waren in JIA 
(maar vergelijkbaar met onze studie geen associatie lieten zien) toonde alsnog een 
(gezamenlijke) associatie van JIA met PTPRC, AFF3, CCR5, TNFAIP3, TNPO3, IL2RA en 
CLEC16A. 
TRAF1/C5 (hoofdstuk 2)
TRAF1/C5 is een genetisch locus wat zowel de genen TRAF-1 (TNF-receptor-associated 
factor-1) als C5 (complement 5) omvat. Genetische associaties in dit locus worden 
gezamenlijk overgeërfd naar een volgende generatie, zonder dat er uitwisseling 
plaatsvindt met genetisch materiaal op het zuster chromosoom. Dit wordt linkage 
disequilibrium (LD) genoemd. Een associatie van JIA met dit TRAF1/C5 locus kan dus 
zowel een associatie zijn met het TRAF-1 gen als met complement 5. Beide genen 
zouden een potentiele rol kunnen hebben in het ontstaan van JIA. TRAF-1 is onderdeel 
van de TNF-pathway, dat mede door het effect van anti-TNF behandeling in JIA, een 
belangrijke rol lijkt te hebben. Daarnaast is complement 5 betrokken bij het aantrek-
ken van neutrofielen en dysregulatie hiervan zou een voortgaande ontsteking kunnen 
veroorzaken. In latere studies in andere cohorten is deze associatie met TRAF1/C5, die 
wij als eerste hebben beschreven, bevestigd, maar niet consequent. Meer onderzoek is 
nodig naar de precieze rol die de TRAF1/C5 locus heeft in JIA. 
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4q27 (hoofdstuk 3)
In ons JIA cohort is als eerste de associatie tussen de 4q27 locus en JIA beschreven. 
De 4q27 locus bevat meerdere genen die mogelijk een belangrijke rol hebben in de 
ontwikkeling van JIA. Dit zijn de genen die coderen voor interleukine 2 (IL2) en inter-
leukine 21 (IL21). Deze zijn in LD met elkaar en worden gezamenlijk overgeërfd. IL2 
heeft een rol in de proliferatie en differentiatie van T-cellen, waaronder regulatoire 
T-cellen. Deze regulatoire T-cellen hebben een rol in het reguleren of dempen van een 
ontstekingsreactie en ontregeling van hun functie kan een excessieve ontstekingsreac-
tie tot gevolg hebben. Genetische variaties in de IL2-receptor (IL2RA) zijn geassocieerd 
met meerdere autoimmuunziekten, waaronder JIA. Dit benadrukt de rol van de IL2-
pathway in JIA. IL21 speelt een rol in de differentiatie en expansie van T-helper-17 
cellen. Deze T-helper-17 cellen spelen een belangrijke rol in het ontstaan van JIA en 
hebben een pro-inflammatoir effect. In meerdere autoimmuunziekten zijn associaties 
met SNPs in het IL21-receptor gen beschreven. Zowel IL2 als IL21 zijn betrokken bij de 
pathogenese van JIA en zijn beide mogelijke kandidaten die de genetische associatie 
met dit locus weerspiegelen. In verschillende andere cohorten is de associatie met de 
4q27 locus gerepliceerd.
CD226 (DNAM-1)(hoofdstuk 4)
De associatie van CD226 met verschillende autoimmuunziekten was al bekend, maar 
de associatie met JIA is als eerste gevonden in ons JIA cohort. CD226 (ook bekend als 
DNAX accessory molecule 1 of DNAM-1) is betrokken bij de co-stimulatie van T-cellen 
en NK-cellen en zou een rol kunnen hebben in de regulatie van de balans tussen de 
pro-inflammatoire en anti-inflammatoire immuunrespons. In andere JIA patiëntengroe-
pen is de associatie met CD226 ook onderzocht, waarbij er geen associatie gevonden 
werd. Echter als alle resultaten samen worden geanalyseerd in een meta-analyse, komt 
er een significante associatie met JIA naar voren. 
Genetische associatie met het beloop van JIA (hoofdstuk 5 en 6)
In ons cohort is voor het eerst gekeken naar de associatie van genetische factoren met 
het beloop van JIA, gedefinieerd aan de hand van het percentage actieve ziekte in de 
eerste twee jaar. Dezelfde SNPs werden geselecteerd als in de studie naar de associatie 
met het ontstaan van JIA. Van de groep van 639 patiënten, was er van 272 patiënten ge-
detailleerde informatie aanwezig om het beloop van JIA te kunnen bepalen. Allereerst 
zijn verschillende klinische parameters onderzocht in relatie tot het voorspellen van 
het beloop van de ziekte (hoofdstuk 5). Hieruit kwam naar voren dat de verschillende 
subtypen JIA een ander beloop hebben; de persisterende oligoartritis heeft het laag-
ste percentage actieve ziekte in de eerste twee jaar, terwijl extended oligoartritis het 
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hoogste percentage actieve ziekte heeft. Tevens werd beschreven dat het percentage 
ziekteactiviteit in de eerste twee jaar representatief is voor de ziekteactiviteit in de 
jaren die daar op volgen en dus een geschikte parameter lijkt om de ernst van de ziekte 
mee weer te geven. Bij de analyse van genetische factoren en het beloop van JIA is er 
gecorrigeerd voor het subtype. De multivariate analyse toont dat VTCN1 (rs10923223) 
geassocieerd is met het beloop van de ziekte (hoofdstuk 6), ongeacht het subtype. Dit 
gen was eerder al geassocieerd met het ontstaan van JIA (met wisselende resultaten) 
en andere autoimmuunziekten, maar lijkt vooral een aandeel te hebben in de verdere 
progressie van de ontstekingsreactie in JIA. VTCN1 codeert voor B7-H4, wat betrokken 
is bij de costimulatie van T-cellen en een inhiberend effect heeft op de immuunres-
pons. Het allel wat het minste voorkomt (minor allel) is geassocieerd met een lager 
percentage ziekte in de eerste twee jaar. Mogelijk zorgt dit allel voor een toegenomen 
functie en dus een sterkere inhibitie van de immuunrespons. Meer onderzoek is nodig 
naar de functionele consequenties van de genetische variatie in VTCN1. Echter zonder 
dat er functionele consequenties bekend zijn, kan dit polymorfisme mogelijk wel van 
waarde zijn in het voorspellen van het beloop van de ziekte en daarmee de (kinder)
reumatoloog ondersteunen in het bepalen van de beste individuele therapie en in-
formeren van de ouders en patiënt. Prospectieve studies zijn nodig om de mogelijk 
voorspellende waarden van VTCN1 te kunnen toetsen.
Genetische associatie en de respons op MTX (hoofdstuk 7)
Zowel klinische parameters als genetische parameters zijn onderzocht in relatie tot de 
respons op MTX in een groep van 55 non-responders en 73 responders. Verschillende 
genen die betrokken zijn bij de folaat en adenosine pathways zijn geselecteerd. In een 
multivariate analyse kwam de tijd tot het starten van behandeling naar voren als de 
belangrijkste parameter geassocieerd met respons op MTX; hoe sneller je de behande-
ling start, hoe beter de respons. Er was geen associatie met genetische parameters, wat 
mogelijk zou kunnen komen door de kleine groep patiënten, waarbij er weinig power is 
om associaties met een klein effect aan te kunnen tonen. 
Deze eerste genetische studies in dit nieuwe cohort met (caucasische) JIA patiënten 
(met een zo veel mogelijk overeenkomstig fenotype) hebben allereest een aantal 
nieuwe associaties in JIA aangetoond (TRAF1/C5, 4q27, CD226 en CD28) en daarnaast 
replicatie van reeds beschreven associaties. Van klinische waarde is de associatie van 
VTCN1 met het beloop van de ziekte, omdat dit mogelijk als voorspeller kan dienen 
voor de ziekteactiviteit in de individuele patiënt, waarmee rekening gehouden kan 
worden met de keuze van therapie. Tevens zou dit een belangrijk aanknopingspunt 
kunnen zijn voor de ontwikkeling van nieuwe therapie.
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Een belangrijk doel voor de toekomst is om dit cohort verder uit te breiden, zodat 
er meer power is om genetische associaties aan te kunnen tonen. Vooral het uit-
breiden van de groepen waarbij het beloop van de ziekte bekend is, vormt daarbij 
een uitdaging. Daarnaast is het verder uitwerken van de functie van VTCN1 in het 
kader van regulatie van de ziekteactiviteit van klinisch belang omdat dit mogelijk 
therapeutische consequenties heeft.




DM1 diabetes mellitus type 1
DMARD disease modifying anti-rheumatic drugs
GWAS genome wide association study
HLA human leukocyte antigen
IAS intra-articular steroids
IL interleukin
ILAR International League of Associations for Rheumatology
JIA International League of Associations for Rheumatology
LD linkage disequilibrium
MAF minor allele frequency
MS multiple sclerosis
MTX methotrexate




SNP single nucleotide polymorphism
STAT signal transducer and activator of transcription
TDT transmission disequilibrium test
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